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Abstract 
The existence of a trauma induced secondary cardiac injury (TISCI) 
remains in doubt.  The risk factors and pathological processes that lead to 
its development are not known, whilst the effects of TISCI on injured 
patient outcome are uncertain.  Concurrently, the incidence of coronary 
heart disease (CHD) in a trauma population and its influence on mortality 
are inconclusive.  The aim of this research project was to address these 
specific areas of uncertainty. 
Critically injured patients (n=135) were retrospectively investigated for 
the incidence and nature of adverse cardiac events (ACEs), and levels of 
the cardiac specific biomarkers Troponin I, B-type Natriuretic Peptide and 
Heart-type Fatty Acid Binding Protein were measured.  Biomarkers and 
cardiac events were evaluated against outcome.  Thereafter, the 
relationship of pro-inflammatory cytokines with TISCI was explored.  A 
prospective cohort study of 199 trauma patients followed, to confirm the 
existence of TISCI and describe its clinical features, risk factors and 
outcomes.  Finally, coronary artery calcium, as a marker of CHD, was 
evaluated on 432 CT scans of the chest of trauma patients aged 45 years or 
over, and its association with survival after injury was established. 
ACEs and early biomarker rises occurred in trauma patients and both 
were unrelated to the severity of chest injury.  Each was associated with 
higher mortality, and confirmed the existence of TISCI.  Risk factors for 
the development of the condition included increasing age, worsening 
tissue injury and shock.  A relationship with cytokines was demonstrated, 
and implicated acute inflammation in the pathogenesis of TISCI.  
Calcification on CT scans revealed the incidence of CHD in an injured 
cohort approached 70%, although its presence did not impact survival. 
There exists a trauma induced secondary cardiac injury which was related 
to poorer outcome.  The condition was associated with inflammation.  
CHD was widespread in older trauma patients but was not associated 
with increased in-hospital mortality. 
 4 
Declaration 
I hereby certify that the work described in this thesis is the result of my 
own independent investigation, except where otherwise stated.  Any 
assistance received has been acknowledged in the text.  
 5 
Publications and Presentations 
Publications  
De’Ath HD, Manson J, Davenport R, et al. Trauma Induced Secondary 
Cardiac Injury is Associated with Hyperacute Elevations in Inflammatory 
Cytokines.  Shock. 2013 May; 39(5):415-420 
De’Ath HD, Rourke C, Davenport R, et al.  Clinical and Biomarker Profile 
of Trauma-Induced Secondary Cardiac Injury.  British Journal of Surgery.  
2012; 99(6): 789–797 
De’Ath HD, Vulliamy P, Davies C, Uppal R.  A Large Ventricular Septal 
Defect Complicating Resuscitation After Blunt Trauma.  Journal of 
Emergencies, Trauma, and Shock. 2012;5: 350-2 
Presentations (Abstract)  
De’Ath HD, Oakland K, Davies C, Brohi K.  Coronary Artery Calcium 
Scores on Admission Trauma CT Scans and Their Association with In-
hospital Survival.  ICNC 11, Nuclear Cardiology and Cardiac CT (ESC).  
Berlin, Germany – May 2013. 
De’Ath HD, Manson J, Rourke C, et al.  Trauma Induced Secondary 
Cardiac Injury is Associated with Acute Inflammation.  European Shock 
Society (ESS) - Taormina, Italy – September 2011. (Shock 2011; 36(S1):12) 
De'Ath HD, Rourke C, Manson J, et al.  Trauma Induced Secondary 
Cardiac Injury.  European Society of Cardiology Congress (ESC) - Paris, 
France -August 2011. (European Heart Journal 2011; 32:726) 
De’Ath HD, Rourke C, Davenport R, et al. Cardiac Dysfunction after 
Trauma:  A Real and Present Danger.  Society of Academic and Research 
Surgery (SARS) - Dublin, Ireland - January 2011. (British Journal of Surgery. 
2011; 98 (S2):7) 
Prizes 
Wellcome Image Award 2012   
 6 
Acknowledgements 
Thank you to Professor Brohi for his supervision, support and guidance, 
and for providing me with the most wonderful and unique opportunities 
during my research.   
I am grateful to Rakesh Uppal for agreeing to be my second supervisor, 
and to Simon Eaglestone for his advice and organisational skills.  Thank 
you also to Professor Martin for her sound guidance and generosity of 
time over the course of my research. 
My gratitude goes to my friends and colleagues in the TCAU for all their 
help and support:  Elaine Cole, Sirat Khan, Ross Davenport, Jo Manson, 
Zane Perkins, Imran Raza, Claire Rourke, Simon Glasgow, Anita West and 
Karen Hoffman.   
A massive thank you to my thoughtful and indispensible friends, who 
along the way have provided me with great motivation and distraction in 
equal measure. 
I am indebted to the patients and relatives who have consented to 
participation in all the studies presented in this thesis.  I greatly appreciate 
and admire their altruistic desire to cooperate and assist with this 
research, in spite of the traumas they have all suffered. 
Finally, to my family, my sisters and especially my parents, without 
whom, quite simply I would never have been able to do this.  I cannot 
describe my appreciation and gratitude for all they have done for me, and 
this thesis is dedicated to them.  
 7 
Table of Contents  
         Page 
Title          1 
Supervisors         2 
Abstract         3 
Declaration         4 
Publications and Presentations      5 
Acknowledgements        6 
Table of Contents        7 
List of Figures         12 
List of Tables         14 
List of Abbreviations        16 
CHAPTER ONE 
Introduction 
 1.1  The Significance of Trauma      19 
1.1.1  The Health Impact       19 
1.1.2  The Financial Burden of Trauma     20 
1.1.3  Trauma and Research       20 
1.1.4  Trauma Associated Cardiac Injury and Dysfunction   21 
1.2  Characteristics of Trauma      22 
1.2.1  Measuring Injury Severity      22 
1.2.2  The Epidemiology of Death in Trauma     23 
1.3  Direct Cardiac Injury       24 
1.3.1  Penetrating Cardiac Injury      24 
1.3.2  Blunt Cardiac Injury       24 
1.4  Indirect, Secondary Cardiac Injury–The Experimental Evidence 27 
1.4.1  Experimental Evidence of Post-traumatic Secondary Cardiac Injury 27 
1.4.2  Limitations and Applicability of the Experimental Evidence  31 
1.5  Indirect, Secondary Cardiac Injury–The Clinical Evidence  34 
1.5.1  Post-Traumatic Secondary Cardiac Injury and Clinical Manifestations 34 
1.5.2  Post-Traumatic Secondary Cardiac Injury and Cardiac Biomarkers 41 
 
 8 
1.6  Trauma, Inflammation and the Heart     51 
1.6.1  SIRS and MODS       51 
1.6.2  Cytokines, Inflammation and the Heart     52 
1.7  Head Trauma and Secondary Cardiac Injury    54 
1.8  Cardiac Disease and Trauma      56 
1.8.1  Cardiac Disease and Survival in Trauma    56 
1.8.2  Limitations of the Literature on Cardiac Disease and Trauma  59 
1.8.3  Cardiac Medications and Outcome in Trauma    60 
1.9  Summary         63 
1.10  Project Aims        66 
CHAPTER TWO 
Trauma Induced Secondary Cardiac Injury 
2.1  Introduction        68 
2.2  Study Aims        70 
2.3  Materials and Methods       71 
2.3.1  Study Design and Setting      71 
2.3.2  Study Population       71 
2.3.3  Data Collection       71 
2.3.4  Outcomes        72 
2.3.5  Blood Collection       72 
2.3.6  Biomarker Assays       72 
2.3.7  Statistical Analysis       77 
2.4  Results         79 
2.4.1  Incidence and Features of Adverse Cardiac Events   79 
2.4.2  Biomarkers and Adverse Cardiac Events    81 
2.4.3  The Relationship Between Adverse Cardiac Events and Injury  83 
2.4.4  Biomarkers and Injury       84 
2.4.5  Adverse Cardiac Events, Biomarkers and Shock    86 
2.4.6  Adverse Cardiac Events, Biomarkers and Mortality   87 
2.5  Discussion        90 
2.6  Limitations        94 
2.7  Conclusions        95 
 9 
CHAPTER THREE 
Trauma Induced Secondary Cardiac Injury and Inflammation 
3.1  Introduction        97 
3.2  Study Aims        99 
3.3  Materials and Methods       100 
3.3.1  Study Design and Setting      100 
3.3.2  Study Population       100 
3.3.3  Data Collection       100 
3.3.4  Outcomes        100 
3.3.5  Blood Collection       100 
3.3.6  Inflammatory Marker Analysis      101 
3.3.7  Biomarker Assays       102 
3.3.8  Statistical Analysis       103 
3.4  Results         104 
3.4.1  Inflammation and Adverse Cardiac Events    104 
3.4.2  Inflammation and Cardiac Injury     108 
3.4.3  Inflammation, Cardiac injury and Survival    112 
3.5  Discussion        118 
3.6  Limitations        123 
3.7  Conclusions        125 
CHAPTER FOUR 
Cardiac Dysfunction in Trauma: A Prospective Study 
4.1  Introduction        127 
4.2  Study Aims        130 
4.3  Materials and Methods       131 
4.3.1  Study Setting        131 
4.3.2  Study Design        131 
4.3.3  Study Population       131 
4.3.4  The Process of Consent       132 
4.3.5  Data Collection       133 
4.3.6  Study Definitions       134 
4.3.7  Statistical Analysis       134 
4.4  Results         135 
4.4.1  Epidemiology and Clinical Features of Adverse Cardiac Events  135 
4.4.2  Adverse Cardiac Events and Takotsubo’s Syndrome   140 
 10 
4.4.3  Characteristics of Patients With and Without Adverse Cardiac Events 140 
4.4.4  Adverse Cardiac Events and Outcomes     142 
4.4.5  Adverse Cardiac Events and Risk Factors    144 
4.5  Discussion        145 
4.6  Limitations        149 
4.7  Conclusions        151 
CHAPTER FIVE 
Coronary Artery Calcium and Trauma 
5.1  Introduction        153 
5.2  Study Aims        156 
5.3  Materials and Methods-Part A      157 
5.3.1  Training        157 
5.3.2  Validation        158 
5.3.3  Inter-observer Agreement      159 
5.4  Materials and Methods-Part B      160 
5.4.1  Study Design and Setting      160 
5.4.2  Study Population       160 
5.4.3  Indication for CT in Study Patients     160 
5.4.4  CT Scan Protocol in Trauma      161 
5.4.5  CT Scan Interpretation       161 
5.4.6  Data Collection       162 
5.4.7  Study Outcome       162 
5.4.8  Statistical Analysis       162 
5.5  Results         164 
5.5.1  Feasibility of Trauma CT scans in Determining Calcium Score  165 
5.5.2  Study Population       165 
5.5.3  Incidence of Coronary Artery Calcium on Trauma CT   166 
5.5.4  Characteristics of Patients with Coronary Artery Calcium  167 
5.5.5  Coronary Artery Calcium and Mortality    168 
5.5.6  Inter-observer Agreement      173 
5.6  Discussion        175 
5.7  Limitations        178 
5.8  Conclusions        180 
 11 
CHAPTER SIX 
Conclusions 
6.1  Summary of Findings       182 
6.2  Strengths and Limitations      184 
6.2.1  Strengths of the Research Project     184 
6.2.2  Limitations of the Research Project     185 
6.3  Future Work        187 
6.4  Conclusions        189 
References         190 
Appendix I         218 
Trauma Associated Cardiac Injury and Dysfunction (TACID) Study Proposal 
Appendix II         253 
Letter of Favourable Ethical Approval from Research Ethics Committee 
Appendix III         256 
TACID Study Patient Information Sheet (TACID A) 
Appendix IV        262 
TACID Study Consultee Information Sheet (TACID A) 
Appendix V         268 
Professional Legally Appointed Representative (TACID A) 
Appendix VI         269 
Subject Consent Form (TACID A) 
Appendix VII        270 
Consultee Declaration Form (TACID A) 
 12 
List of Figures 
            Page 
CHAPTER ONE 
Introduction 
1.1. A summary of trauma in England and Wales from 2002 to 2011  22 
1.2. Traumatic ventricular septal resulting from blunt thoracic injury  25 
1.3. The action of BNP       42 
1.4. The cardiac sarcomere during diastole and systole   44 
CHAPTER TWO 
Trauma Induced Secondary Cardiac Injury 
2.1. Numbers of adverse cardiac events by diagnosis    79 
2.2. Biomarker concentrations in patients without and with ACEs  81 
2.3. The number of ACEs in each category of chest injury   83 
2.4. The relationship between ACEs and overall injury (ISS)   84 
2.5. Number of patients with ACEs per admission lactate quartile  86 
2.6. The relationship between ACEs, biomarkers and death   87 
2.7. The relationship of H-FABP with death     88 
2.8. The relationship of BNP with death     88 
2.9. The relationship of Troponin I with death    89 
CHAPTER THREE 
Trauma Induced Secondary Cardiac Injury and Inflammation 
3.1. Relationship of TNFα, IL-6, IL-8 and IL-1β with adverse cardiac events 105 
3.2. Correlation between admission levels of cytokines and H-FABP  109 
3.3. The relationship between inflammation and H-FABP on admission with  
in-hospital mortality       112 
3.4. The relationship between TNFα and BNP on admission with in-hospital 
mortality        114 
3.5 The relationship between IL-6 and IL-8 with BNP on admission with  
in-hospital mortality       114 
3.6. The relationship between TNFα and Troponin I on admission with  
in-hospital mortality       116 
3.7 The relationship between IL-6 and IL-8 with Troponin I on admission  
with in-hospital mortality      116 
 13 
CHAPTER FOUR 
Cardiac Dysfunction in Trauma:  A Prospective Study 
4.1. Numbers of adverse cardiac events by diagnosis    136 
4.2. Percentage of ACEs occurring each day post admission   136 
4.3. Admission ECG findings in patients who developed an ACE  137 
4.4. Scatter plot of Troponin T values in patients with ACEs   139 
4.5. Medication requirements of the No ACE and ACE cohorts  142 
4.6. The mortality rate in patients with and without ACEs   143 
4.7. Timing of death of the deceased patients     143 
CHAPTER FIVE 
Coronary Artery Calcium and Trauma 
5.1. Bland Altman plot of inter-observer agreement in validation exercise 159 
5.2. Axial views of the heart on a trauma CT scan    162 
5.3. Flow diagram depicting selection of study population   164 
5.4. Death rate based on the absence or presence of coronary artery calcium 168 
5.5. Death rate per coronary artery calcium score quartile   168 
5.6. Death rates according to grade of coronary artery calcium  170 
5.7. Odds ratios of death (with 95% CI) according to grade of coronary artery  
calcium         170 
5.8. Mortality according to number of calcified vessels observed  172 
5.9. Odds ratios of death (with 95% CI) according to number of calcified  
 coronary vessels       173 
5.10. Bland Altman plot of inter-observer agreement of estimated coronary  
artery calcium scores       174 
CHAPTER SIX 
Conclusions 
6.1. Trauma associated cardiac injury and dysfunction: an illustrative summary  
of the principle findings of this thesis     183 
 14 
List of Tables 
Page 
CHAPTER ONE 
Introduction 
1.1. AIS Scores Illustrated with Examples of Chest Injury   23 
1.2. Beta-blockers and Statins in Trauma – Summary of Evidence  61 
1.3. Summary of Dedicated Clinical Studies of Secondary Cardiac Injury and  
Dysfunction in Trauma       64 
CHAPTER TWO 
Trauma Induced Secondary Cardiac Injury 
2.1. Heart-type Fatty Acid Binding Protein (Hycult biotech Cat No. HK402) 74 
2.2 B-type Natriuretic Peptide (EIA Biomedica Cat No. BI-20852)  74 
2.3 Troponin I ([human cardiac-specific] Life Diagnostics, Cat No.2010) 74 
2.4 Patient Demographics, Characteristics and Outcomes   80 
2.5. Correlation between Biomarkers and ISS    85 
2.6. Correlation between BNP and Troponin I and Head and Neck AIS 85 
2.7. Correlation between Biomarkers and Admission Lactate and SBP 87 
CHAPTER THREE 
Trauma Induced Secondary Cardiac Injury and Inflammation 
3.1. Control Group Characteristics and Admission Cytokine Levels  102 
3.2. Patient Characteristics, Adverse Cardiac Events and Outcomes  104 
3.3. Levels of IFNγ, IL-10 and IL-12 and Adverse Cardiac Events  107 
3.4. Relationship of Cytokines with Age     108 
3.5. Correlation between Cytokine Levels and Biomarkers   111 
3.6. The Relationship Between H-FABP and the Covariates   111 
CHAPTER FOUR 
Cardiac Dysfunction in Trauma:  A Prospective Study 
4.1. Mayo Criteria for a Diagnosis of Takotsubo’s Cardiomyopathy  129 
4.2. Trauma Team Activation Criteria     132 
4.3. Patient Demographics, Injuries and Admission Physiology  135 
4.4. Echocardiogram Findings in Patients with Adverse Cardiac Events 138 
4.5. Pre-morbid Diagnoses and Medications     141 
 
 15 
4.6. Crude Odds Ratios and Propensity Adjusted Multivariate Predictors  
of Adverse Cardiac Events in 199 Trauma Patients   144 
CHAPTER FIVE 
Coronary Artery Calcium and Trauma 
5.1. Grades of Calcium Based on Corresponding Calcium Score  158 
5.2. Study Population Characteristics     165 
5.3. Documented Patient Co-morbidities on Admission   166 
5.4. Patient Characteristics Based on Coronary Artery Calcium Grade  167 
5.5. Predictors of Death in Trauma Patients Over the Age of 45  169 
5.6. Odds Ratio of Mortality per Calcium Grade Stratified by Injury Severity  
Score in Patients Aged <65 Years     171 
5.7. Odds Ratio of Death per Calcium Grade Stratified by Injury Severity  
Score in Patients Aged 65≤ Years     172 
5.8. Relationship of Each Coronary Artery with Mortality   173 
 
 16 
List of Abbreviations 
AA   Atrial Arrhythmias 
ACE   Adverse Cardiac Event 
ACS   Acute Coronary Syndrome 
AF   Atrial Fibrillation 
AIS   Abbreviated Injury Score 
BNP    B-Type Natriuretic Peptide 
BCI   Blunt Cardiac Injury 
CAC   Coronary Artery Calcium 
CHD   Coronary Heart Disease 
CI   Confidence Intervals 
CT    Computerised Tomography 
Cx   Circumflex (Coronary Artery) 
CAC   Coronary Artery Calcium 
CACS   Coronary Artery Calcium Score 
ECG    Electrocardiogram 
ED    Emergency Department 
EDTA   Ethylenediaminetetraacetic Acid 
ELISA   Enzyme-Linked Immunosorbent Assay  
fmol    Fentomole 
GCS   Glasgow Coma Scale 
H-FABP   Heart-type Fatty Acid Binding Protein 
hr(s)   Hour(s) 
ICU   Intensive Care Unit 
IL-1β   Interleukin 1 Beta  
IFNγ   Interferon Gamma  
IL-6    Interleukin 6 
IL-8    Interleukin 8 
 17 
IL-10    Interleukin 10 
IL-12    Interleukin 12 
IQR   Interquartile Range 
ISS    Injury Severity Score 
L   Litre 
LAD   Left Anterior Descending (Coronary Artery) 
mEq/L  Milliequivalents per Litre 
MI   Myocardial Infarction 
mins   Minutes 
ml    Millilitre 
mmol   Millimoles 
MODS  Multiple Organ Dysfunction Syndrome 
n   Number 
n/a   Not Applicable 
ng    Nanogram 
nm   Nanometre 
NT-proBNP  N-terminal pro-Brain Natriuretic Peptide 
OR   Odds Ratio 
Pg   Picogram 
RCA   Right Coronary Artery 
RR   Relative Risk 
SBP   Systolic Blood Pressure 
SD   Standard Deviation 
secs   Seconds 
SIRS   Systemic Inflammatory Response Syndrome 
TISCI    Trauma Induced Secondary Cardiac Injury 
TNFα    Tumour Necrosis Factor Alpha  
l   Microlitre 
vs   Versus 
 18 
 
 
 
 
 
CHAPTER ONE 
Introduction 
 
 
 
 
 
   
 19 
1.1 The Significance of Trauma 
1.1.1 The Health Impact  
Trauma may be defined as injury resulting from penetrating or blunt 
physical force such as stabbings, falls or road traffic accidents (RTAs).  It is 
a leading cause of death throughout the world.  Internationally, trauma 
leads to nearly six million fatalities per year (WHO, 2009).  In the United 
Kingdom (UK), 16,000 people die annually as a result of injury (Office for 
National Statistics, 2005).  It typically affects a younger, active population, 
and it is the predominant cause of death in people between the ages of one 
and forty-four years (CDC, 2010). 
Trauma is also the cause of significant morbidity worldwide.  It is 
estimated that for every death due to injury, there are two patients left 
with permanent serious disabilities (TARN, 2006).  In 2004, according to 
the World Health Organization, the average global burden of disease was 
237 DALYs (Disability Adjusted Life Years) per 1000 population (WHO, 
2004).  RTAs alone were the ninth leading cause, accounting for 2.7% of 
the total.  Comparatively, the principal source of disease burden was 
lower respiratory tract infections, which constituted only a slightly higher 
6.2% of all DALYs.  
Following trauma, patients may not only be affected with physical 
impairments but may also suffer from psychological disorders.  Injured 
individuals may experience dramatic changes in their social 
circumstances, with an inability to return to work, thereby incurring 
financial difficulties.  Others may have problems integrating back into 
society.  
The detrimental aftermaths of injury are not solely limited to the trauma 
patient.  Family and friends may become permanent carers for those with 
disabilities and may have to dramatically alter their own lifestyles.   
Patients may experience behavioural and mood changes and pose risks to 
themselves or others, which in turn can result in breakdown of 
relationships and family. 
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1.1.2 The Financial Burden of Trauma 
The management of trauma is very expensive and represents a serious 
fiscal strain to healthcare providers, individuals concerned and society 
alike.  Studies have estimated that in the National Health Service (NHS), 
the mean hospital cost of a blunt trauma patient is £9,530 (Christensen et 
al., 2008b), whilst that of an individual with penetrating injury is £7,983 
(Christensen et al., 2008a).  National Audit Office (NAO) figures place 
estimated NHS expenditure of complex trauma management around £0.3-
0.4 billion annually (NAO, 2010).  Although harder to calculate, the NAO 
further states that the loss of economic output caused by major trauma 
could be up to £3.7 billion.  
According to data describing the financial burden of trauma in the United 
States (US), for example, the cost of 50 million injuries in the year 2000 
alone was $406 billion (Finkelstein et al., 2006).  In terms of productive 
years lost, therefore, trauma in the US now surpasses any other disease 
and represents the most expensive category of medical treatment. 
1.1.3 Trauma and Research 
In spite of the global impact of trauma, it remains a field characterised by 
a lack of evidence-based practice.  This is fundamentally due to a relative 
paucity of research. 
Both the Rand report in the UK (Morgan Jones et al., 2011) and the 
National Trauma Institute in the US have recently highlighted that trauma 
remains a poorly recognised public health problem with 
disproportionately low investments into research.  The Rand report 
concluded that less than one percent of the total UK public expenditure on 
health research is allotted to trauma.  Whilst in the US, in terms of 
potential life years lost (defined by the millions of dollars per years of 
potential life lost per 100,000 population), the National Institutes of Health 
(NIH) support ratio for trauma is only 10 cents, contrasted with US $3.51 
for HIV and US $1.65 for cancer.  Indeed the total 2008 NIH budget 
allocation for traumatic injury research was $308 million, compared to a 
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cancer research allowance of $5.6 billion and an HIV/Aids provision of 
$2.9 billion (National Trauma Institute, 2010).   
In addition to poor funding, trauma remains a challenging field in which 
to undertake clinical research given that there are difficulties in enrolling 
patients who may present in physiological extremis, and outside 
traditional working hours.  This is further compounded by the problems 
associated in obtaining consent in patients who may be unconscious, 
distressed or lacking capacity. 
Consequently, not only is the overall volume of research in trauma 
limited, but the specific clinical fields investigated within the specialty are 
narrow. 
1.1.4 Trauma Associated Cardiac Injury and Dysfunction 
The heart is one of the body’s vital organs, yet there exists little evidence 
on the relationship between it and trauma.  To date, most of the literature 
on the interaction between trauma and the heart has been limited to 
studies of direct cardiac injury (Section 1.3).  Much of this evidence is 
restricted to individual clinical reports or case series. 
Indirect, secondary cardiac injury remains a relatively unexplored clinical 
phenomenon (Section 1.5), despite the fact that it has been reported in the 
non-trauma literature, and demonstrated in experimental studies of 
trauma-haemorrhage (Section 1.4).  A trauma induced secondary cardiac 
injury (TISCI) has neither been specifically identified, nor fully 
characterised even though it may have important clinical implications in 
injured patients and their outcomes. 
There also remains inconclusive evidence on both the overall incidence of 
pre-morbid cardiac disease in trauma together with its influence of on 
outcome, and particularly survival (Section 1.8). 
The overall aim of this project, therefore, was to provide further 
evidence and clarification on the relationship between trauma and the 
heart; a neglected, important and novel area for research. 
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1.2 Characteristics of Trauma  
In civilian trauma, young males are most often affected and a blunt 
mechanism of injury predominates.  In the UK, falls are the commonest 
cause of trauma (Figure 1.1).  Naturally, specific characteristics vary 
between each country.  
  
Figure 1.1.  A summary of trauma in England and Wales from 2002 to 
2011 
Blow includes blunt assaults, Others relate to injuries sustained following 
industrial and farming accidents, for example.  (Data courtesy of the Trauma 
Audit & Research Network). 
1.2.1 Measuring Injury Severity 
The extent of overall injury is classified by the injury severity score (ISS), 
an anatomical scoring system.  The body is divided into six regions (head 
and neck, face, chest, abdomen, extremity and external) and each area is 
ascribed an abbreviated injury score, the AIS, from 0 to 6 (Table 1.1).   
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Table 1.1.  AIS Scores Illustrated with Examples of Chest Injury 
AIS Severity of Injury Examples 
0 None Not applicable 
1 Minor Rib fractures at any location (unilateral/bilateral) 
with no flail segment 
2 Moderate Sternal fracture 
3 Serious Unilateral lung contusion or haemothorax 
4 Severe Haemothorax with >20% circulating volume loss 
5 Critical Tension pneumothorax or laryngeal/tracheal 
separation 
6 Unsurvivable Heart avulsion  
 
1.2.2 The Epidemiology of Death in Trauma 
The majority of deaths in trauma occur early, either in the pre-hospital 
phase or in the acute period following arrival to hospital (Evans et al., 
2009, Cothren et al., 2007).  Most of these fatalities are the result of central 
nervous system injury.  Thereafter, exsanguination is the second leading 
cause (Chalkley et al., 2011, Søreide et al., 2007).  In patients admitted to 
hospital, multiple organ dysfunction syndrome (MODS) is the major cause 
of late death, especially amongst those in critical care (Sauaia et al., 1995, 
Ciesla et al., 2005).  Currently, however, neither the extent nor the clinical 
relevance of cardiac dysfunction in post-traumatic MODS is known. 
Following discharge, trauma patients’ risk of death is approximately twice 
as high as age and sex matched uninjured cohorts for up to ten years post 
injury (Cameron et al., 2005, Davidson et al., 2011).  Cardiovascular 
disease may account for nearly 25% of these deaths (Probst et al., 2009), 
and is also more common in patients suffering from post-traumatic stress 
disorder (Bedi et al., 2007).  This suggests that trauma could be linked to 
secondary cardiac dysfunction associated with poorer long-term survival.   
However, the relationship between injury and the heart is poorly 
understood at present.  There is a need, therefore, for research on the 
theme of trauma associated cardiac injury and dysfunction.  
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1.3 Direct Cardiac Injury 
Direct cardiac injury is primary cardiac damage.  It is the result of either 
penetrating or blunt physical trauma directly to the thorax and heart.  
1.3.1 Penetrating Cardiac Injury 
Penetrating cardiac injuries are associated with very high mortality rates, 
and are usually the result of stab or gun shot wounds (Tang et al., 2011).  
The heart chamber most commonly affected is the right ventricle, followed 
by the left ventricle (Asensio et al., 1998).  Combinations of injuries may 
occur, and the treatment of penetrating cardiac trauma is usually surgical. 
1.3.2 Blunt Cardiac Injury 
Blunt cardiac injury (BCI) is a term used to encompass a range of 
pathologies.  These include myocardial contusions, atrial and ventricular 
septal defects (Figure 1.2 A&B), valve and coronary artery damage and 
cardiac rupture.  They are often accompanied by trauma to additional 
areas, including other thoracic structures, the head, abdomen, spine and 
the extremities. 
The leading cause of BCI is an RTA, followed by falls from height.  The 
right side of the heart is most frequently damaged (Turan et al., 2010).   
There are several mechanisms implicated in leading to BCI.  These include 
direct praecordial impact with subsequent transmission of kinetic energy 
to the heart, and sudden deceleration leading to cardiac disruption.  In 
addition, crush injury from compression of the organ between the spine 
and sternum, and sudden rises in intra-thoracic pressure due to 
compression of the abdomen or lower extremities have all been implicated 
(Schultz et al., 2004).  
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Figure 1.2. A&B.  Traumatic ventricular septal resulting from blunt 
thoracic injury 
A:  View of the defect.  B:  Photograph of bovine patch parachuted into place to 
seal the defect (images taken during open cardiothoracic repair). 
The commonest BCIs are myocardial contusions.  Their precise incidence 
is unknown, however, as there exists no standard global consensus on 
their diagnostic criteria.  In addition, because the clinical significance of 
contusions remains contentious, some clinicians may not always actively 
seek to detect their presence. 
The presentation of BCI is variable, and dependent both on the nature and 
location of the injuries (Shorr et al., 1987).  Myocardial contusions may 
present silently, or alternatively may lead to arrhythmias (Guan et al., 
2007, Riezzo et al., 2008).  Cardiac ruptures are usually fatal and 
diagnosed during postmortem examination.   
Other manifestations of BCI include evidence of cardiac ischaemia or 
dysfunction, including arrhythmias (Ismailov et al., 2007), heart failure 
and cardiogenic shock.   
A B 
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The presentation of BCI may be delayed (Sakka et al., 2000) and lead to 
chronic health problems.   
Limited evidence from a handful of patients has suggested that 
myocardial injury may lead to potentially fatal arrhythmias even up to a 
year after the initial traumatic event (Amino et al., 2009).  Indeed, there is 
research to suggest that BCI associated with valvular insufficiency could 
be a potential risk factor for congestive heart failure in the long-term 
(Ismailov et al., 2005). 
The basis for diagnosis of BCI is the subject of ongoing debate.  
Electrocardiographic (ECG) findings are both variable and non-specific, 
and may include sinus tachycardia, conduction defects, bundle branch 
blocks or evidence of global ischaemia (Babu et al., 2009).  Cardiac 
biomarkers are helpful, particularly in the diagnosis of contusion, and the 
evidence currently favours the use of Troponin (primarily T and I) (Peter 
et al., 2006, Sybrandy et al., 2003). 
Echocardiography may facilitate the diagnosis of BCI, and is useful in 
assessing cardiac function.  A transoesophageal approach may be of value 
when transthoracic images are suboptimal (Karalis et al., 1994).  More 
recently, there is mounting evidence that cardiac magnetic resonance 
imaging (MRI) may provide the most detailed assessments of cardiac 
function and morphology following blunt chest trauma (Dellegrottaglie et 
al., 2008). 
The treatment of BCI is predominantly based on direct management of the 
complications that may arise, such as arrhythmias or heart failure. 
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1.4 Indirect, Secondary Cardiac Injury – The Experimental 
Evidence  
Post-traumatic secondary cardiac injury is the development of cardiac 
injury or dysfunction in the absence of direct trauma to the heart.   
1.4.1 Experimental Evidence of Post-traumatic Secondary Cardiac 
Injury  
The majority of evidence to suggest that trauma can lead to secondary 
cardiac injury and dysfunction has been presented in animal studies of 
experimental trauma-haemorrhage.  Most of the published literature has 
focused on research in rodents. 
One unit that has been notably active in this field is the centre led by Dr I 
H Chaudry, at the University of Alabama in the US.  The group have not 
only sought to determine the pathogenic processes that lead to post-
traumatic secondary cardiac injury, but also to identify mechanisms that 
may mitigate such damage to the heart.   
To replicate the clinical scenario of soft tissue trauma with blood loss and 
associated hypotension, both this unit and others have based their 
research on variations of the following methodology.  A laparotomy 
incision is combined with controlled haemorrhage (through cannulated 
femoral arteries) until a mean arterial pressure (MAP) of 35 +/- 5 mmHg 
is achieved.  When the animals can no longer maintain this pressure, 
Ringer’s lactate is given until 40% of the volume bled out is returned.  
Thereafter, animals are resuscitated with shed blood, and eventually 
euthanised at varying time points following the experiments. 
Using this methodology, studies have demonstrated that cardiac 
dysfunction occurs within two hours (hrs) of trauma-haemorrhage, and 
may remain 24 hrs thereafter.  Cardiac output, stroke volume and positive 
and negative dP/dt (an index of ventricular performance) are all 
diminished following soft tissue injury and haemorrhage, whilst total 
peripheral resistance is amplified (Yang et al., 2007).   
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Interleukin 6 (IL-6) is an inflammatory cytokine produced by several cells 
including monocytes, T and B lymphocytes, fibroblasts, endothelial cells, 
neutrophils, macrophages and cardiomyocytes.  Secondary cardiac 
dysfunction following trauma-haemorrhage may be associated with 
increases in both plasma and cardiac IL-6 (Yang et al., 2004), as well as 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
intercellular adhesion molecule 1 (ICAM-1), myeloperoxidase (MPO) 
activity, and cytokine-induced neutrophil chemoattractant (CINC) 1 and 3 
amongst others (Yang et al., 2006).  CINC 1 and 3 belong to the interleukin 
8 (IL-8) family, which are in turn produced by a variety of cells including 
monocytes, T lymphocytes and macrophages.  These proteins are all 
potent chemotactic factors for neutrophils.  
Blockade of IL-6 with antagonists leads to diminished levels and activities 
of the molecules described above, implicating inflammation, and IL-6 in 
particular, in secondary cardiac dysfunction induced by trauma-
haemorrhage.  
Non-lethal mechanical trauma has also been shown to induce the 
production of tumour necrosis factor alpha (TNFα), an inflammatory 
cytokine produced primarily by macrophages.  When normal 
cardiomyocytes are exposed to TNFα in the plasma from animals subject 
to such injury, increased activation of caspase-3 (a marker of apoptosis) 
was seen (Li et al., 2007).  In association, amplification of inducible nitric 
oxide synthase (iNOS) expression with nitric oxide (NO) and superoxide 
production occurs.  Decreased adiponectin (an anti-inflammatory 
adipokine) concentrations are also observed (Liu et al., 2011).  In these 
models, cardiomyocyte apoptosis is related to cardiac dysfunction, and 
this may be reversed when apoptosis is blocked (Tao et al., 2005). 
The inhibition of TNFα may lead to reduction of this cellular apoptosis 
and further limit the expression of iNOS, the overproduction of NO and 
superoxide and the excessive protein nitration in the heart (Li et al., 2007).  
Additionally, adiponectin levels may be restored with subsequent 
attenuation of cardiac ischaemia-reperfusion injury.   
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Haemorrhagic shock alone may lead to an increase in cardiac TNFα in 
mice within an hour of resuscitation, and this is associated with left 
ventricular dysfunction within six hours (Vallejo et al., 2004).  Importantly, 
the failure to restore cardiac systolic function, including blood pressure, 
may be a major determinant of mortality (Chatpun et al., 2011).  Following 
haemorrhage, the phosphorylation of p38 mitogen-activated protein 
kinase (p38 MAPK) in the heart is also associated with increased TNFα 
messenger RNA expression.  The activation of p38 MAPK is in turn linked 
to subsequent ventricular arrhythmias, and microscopic inflammatory 
damage to the heart, including neutrophil accumulation (Sato et al., 2007).  
When haemorrhagic shock and ventricular fibrillation (VF) are induced in 
pigs, and followed by resuscitation, female animals manifest lower 
evidence of cardiac injury (lower Troponin I levels) and higher survival 
rates compared to males (Semenas et al., 2010).  Although demonstrated in 
this study of sexually immature piglets with similar hormone levels across 
the sexes, there is a bulk of convincing evidence that the female gender 
confers protection to the heart against post-traumatic secondary injury 
(Yang et al., 2006, Wang et al., 2005).   
Research suggests a principal mechanism is the attenuation of the 
inflammatory response by oestrogen.  The administration of 17β-
oestradiol after trauma-haemorrhage has been shown to restore cardiac 
function and reduce injury to the heart.  17β-oestradiol is believed to 
mediate its cardioprotective effects mainly through cardiac ER-β receptors 
(Ba et al., 2008), and the specific pathways through which its effects are 
exerted are the subject of multiple studies (Yu et al., 2007).  
One such mechanism suggested is the upregulation of p38 MAPK 
activation, together with increased endothelial NOS expression in the 
heart (Kan et al., 2008).  Other studies have also shown the administration 
of 17β-oestradiol prevents increases in plasma IL-6, TNFα, CINC-1 and 
ICAM-1, and improved cardiac performance results (Mizushima et al., 
2000a). 
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Another proposed mechanism for the cardioprotective role of oestrogen is 
via the hypoxia-inducible factor (HIF) 1α pathway.  HIF-1 α is a protein 
complex which is expressed in response to hypoxia and cellular stress and 
it is found in higher levels in the heart following trauma-haemorrhage.  It 
increases vascularisation of hypoxic areas and upregulates expression of 
IL-6.   
Administration of both oestrogen and HIF-1α inhibitors has been shown 
to reduce cardiac levels of molecules implicated in cardiac damage.  These 
include IL-6, HIF-1α and NF-κB (Nickel et al., 2009).   
The administration of 17β-oestradiol has been shown to improve cardiac 
performance and normalise cardiac and systemic levels of IL-6 and TNFα, 
together with several cardiac chemokines including MPO, ICAM-1, CINC-
1.  This action may also be the result of the upregulation of heme 
oxygenase 1, a heat shock protein (Hsu et al., 2009).  Heat shock proteins 
(hsp) provide cellular protection against exogenous stress and the 
upregulation of others including hsp 32, 60, 70, and 90 has also been 
shown following 17β-oestradiol administration, with a subsequent 
cardioprotective effect (Yu et al., 2006).  Similarly, cellular stress prior to 
trauma-haemorrhage leads to the induction of hsp 70, and diminished 
plasma TNFα levels and improved cardiac function may result 
(Mizushima et al., 2000b, Meng et al., 2002). 
A small number of further studies have examined the roles of additional 
hormones such as Flutamide (Hsieh et al., 2005a, Hsieh et al., 2005b) and 
others (Shimizu et al., 2006) in trauma-haemorrhage models.  All have 
repeatedly demonstrated secondary cardiac injury and dysfunction 
following soft tissue injury and haemorrhage, and have also implicated 
inflammation in the process.  
Additional mechanisms in post-traumatic secondary cardiac injury and 
dysfunction have also been proposed.  These include gut-induced cardiac 
dysfunction in association with abnormalities of calcium handling 
(Sambol et al., 2008, Lee et al., 2008).   
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Furthermore, the importance of mitochondria has been highlighted (Jian et 
al., 2011), and both the upregulation and improvement of their function 
are suggested to be cardioprotective following trauma-haemorrhage 
(Hsieh et al., 2006, Jian et al., 2012).   
Similarly, increased tissue levels of O-linked N-acetylglucosamine (O-
GlcNAc) may improve cardiac function and diminish TNFα and IL-6 
mRNA levels, NF-κB and NF-κB DNA binding and ICAM-1, and MPO 
activity in the heart (Zou et al., 2007, Zou et al., 2008). 
In general, the experimental evidence establishes the existence of an 
acquired secondary cardiac injury and dysfunction in animal models of 
trauma and haemorrhage.  The studies demonstrate that cytokines and 
inflammation lead to functional rather than structural changes in the 
heart.  These result in decreased contractility and myocardial depression 
mediated by endogenously produced pro-inflammatory factors.  They also 
generate cardiomyocyte injury and apoptosis through oxidative and 
nitrative stresses.  This in turn may further compound cardiac 
dysfunction.   
Inhibition of inflammation and pro-inflammatory factors may normalise 
cardiac function and reduce the extent of injury to the heart.  Indeed, there 
is evidence that anti-inflammatory resuscitation may confer a survival 
benefit, but whether this is due to an improvement in cardiac function has 
not been proven (Cai et al., 2009). 
1.4.2 Limitations and Applicability of the Experimental Evidence  
The experimental literature presents convincing evidence that tissue 
injury and haemorrhage may lead to secondary cardiac injury and 
dysfunction.   
The studies have combined histological analysis of heart tissue complete 
with assessments of cardiac function to provide confirmation of indirect 
injury to the heart resulting from trauma and blood loss.  They 
demonstrate that acquired myocardial dysfunction occurs in the absence 
of pre-existing, intrinsic cardiac disease.  
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There are, however, restrictions to the experimental studies which limit 
both their applicability and their relevance to the clinical setting.   
Trials are designed to create damage to the heart, leading to artificial and 
prescribed scenarios that are not reflective of the true clinical context in 
which trauma patients are observed and managed.  Secondary cardiac 
injury and dysfunction are observed because they are the actively desired 
product of the research methodology.   
In these studies, the animals are severely traumatised and shocked 
artificially, usually with an identical mechanism of injury and the same 
degree of physiological shock.  Consequently, it is difficult to draw 
conclusions from the experimental evidence and apply them to whole 
trauma populations, who present with a very wide variety of injuries and 
a broad spectrum of physiological derangement. 
Furthermore, physiological traits are not comprehensively reported and 
ISS is not measured in animal tests.  As such, these studies fail to identify 
or even to suggest those patients at risk of secondary cardiac injury 
outside of those who are severely injured and shocked.   
Moreover, all creatures are euthanised after the experiments at designated 
time points.  Clinical outcomes of secondary cardiac injury and 
dysfunction can therefore seldom be identified, especially if these include 
aspects commonly reported in the clinical literature such as length of stay 
or in-hospital mortality.  In addition, the experiments themselves are 
limited to small numbers of animals, which potentially undermine the 
statistical power of their findings.   
One centre has dominated the literature, so evidence lacks validation from 
multiple units reporting additional varied experiments in this field. 
Finally, the experimental literature is not directly translational to clinical 
practice.  The animals are not exposed to the same degree and nature of 
interventions as trauma patients are, including medication, procedures, 
multiple operations and superimposed factors such as infection.  The 
effects these have on the human heart are therefore inevitably neglected.   
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Most of the studies are performed in rodents, which make results poorly 
comparable to humans.  Animals are young and healthy, and do not suffer 
co-morbidity or poor background physiology (e.g. due to age, smoking, 
alcohol excess or obesity).  This further limits the applicability of the 
experimental evidence to the clinical context.  
Clinical evidence is required, therefore, to substantiate the findings of the 
animal model experiments. 
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1.5 Indirect, Secondary Cardiac Injury – The Clinical 
Evidence 
There are few clinical studies investigating the relationship between 
trauma and secondary cardiac injury and dysfunction.  Those in existence 
can be divided broadly into two categories.  The first are studies that have 
demonstrated cardiac damage through clinical manifestations (such as 
adverse cardiac events or histological evidence, Section 1.5.1).  The second 
are those that have demonstrated injury to the heart using cardiac 
biomarkers (Section 1.5.2). 
1.5.1 Post-Traumatic Secondary Cardiac Injury and Clinical 
Manifestations  
Perhaps the earliest published evidence to suggest that the heart is 
susceptible to post-traumatic secondary cardiac injury was presented as 
far back as 1922.  Cardiac rupture was described in an individual who 
sustained a crush injury to the abdomen, in spite of the absence of trauma 
to the thorax (Stephens, 1922).  In 1933, postmortem descriptions of heart 
rupture without chest wall injury were presented, and a mechanism of 
increased intravascular hydrostatic pressure due to compression of the 
legs and abdomen was proposed (Beck et al., 1933).  Subsequently, an 
isolated study of traumatic heart disease found no relationship between 
the severity of thoracic trauma with the incidence of cardiac injury 
(Arenberg, 1943). 
Thereafter followed a relative hiatus of research in this field, and only a 
handful of studies have since investigated the specific relationship 
between trauma and indirect, secondary cardiac injury and dysfunction.   
Amongst the first was a postmortem survey which revealed secondary 
myocardial lesions in the victims of homicide (Cebelin et al., 1980).  In the 
analysis, coroners’ records of 15 patients were examined whereby death 
followed assault, but no trauma to the brain, the viscera or any significant 
bone fractures were present. 
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Microscopic examination of the hearts revealed the majority of individuals 
had myofibrillar degeneration, namely scattered clusters of myocytes with 
homogeneous eosinophilic transverse bands alternating with areas of fine 
granulation.  Moreover contraction bands were observed, a process 
whereby hypercontraction (secondary to catecholamine surges) of the 
cardiac muscle leads to structureless masses of contractile protein.  
Accordingly, the data presented provided good evidence of post-
traumatic secondary cardiac injury, and suggested that such heart damage 
was the result of the cardiotoxic effect of catecholamines.  
Nonetheless, this study was prone to weaknesses including its 
retrospective nature and small study population.  By virtue of postmortem 
data, these findings could not be translated to living patients, and 
microscopic evidence of cardiac injury is of uncertain clinical significance.  
Because neither the degree of injury severity nor physiological 
derangement prior to death was detailed, those at risk of secondary 
cardiac injury could not be deduced from this work.   
Finally, 53% (n=8/15) of the study subjects had pre-existing heart disease.  
To accommodate for this a control group was created and included 
patients who died pre-hospital with atherosclerotic disease.  These 
individuals demonstrated no such changes in their myocardium.  They 
did not receive resuscitation in hospital, however.  Hence they neither 
were directly comparable, nor excluded the possibility that pre-morbid 
heart disease was the underlying cause of the post-traumatic secondary 
cardiac injury observed. 
In spite of these limitations, the findings of this study were reinforced by 
later work in pathology, which demonstrated similar myocardial lesions 
induced by trauma and its subsequent treatment (Yoshida et al., 1992).  In 
addition to contraction bands, varying concentrations of calmodulin (a 
marker of early cardiac ischaemia) were present in the hearts of dead 
patients who had been subject to severe injury followed by attempts at 
resuscitation.   
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This marker was observed despite in many cases an absence of 
macroscopic cardiac damage.  In this particular analysis, however, chest 
injury and cardiac damage were not identified independently. 
An earlier cohort study of some 2,820 individuals revealed that critical 
illness was associated with an increase in cardiac arrhythmias (Artucio et 
al., 1990).   
Severely injured patients accounted for four percent of the population, 
and nearly half of these had a cardiac arrhythmia (44%).  Atrial 
tachyarrhythmias were the most common, and occurred in ten percent of 
the trauma patients.  Of these, atrial fibrillation (AF) was the most 
frequent diagnosis.  In addition, ventricular arrhythmias, nodal rhythms, 
atrial bradyarrhythmias and conduction defects were also observed.  More 
than half the trauma patients with cardiac arrhythmias died, but rhythm 
disturbances were not significantly associated with death. 
This study was among the earliest to describe cardiac arrhythmias in a 
trauma population, and revealed that the incidence of such disorders was 
high.  Nonetheless, the analysis was retrospective, and because the 
research was not solely dedicated to trauma, the actual injured population 
included was relatively small (107 patients).   
Furthermore, in the absence of detail on patient characteristics such as the 
ISS and the extent of thoracic injury, no conclusions could be drawn on 
whether these arrhythmias were manifestations of secondary cardiac 
injury and dysfunction.  Finally, although the study revealed that cardiac 
arrhythmias were not associated with a higher risk of death, the authors 
themselves acknowledge that the study was not designed to establish the 
outcomes associated with such rhythm disturbances. 
A decade later, the link between trauma and myocardial infarction (MI) 
was investigated in a single centre, retrospective database analysis 
(Moosikasuwan et al., 2000).  Of the 11,866 injured patients identified over 
a period of nearly ten years, nineteen (0.16%) were diagnosed with an MI.  
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In five (0.04%) of these individuals, the MI occurred definitively post-
injury. 
This led the authors to conclude that trauma may predispose patients to 
an increase in adverse cardiac events (ACEs).  
The study was nonetheless subject to a number of limitations.  In the first 
instance, the research investigated only one diagnosis, namely MI, and did 
not establish the incidence of a wider range of ACEs, such as arrhythmias 
or bundle branch blocks for example.  Because of its retrospective nature 
and the use of a database to ascertain events, it is likely that the authors 
also underestimated the true incidence of MI following trauma.  Only 
0.16% of the study population had an MI despite the fact that the national 
incidence of MI in the US is around 2.7% (Roger et al., 2012).  All the 
patients in whom an MI was diagnosed were older, and each had risk 
factors for developing cardiovascular events, including pre-existing heart 
disease.  Two (40%) of the patients also sustained significant chest injuries.   
The number of individuals reported was very small, with insufficient 
detail about injury and physiology characteristics.  Accordingly, the study 
suggested more that injury predisposes to cardiac events in older frailer 
patients with pre-existing heart disease, and rather less that trauma may 
lead to secondary cardiac injury. 
A small case-control study published in 2003 investigated the incidence of 
cardiac events following burns.  Trauma patients, matched for age, sex 
and length of hospital stay were used as the control group (Meyers et al., 
2003).  Although the authors found that burns patient were at an increased 
predisposition to cardiac events, trauma patients, in contrast, were not.  In 
56 injured individuals, there were no cases of MI, and only one of 
ventricular tachycardia.  Three instances of premature ventricular beats 
and 12 cases of sinus tachycardia (ST) were also recorded.  Accordingly, 
the study provided no supporting evidence for the existence of trauma 
induced secondary cardiac injury or dysfunction.   
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Little detail, however, is provided about these injured patients thereby 
making it difficult to interpret the paper’s findings in the wider trauma 
context.   
Being retrospective in nature, the authors acknowledge they may have 
underestimated the incidence of cardiac events, and in particular brief 
spells of arrhythmia.  The research was also further limited by its 
relatively small study population. 
In contrast, a link between trauma and secondary cardiac injury and 
dysfunction was presented in an American retrospective review of a 
million injured patients (Ismailov et al., 2005).  Data from 19 states were 
examined to identify the nature of injuries associated with the risk of 
developing an acute MI, based on the International Classification of 
Diseases - Ninth Revision-Clinical Modification (ICD-9-CM) discharge 
diagnosis codes.   
Of some 1,051,081 injury discharges, 32,616 (3.10%) acute MIs were 
diagnosed.  The study revealed blunt chest trauma was associated with an 
increased risk of MI.  More significantly, the authors demonstrated that 
abdominal or pelvic trauma led to a 65% (Odds Ratio [OR] 1.65, 95% 
Confidence Intervals [95% CI] 1.26-2.16) increase in the risk of acute MI in 
patients below the age of 46 years, regardless of confounders or coronary 
artery status.   
In patients over the age of 46 years, abdominal or pelvic trauma alone 
nearly doubled the risk of acute MI (OR 1.93, 95% CI 1.42-2.62).  When the 
diagnosis was confirmed by coronary angiography, the risk of MI was six 
times greater (OR 6.33, 95% CI 4.00-9.99). 
This landmark study was the first large-scale analysis to demonstrate that 
trauma could be a non-atherosclerotic mechanism that could lead to MI.  It 
provided good evidence that trauma may be associated with secondary 
cardiac damage, independent of the severity of thoracic injury.  It also 
implied that previous investigations of cardiac events in trauma 
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(Moosikasuwan et al., 2000) had significantly underestimated the 
incidence of MI in injured populations.   
Conversely, this study was limited to analysing discharge codes for 
diagnoses, and was essentially retrospective in nature.   
It too was therefore subject to potential under-reporting of cardiac events 
and data inaccuracies.  Such methodology also meant that neither 
individual patient characteristics nor specific risk factors for post-
traumatic MI were identified.   
It is also worth noting that when the diagnosis of MI was confirmed by 
coronary angiography in patients under the ages of 46 years, abdominal 
and pelvic trauma was no longer a significant risk factor when adjusted 
for using logistic regression (OR 0.88, 95% CI 0.21-3.76).  The study only 
investigated the dependent variable of MI, but did not look at the nature 
and features of other ACEs.  It was also not clear whether skull fractures, 
intracranial injuries, and extremity trauma were excluded, thus restricting 
the applicability of the findings to a specific subset of injured patients 
only.  The final limitation of the study is that the authors did not examine 
and compare the outcomes of trauma patients with and without MI, and 
so whilst they demonstrated the possible existence of post-traumatic 
secondary cardiac injury, they did not reveal the clinical significance of it. 
A later French paper reported the incidence and risk factors associated 
with AF in injured patients on a surgical intensive care unit (ICU) (Seguin 
et al., 2006).  Over an 18 month period, 293 patients were prospectively 
recruited, of which 16 (5.5%) developed AF.   
Risk factors for AF were identified using logistic regression analysis and 
included age over 40 years (OR 6.3, 95% CI 1.4-28.7), three or more body 
regions injured (OR 6.2, 95% CI 1.8-21.4), catecholamine use (OR 5.7, 95% 
CI 1.7-19.1), the presence of systemic inflammatory response syndrome 
(SIRS) (OR 4.4, 95% CI 1.2-16.1) and finally the degree of physiological 
derangement using the Simplified Acute Physiology Score II (OR 11.6, 
95% CI 1.3-10.3).   
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Although AF was associated with twice the death rate, this was not found 
to be statistically significant.  ICU length of stay was longer in the AF 
cohort. 
This study was not only the first to investigate AF specifically in trauma 
patients, but also to be undertaken prospectively.  As such, it provided 
data on risk factors for AF, and described the outcomes associated with 
this cardiac event.  This was also the first clinical paper to hint indirectly at 
a relationship between a post-traumatic secondary cardiac event and 
inflammation, through the association of AF with factors known to cause 
or result from inflammation. 
In contrast to their previous research (Seguin et al., 2004), this analysis 
demonstrated that AF was not associated with thoracic injury, and hence 
provided further evidence that trauma may cause secondary damage to 
the heart.  These conflicting results might be explained by the fact that the 
authors’ previous investigation in 2004 examined AF in a heterogeneous 
population of patients on ITU.  It was thus not specific to trauma patients 
(who accounted for 34% of the study with only 1% developing AF).  
Moreover, in their prior analysis blunt thoracic trauma was the only 
variable measured. 
Nonetheless, there were limitations to the more recent dedicated trauma 
study of 2006.  Again only one ACE was investigated despite previous 
evidence that trauma may also lead to MI.  The research was conducted in 
a specific cohort of patients, namely the critically injured, and thus the 
overall incidence and risk factors associated with secondary cardiac injury 
in all types of trauma populations was not identified.  Finally, given the 
wide confidence intervals produced by the logistic regression model, it 
may be that this study was underpowered and included too few numbers 
of patients.  This may have led to inaccurate results. 
Atrial arrhythmias (AA) were the subject of a retrospective study of 3,499 
critically injured patients on an American ICU (Hadjizacharia et al., 2011). 
AA were present in roughly six percent of their population (n=210).   
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In this analysis the only independent risk factor for developing an 
arrhythmia was age over 55 years (OR 4.61, 95% CI 3.44-6.17).  AA were 
associated with poorer outcomes, including higher mortality (OR 2.24, 
95% CI 1.50-3.33), longer lengths of hospital and ITU stay, and more days 
spent on a ventilator.  Patients with AA on beta-blockers had lower 
mortality (OR 0.41, 95% CI: 0.17-0.91).   
Again this study suggested the existence of trauma associated cardiac 
dysfunction and in this instance, its association with worse outcomes.  No 
relationship was found between AA and chest trauma, although the 
authors did not state that this was clearly adjusted for in a regression 
model.  The study was also weakened by its retrospective nature, the 
investigation of solely one category of ACE (AA) and once again 
restricting the analysis to critically injured patients only. 
Remarkably, all of the studies described above are also limited by the fact 
that none have attempted to substantiate further the presence of 
secondary cardiac dysfunction with biochemical evidence of heart injury.   
The use of cardiac specific biomarkers is common both in clinical practice 
and research in predominantly medical specialties.  In trauma, cardiac 
biomarkers have primarily been investigated in the context of BCI, and 
only a handful of studies have investigated their applicability in 
determining the secondary effects of trauma on the heart. 
1.5.2 Post-Traumatic Secondary Cardiac Injury and Cardiac 
Biomarkers 
1.5.2.1  Brain-type Natriuretic Peptide 
BNP is a cardiac neurohormone synthesised and secreted by the ventricles 
of the heart.  It is released as the precursor molecule pre-prohormone 
BNP, and is subsequently cleaved by proteolysis into proBNP (108 amino 
acids) and a signal peptide (26 amino acids).  Thereafter, proBNP is split 
into BNP (32 amino acids) and the inactive N-terminal fragment 
prohormone BNP peptide (NT-proBNP, 76 amino acids).   
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BNP is released in response to excessive stretching of cardiomyocytes.  It 
causes a decrease in peripheral vascular resistance leading to a reduction 
in blood pressure (Figure 1.3).  BNP suppresses the renin-angiotensin-
aldosterone axis and leads to natriuresis (Levin et al., 1998). 
 
 
Figure 1.3.  The action of BNP 
Traditionally, BNP has been used as marker of cardiac failure.  
Increasingly, however, it is being recognised as an indicator of myocardial 
dysfunction and injury in a variety of disease states.  Evidence has 
demonstrated its prognostic value in terms of predicting both ACEs and 
survival in non-traumatic conditions (Post et al., 2008, Meyer et al., 2007, 
Choi et al., 2009, Charpentier et al., 2004, Kistorp et al., 2005).   
In trauma patients, BNP been shown to be elevated in the absence of 
echocardiographic evidence of congestive heart failure, with release 
unrelated to head injury (Stewart et al., 2007).  Less convincing data has 
also suggested a relationship between increasing BNP levels and volume 
overload (Friese et al., 2007).   
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Indeed a very weak pattern of association between lower biomarker 
values and blood loss has been proposed (Kia et al., 2006). 
In a prospective study of 26 multiply injured patients, an inverse 
relationship was established between NT-proBNP and cardiac index 
(Kirchhoff et al., 2008).   
The biomarker was measured at six time points between admission and 72 
hrs.  All the patients had rises in NT-proBNP, and levels were significantly 
correlated with MODS.  This data suggested that NT-proBNP may be 
valuable in evaluations of cardiac impairment, and might indicate the 
severity and prognosis of MODS in the trauma setting. 
Nonetheless, the findings were from a very small pilot study of critically 
injured patients.  Individuals with head injuries and pre-existing heart 
disease were excluded.  Consequently, the findings of this research were 
not directly translational to whole trauma populations given that these are 
by definition very heterogeneous in nature. 
1.5.2.2  Troponin I 
Troponin is found in skeletal and cardiac muscle and is made up of three 
subunits, Troponin C, Troponin T and Troponin I. 
Troponin C binds with calcium to produce changes in Troponin I.  
Troponin T and I are cardiac regulatory proteins that control the 
interactions between actin and myosin (Sharma et al., 2004).  Troponin I 
inhibits the formation of bridges between actin and myosin in the resting 
state, and is highly specific to the heart (Figure 1.4). 
Plasma elevations of Troponin I reflect damage to the heart but do not 
indicate the mechanism (Babuin et al., 2005).  Raised levels have 
demonstrated cardiac injury in a number of disease states (Adams et al., 
1993, Lim et al., 2006).   
Troponin I has also been shown to be of prognostic value, predicting both 
future ACEs and death in a variety of clinical settings (Wu et al., 2004, 
Quenot et al., 2005, King et al., 2005, Kim et al., 2002, Chong et al., 2008).   
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Figure 1.4.  The cardiac sarcomere during diastole and systole   
A.  Troponin I inhibits the binding of myosin to actin in the relaxed state 
(diastole).  B.  When Troponin C binds with calcium, this inhibition is cancelled 
and Tropomyosin settles between two grooves of actin to enable myosin binding, 
leading to shortening of the sarcomere and contraction of muscle (systole), 
TnT=Troponin T, TnC=Troponin C, TnI=Troponin I (Modified from Hamdani et 
al., 2008, with permission).  
The first study to investigate secondary cardiac injury in trauma using 
Troponin I was a prospective analysis on a French ICU of young critically 
injured individuals (Edouard et al., 1998).  Patients with a history of pre-
existing cardiovascular disease were excluded.  Six (35%) of the cohort 
demonstrated a rise in Troponin I, which occurred in the absence of 
echocardiographic evidence of myocardial contusion, thereby suggesting 
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secondary cardiac injury.  In addition, biomarker rises were associated 
with hypotension and MODS.   
These findings should nonetheless be interpreted in the context of a very 
small and selective study of critically injured patients, and could not be 
applied to the general trauma population at large.  Furthermore, Edouard 
published a much larger analysis of 728 patients six years later and 
suggested that Troponin I release was in fact fundamentally the result of 
direct cardiac injury (Edouard et al., 2004).  In this later study, elevations 
in Troponin I occurred in 86 (12%) individuals, seven of whom had 
“medical ischaemia”.  Of the 54 early survivors in this group, 35 (65%) had 
a chest injury and 23 (43%) a myocardial contusion based on ECG 
changes.   
Throughout the whole population, ECG changes were noted in 35 (4.8%) 
patients and included ST segment depression and elevation, bundle 
branch blocks and arrhythmias.   
The 17 patients with significant and sustained release of Troponin I 
included seven (41%) patients diagnosed with coronary artery injury and 
nine (53%) with echocardiographic abnormalities.  Troponin I release was 
not prognostic of late mortality (OR 1.32, 95% CI 0.61–2.85). 
Although a much larger study, the power of this analysis remained 
potentially low given the relatively small number of patients with a 
Troponin I rise.  Accordingly, the prognostic significance of this biomarker 
was not conclusively determined by this research.  While many of the 
patients with Troponin I rises had chest injuries, certain diagnoses of 
myocardial contusion were based on ECG abnormalities.   
Contusions may present with a wide and non-specific spectrum of ECG 
changes and there is no global consensus on their diagnostic criteria.  It 
should not have been assumed, therefore, that patients had myocardial 
contusions unless there was echocardiographic confirmation.   
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As with previous research, this analysis also limited itself to a critically 
injured cohort, and hence the findings might not be applicable to all 
trauma patients. 
Lastly, timings of the biomarker samples were poorly described.  
Troponin I were reported as measured on admission to ICU, at six and 12 
hrs thereafter and continued until levels normalised.  In the first instance, 
the time to admission to ITU following injury is variable.  Some patients 
may be admitted rapidly and directly to a unit, whilst others may be 
delayed by the need for imaging or emergent intervention first.  Second, 
the authors gave no indication as to the point at which Troponin I levels 
normalised.  Consequently, the paper provided no detail on the 
relationship of cardiac injury with time.  
Perhaps the most significant study of Troponin I as a marker for 
secondary cardiac injury in trauma was published in 2005.   
Critically injured patients admitted to an ICU with two sequential 
Troponin I measurements were included (M. Martin et al., 2005).  Over a 
thousand individuals were recruited and just under a third of the cohort 
(29%) had a rise in Troponin I.  When adjusted for, only the severity of 
injury, base excess and degree of physiological derangement were 
predictors of Troponin I increase.   
Neither the presence nor severity of thoracic injury, however, was 
associated with Troponin I suggesting again that trauma might cause 
secondary cardiac injury.   
Elevated Troponin I levels were also a significant predictor of mortality 
(OR 2.1, 95% CI 1.4–3.1).  Fifty patients (4.6%) had an ACE of some 
description and these were associated with increases in Troponin I.  The 
precise nature of such cardiac events was not reported.  The analysis also 
demonstrated that beta-blockers were linked to survival, and a 50% 
decrease in mortality was seen in patients with Troponin I increases on 
these medications. 
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This study was limited, however, by its retrospective nature and once 
again, the findings remained pertinent to critically injured patients only.  
The authors failed to describe their exclusion criteria, and provided no 
significant details on the features and diagnoses of patient ACEs.  The 
analysis was based on the peak Troponin I concentration of each patient, 
and the timing of sampling in this study was also vague.  Consequently, 
deductions on the significance of chronology, and the patterns of release 
of this biomarker after trauma could not be made.  
Troponin I was measured in another European study of 106 patients 
presenting after mild trauma (Lagi et al., 2008).  Only individuals who 
presented without evidence of acute cardiac events were included.  
Biomarker levels were measured during the first 24 hrs (at six hourly 
intervals) and individuals were followed up for six months after discharge 
for either death or cardiac morbidity.  Seventeen patients (16%) had a rise 
in Troponin I, of which eight (47%) had an ACE during follow up.   
ACEs included two cases of acute MI, two of cardiac syncope and three 
instances of cardiac death.  The results implicated that cardiac injury and 
dysfunction may follow even mild trauma.  Importantly, this was also the 
first study to suggest the prognostic significance of Troponin I in non-
critically ill trauma patients, and further the biomarker’s predictive value 
of future, longer term cardiac events.  
Nevertheless, the lack of detailed methodology made the study difficult to 
interpret.  Injury severity was not measured using an ISS score, but 
instead an arbitrary scale scantily explained.  As such the authors’ 
definition of mild trauma was vague.  Injury and patient characteristics 
were not given, and associations between cardiac events and Troponin I 
not adjusted for.  The relationship between chest injury and Troponin I 
rise or ACEs was not provided and as such the study provided no 
evidence either to support or negate the existence of post-traumatic 
secondary cardiac injury. 
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In paediatric trauma patients, Troponin I has also been shown to rise 
(Sangha et al., 2012).  In 59 patients aged between 1-17 years, 16 (27%) had 
a rise in the biomarker.   
Four (25%) of these individuals had an abnormal echocardiogram, 
although the anomalies were trivial in nature.  All patients had normal 
ECGs but 15 had chest injuries.  Troponin I rises were associated with 
worsening injury severity, greater fluid requirements and higher rates of 
intubation.  Three children (5%) died from catastrophic brain injury, all 
with a rise in Troponin I.   
This study demonstrated that children may also develop Troponin I rises 
which could not be due to pre-existing cardiac disease given such 
individuals were excluded.  Although an increase in Troponin I was 
associated with chest injury, only four patients actually had any evidence 
of BCI on their echocardiogram.  Accordingly, it is possible that some of 
these patients were in fact manifesting secondary cardiac damage. 
Although perhaps the first dedicated study of Troponin I in paediatric 
trauma patients, the research was nonetheless limited to a relatively small 
sample size, and failed to adjust for any of its variables. 
The relationship between cardiac injury (defined by a rise in Troponin I) 
and infection was most recently investigated in a review of 1752 patients 
on a trauma ICU (Monaghan et al., 2012).  Individuals were 
retrospectively reviewed for demographics, the presence of co-morbidity 
and injury characteristics.  Laboratory records identified patients in whom 
a Troponin I was ordered and the value thereof, while microbiology data 
revealed those diagnosed with urinary tract infections (UTI) or ventilator-
associated pneumonia (VAP). 
Cardiac injury (Troponin I >0.15ng/mL) was present in 160 (9%) critically 
injured individuals, whilst severe cardiac injury (Troponin I >1.0ng/mL) 
was found in 63 (4%).  Age, chronic obstructive pulmonary disease, UTI, 
VAP and ISS were all predictors of cardiac injury.   
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Conversely the presence of pre-morbid congestive heart failure (CHF) was 
not associated with a Troponin I rise.  Only age and diabetes were 
significant risk factors for severe cardiac injury.  
These findings led the authors to conclude that there exists an association 
between infection with an increased risk of cardiac injury, and that this 
could be due to “infection-related, inflammatory mediated cardiac 
dysfunction”. 
Age, CHF and increasing ISS were predictors of mortality, and 
hypertension appeared protective.  Although severe cardiac injury alone 
did not meet significance (p<0.063), the interaction between severe cardiac 
injury and age was associated with death. 
The study was well powered.  It attempted to investigate a potentially 
important yet previously unreported cause of late death in trauma, 
namely the association between infection and cardiac injury.  
Nonetheless, it was subject to multiple limitations.  Suspicion of cardiac 
injury was based on including any patient in whom a Troponin I was 
ordered, in spite of a wide spectrum of clinical indications, and the likely 
variability between one clinician and another’s motivation for seeking the 
test.  Testing bias was therefore not adjusted for.  The analysis did not 
reveal the relationship of Troponin I to chest trauma, and no other 
markers of cardiac dysfunction were examined.  Accordingly, the study 
did not demonstrate whether Troponin I rises were the result of BCI or 
secondary cardiac injury.  Furthermore, the analysis calculated threshold 
levels for the biomarker despite variations in normal values, thus 
rendering the findings poorly translational to other trauma populations.  
Being retrospective in nature, results were dependent on accuracy of 
documentation and data recollection, which may have led to an under-
estimation of effect sizes.  Moreover, given the relatively small frequencies 
of co-morbidities, the statistical tests may have been underpowered. 
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The study provided little further insight, therefore, into post-traumatic 
secondary cardiac injury, its pathogenesis and associated clinical 
outcomes. 
1.5.2.3  Heart-type Fatty Acid Binding Protein 
Heart-type Fatty Acid Binding Protein (H-FABP) is a small cytoplasmic 
protein (12-15 kilodaltons, KDa) found abundantly in the heart.  It 
transports insoluble fatty acids from the cell membrane to mitochondria 
for lipid oxidation, to enable the production of energy (Alhadi et al., 2004).  
It is normally present at low levels in the plasma, but appears in the 
circulation more rapidly than the Troponins following damage to heart 
cells.  It is a reliable marker of myocardial cell damage, and may be the 
earliest, most sensitive biomarker to rise following cardiac injury 
(McMahon et al., 2012 ).   
H-FABP is also a significant predictor of poor outcomes, and raised levels 
have been associated with mortality and risk of future adverse events in 
various disease states (Viswanathan et al., 2010, Jo et al., 2012). 
In trauma, H-FABP has only been assessed in an experimental setting of 
myocardial injury, and was found to be a good early marker of cardiac 
damage (Clements et al., 2010).   
Yet despite evidence supporting its value as an early and highly sensitive 
cardiac biomarker with good prognostic capabilities, it remains one that 
has never been described in the clinical setting of trauma.  It therefore 
represents an appropriate original target for investigation in injured 
patients. 
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1.6 Trauma, Inflammation and the Heart 
Of the studies described previously in Section 1.5, few have attempted to 
determine the underlying mechanisms that may have led to post-
traumatic secondary cardiac injury and dysfunction.  Amongst those that 
have, links to inflammation, and conditions such as SIRS and MODS have 
most often been implicated. 
1.6.1 SIRS and MODS 
Trauma induces an inflammatory response in injured patients which may 
lead to SIRS.  The degree of SIRS is dependent both on endogenous (e.g. 
hypoxia and metabolic acidosis) and exogenous factors such as the extent 
of tissue injury and shock (Keel at al., 2005).  Mild to moderate SIRS is an 
appropriate response to trauma and is designed to facilitate the body’s 
stress response to injury.  Exaggerated SIRS, however, leads to MODS, a 
syndrome defined by the failure of two or more organ systems (Hassoun 
et al., 2001).   
Both the SIRS score on admission (Napolitano et al., 2000) and the degree 
of post-traumatic secondary organ dysfunction are critical factors in 
determining the outcomes of injured patients, including their length of 
stay, survival and, ultimately, longer-term quality of life (Dewar et al., 
2009). 
In trauma, SIRS and MODS are the result of the immune response.  
Following sterile tissue injury, alarmins are released into the circulation 
(such as high-mobility group box protein 1 [HMGB1] and mitochondrial 
DNA) and recognised by receptors present both on the surface and on the 
inside of cells.   
This triggers the innate immunity and results in cytokine production and 
inflammation (Manson et al., 2011).  This may also lead directly to 
ischaemia–reperfusion injury to the heart (Andrassy et al., 2008).   
In injured patients, cytokine levels may predict the severity of illness, the 
development of MODS and survival (Hranjec et al., 2010).   
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In the clinical trauma literature on cytokines, TNFα, IL-6 and IL-8 have 
been the principal focus of research.   
TNFα exerts multiple effects throughout the body, including the heart, 
where it causes cardiac muscle cell (cardiomyocyte) injury and 
dysfunction (Horton et al., 2000).  IL-6 is a cytokine with numerous 
biological functions, and is a potent inducer of the acute phase response 
(Van Snick, 1990).  IL-8 exhibits chemotactic properties and performs 
multiple functions such as the induction of lysosomal enzyme release 
from neutrophils (Harada et al., 1994).  The production of IL-8 occurs in 
response to inflammatory stimuli, including the presence of TNFα. 
1.6.2 Cytokines, Inflammation and the Heart 
Cytokines, and in particular TNFα, IL-6 and IL-8 have been shown to rise 
acutely after trauma and production may be correlated to the ISS (Jiang et 
al., 1997).  The three cytokines demonstrate different timings of release 
following injury, and levels may not only discriminate those at risk of 
MODS (Jastrow et al., 2009), but also might identify which organs are 
likely to become dysfunctional (Maier et al., 2007). 
In non-trauma literature, cytokines and inflammation have been 
associated with both acute and chronic cardiac disease and heart failure 
(Hohensinner et al., 2011, Prabhu et al., 2004, Chen et al., 2008).  
TNFα leads to cardiomyocyte apoptosis through caspase activation and 
subsequent deoxyribonucleic acid (DNA) fragmentation.  TNFα has 
negative inotropic effects, and also initiates the cytokine cascade leading 
to the production of IL-6 and Il-8 amongst others.  This results in greater 
inflammation and worsening injury to the heart (Prabhu, 2004).  IL-6 leads 
directly to cardiac dysfunction, through iNOS mediated depressions of 
myocardial contractility, in combination with disorders of cellular calcium 
homeostasis (Saini et al., 2005).  IL-8 may lead to granule enzyme release 
and oxidative burst in neutrophils which damage the heart, particularly in 
the context of ischaemia reperfusion injury (Stangl et al., 2002).  
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In trauma, the cardiovascular impairment associated with SIRS appears 
mainly the product of decreases in afterload and myocardial contractility 
(R. S. Martin et al., 2005).   
In a model of early post-traumatic MODS (i.e. occurring by day three of 
admission), the heart was shown to be the predominant organ of 
dysfunction (Moore et al., 1996).  However, this study graded the extent of 
cardiac failure according to the level of inotropic support, despite the fact 
that these medications are used in multiple clinical scenarios and do not 
necessarily reflect abnormalities of myocardial function.   
Although damage to heart tissue and function is recognised in post-
traumatic SIRS and MODS, the specific association of the heart with 
cytokines and inflammation after trauma has been the subject of very little 
investigation.   
Merely one clinical study of 17 severely injured patients has attempted to 
describe the relationship between rises in TNFα, IL-6 and IL-8 with 
secondary cardiac injury (Jiang et al., 1997).  Although suggestive, the 
analysis was limited by its small population, and most notably by the use 
of creatine phosphokinase (CPK) as the indicator of heart damage.  
Because CPK is not specific to heart tissue and is released following 
skeletal muscle trauma, the evidence no longer favours its utility as a 
cardiac biomarker.  Given the patients in the study were severely injured, 
CPK will have been raised regardless of the presence of cardiac injury.  
Furthermore, the presence or extent of chest trauma was not described, 
and hence the study did not reveal whether cardiac injury was the result 
of direct cardiac damage or was secondary in nature. 
Consequently, the association between cytokines, inflammation and 
secondary cardiac injury and dysfunction in trauma remains a novel and 
necessary area of research.    
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1.7 Head Trauma and Secondary Cardiac Injury 
Damage to the brain can to lead to indirect injury to the heart.  Studies 
have reported Troponin I rises, ECG abnormalities and histological 
changes in the myocardium secondary to intracranial bleeding, primarily 
following subarachnoid haemorrhage (Tanabe et al., 2008, Andreoli et al., 
1987, Elrifai et al., 1996).   
In trauma, the secondary effects of head injury on the heart have also been 
investigated.  Small studies have revealed ECG abnormalities in patients 
with head trauma (Mcleod et al., 1982), allied with histological evidence of 
cardiac injury.  Others have reported myocardial dysfunction and 
neurogenic pulmonary oedema in patients with isolated head injury.  
These were associated with high mortality rates, and further pathological 
confirmation of myocardial damage was presented (Bahloul et al., 2006).  
Research in brain injured children has also reported a high incidence of 
cardiac arrhythmias, including ventricular tachycardias (Bourdages et al., 
2010).  In this study, however, no child manifested asystole, 
atrioventricular block, AA or ventricular fibrillation.  Arrhythmias 
occurred in the absence of primary cardiovascular trauma, and were more 
common in hypothermic patients. 
Following traumatic subarachnoid haemorrhage, cardiac arrhythmias and 
myocardial ischaemia were again demonstrated in approximately half of 
the 35 individuals recruited to the study (Baffoun et al., 2011).   
Although a very limited investigation with errors in reporting and 
statistical analysis, the authors also found a Troponin I rise in 12 patients 
which was independently associated with increased mortality. 
A retrospective review of all blunt trauma patients with severe head 
injury (head AIS 3≤) and lesser injuries to the remainder of body regions 
(AIS <3) revealed Troponin I rises in nearly a third (29.8%) of the study 
cohort (Salim et al., 2008).  Both admission and peak Troponin I elevations 
were associated with a lower Glasgow Coma Scale (GCS), higher ISS and 
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greater mortality when compared to individuals with normal biomarker 
levels.  Peak, but not admission, Troponin I was an independent predictor 
or mortality (OR 8.5, 95% CI 3.46-22.15, p<0.001).   
Although this study did not explicitly examine the relationship between 
chest injury and Troponin I release, patients with severe thorax trauma 
were excluded from the analysis.  Accordingly, it supports the notion that 
secondary cardiac injury occurs in trauma, albeit following head injury in 
such cases. 
BNP levels may also rise following neurological trauma, and may 
correspond to both hyponatraemia and elevated intracranial pressure 
(ICP) (Wu et al., 2011).  Elevations in NT-proBNP have also been noted in 
both the plasma and cerebrospinal fluid of brain injured patients 
(Kirchhoff et al., 2006), and may be associated with higher ICP 
measurements (ICP >15 mmHg).  
To date, catecholamines and sympathetic overactivity have been amongst 
the most widely implicated mediators of secondary cardiac injury 
following head injury (Samuels, 2007).  This may explain the survival 
benefits of beta-blockers seen in limited studies of patients with 
neurological trauma (Table 1.2). 
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1.8 Cardiac Disease and Trauma 
Increasing age is associated with poorer survival following injury.  
Trauma patients over the age of 45 years have worse outcomes and this 
increases linearly with age.  All cause mortality in individuals over 60 
years may approach up to 20% (Tornetta et al., 1999), and those over 65 
have a two to threefold higher risk of death than younger individuals 
(Taylor et al., 2002).   
Higher death rates are not only seen in-hospital but are observed over the 
course of several years following the index injury (Claridge et al., 2010, 
Laupland et al., 2010, Davidson et al., 2011).   
A factor leading to the increased death rate of older trauma patients is the 
presence of co-morbidity.  The isolated influence of heart disease on 
survival following injury is controversial, however. 
1.8.1 Cardiac Disease and Survival in Trauma 
Not only the presence but the number of pre-morbid conditions may 
influence the death rate in trauma (Bamvita et al., 2007).  In this study of 
all acute trauma deaths within 30 days of emergency department (ED) 
arrival, a bivariate statistical model initially revealed cardiac disease as a 
predictor of death.  When adjusted for using multivariate regression, 
conversely, heart conditions no longer remained significantly associated 
with survival.  However, cardiac disease led to death in 19.2% of cases, 
making it the third highest cause of death in this study sample (although 
individual diagnoses were not specified). 
In a larger investigation of a Japanese population, only the presence of 
congestive heart failure alone was linked to a greater death rate, but this 
was itself limited to two specific groups of injured patients, namely those 
with an ISS of 1-15 and an ISS of 16-24 (Shoko et al., 2010).  Overall, 
however, cardiac disease per se was not associated with increased death 
rates in this cohort of adult trauma patients.   
 57 
In conjunction, an earlier study of injured individuals over the age of 65 
years revealed that the presence of cardiac disease was not generally 
associated with increased odds of death.  Only congestive heart failure 
was predictive of poorer survival, but solely in older patients who 
presented following a fall (Grossman et al., 2002). 
Prior research designed to determine the factors which influence outcome 
in the elderly also assessed the effect of pre-existing medical conditions.  
In a comparison of older (age ≥65 years) versus (vs.) younger patients (<65 
years), increasing age was associated with worsening survival (Smith et 
al., 1990).  The presence of co-morbidity, including cardiac disease, did not 
affect mortality.  Similar studies in older individuals admitted to a surgical 
ICU (Horst et al., 1986) and in injured patients over the age of 70 
(Oreskovich et al., 1984) reached identical conclusions.   
In a more recent report of trauma patients with severe injury, 
cardiovascular disease in isolation was not associated with a higher risk of 
death (Efron et al., 2008).  When considered in combination with statin 
use, however, the presence of a diseased heart negatively influenced 
survival. 
A landmark study in the field highlighted that the presence of ischaemic 
heart disease nearly doubled the risk of death in adult trauma patients 
(Morris et al., 1990).  However, the detrimental impact of the condition 
was lost in older and more severely injured patients.  In those over the age 
of 65 years with an ISS ≥13, the presence of any pre-morbid condition had 
no longer any significant effect on mortality. 
In contrast, perhaps the only prospective study in trauma examining the 
influence of co-morbidity on outcome revealed a positive association 
between pre-morbid conditions, including cardiac disease, and mortality 
(Milzman et al., 1992).  This relationship remained true even after 
controlling for both ISS and age.  The effect of co-morbidity on survival 
was most pronounced in younger, less severely injured patients. 
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Moreover, in a study of the moderately injured (mean ISS of 10.7), older 
individuals were more likely to suffer late mortality when compared to 
younger patients (Perdue et al., 1998).  In individuals over the age of 65 
years, the presence of pre-existing cardiovascular disease was not only 
associated with higher death rates, but was additionally related to other 
poorer outcomes including cardiac, respiratory, renal, and infectious 
complications.   
These findings were reinforced by work in more severely injured patients 
(ISS ≥16), which demonstrated that heart disease and indeed peripheral 
vascular disease were associated with higher mortality even after 
adjusting for age and severity of injury (Wutzler et al., 2009).   
However, an earlier paper reported that when the mortality of patients 
over 50 years of age was analysed in relation to ISS (Mcgwin et al., 2004), 
heart disease only had a marked impact on those less injured (ISS 1-15), 
and to a lesser extent those with severe injuries (ISS 16-25).  In critically 
injured patients (ISS ≥26), heart disease did not significantly influence 
outcome. 
These findings were supported by a British study of adult trauma patients, 
which demonstrated that the presence of co-morbidity was associated 
with a negative impact on survival only in mildly and moderately injured 
patients (Hollis et al., 2006).  In patients with an ISS <16, cardiovascular 
disease was associated with a seven-fold increase in death (OR 7.0, 95% CI 
5.1-9.6, p<0.001).  Conversely, pre-existing medical conditions had no 
significant effect on mortality in the severely injured.  Amongst this 
cohort, cardiovascular disease was the most common co-morbidity, 
affecting nearly a third of the population.  Strokes were included in these 
figures, however, so the true incidence of cardiovascular disease alone 
was not revealed.   
Again in the UK, multiple studies conducted by the same author revealed 
that cardiovascular disease was the most prevalent type of co-morbidity 
observed in injured patients, and was consistently associated with a 
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significant increase in the death rate following trauma (Wardle, 1999).  
Nonetheless, these findings were subject to regional differences in public 
health and cannot therefore be assumed to represent the trend throughout 
the UK, nor indeed the rest of the world. 
Most recently, poorer long-term survival after major injury was 
demonstrated in a non-validated predictive model of co-morbidity in 
trauma (Niven et al., 2012).  Cardiopulmonary disease accounted for 26% 
of deaths at one year, but in contrast, led to only 6% of fatalities during 
hospitalisation after the index event.  Nonetheless, the study did not 
isolate cardiac disease from respiratory illness (including chronic 
obstructive pulmonary disease), thus it provided little further indication 
of the independent effect of heart conditions on survival after trauma.   
Indeed the only research to investigate specifically the relationship 
between cardiac disease in isolation and trauma was a dedicated 
retrospective database analysis of nearly 6000 patients (Ferraris et al., 
2010).  Approximately 43% of survivors and 69% of non-survivors were 
documented as having pre-morbid cardiovascular disease.  Amongst the 
deaths from trauma, 236 (33%) had an adequate medical history.  
Although multiple cardiovascular diseases and medications were 
associated with increased death rates, only three remained significant 
when adjusted for using multivariate analysis; pre-morbid warfarin use, 
beta-blockade and congestive heart failure.  Although these were 
associated with decreased survival, their effects were less when compared 
to more traditional risk factors such as age, GCS and ISS.  
1.8.2 Limitations of the Literature on Cardiac Disease and Trauma 
While some studies are suggestive of increased mortality in injured 
patients with cardiovascular disease, the isolated effect of heart conditions 
on post-traumatic survival remains nonetheless inconclusive.   
There are only a relatively small number of trauma papers that have 
reported the effect of pre-morbid disease on outcome, and just one has 
specifically investigated cardiac disease in isolation.   
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Furthermore, many of the studies’ findings are conflictive, and all are 
subject to limitations.  Most of the evidence is derived from observational, 
retrospective database analyses which enable the investigation of large 
study populations.  However diagnoses are based on coding criteria such 
as those of the ICD-9-CM.  Consequently, these studies are dependent on 
accurate documentation, and vulnerable to the latitude of definitions of 
heart disease, such that none can discriminate the actual level of 
physiological derangement and physical limitation associated with each 
cardiac diagnosis.  Furthermore, such methodology precludes patients 
with existing, but undiagnosed, cardiovascular disease.   Consequently, 
the true incidence of heart disease, including both symptomatic and 
asymptomatic presentations, is not known in trauma.   
Studies have varied in their patient populations and assessment of 
cardiovascular conditions rendering them difficult to compare and 
contrast.  None have specifically investigated atherosclerotic disease 
despite it being amongst the most prevalent of cardiovascular pathology.  
Finally, many papers have limited their inclusion criteria to patients aged 
60 years or over, thus neglecting younger individuals either with, or at 
risk of, cardiovascular disease (Grundy et al., 1999).  Accordingly, the true 
incidence and impact of cardiac disease on survival in trauma patients 
remains unknown. 
1.8.3 Cardiac Medications and Outcome in Trauma 
In addition to cardiac disease, several clinical studies have investigated 
the influence of cardiac medications, and particularly beta-blockers, on 
outcomes following injury. 
Overall the evidence is favourable and suggests that the pre-morbid use of 
beta-blockers is associated with improved survival.  This is perhaps most 
notable in patients with head injuries, wherein beta-blockers are proposed 
to attenuate the deleterious effects of the sympathetic hyperactivity and 
catecholamine surges that occur in neurological trauma.  The benefits of 
statin therapy are less clear (Table 1.2). 
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Table 1.2.  Beta-blockers and Statins in Trauma - Summary of Evidence 
 
The evidence on the benefits of these medications, however, is limited to a 
handful of studies.  These investigations are mostly retrospective and thus 
vulnerable to errors in documentation and reporting of medication use.  
Results are restricted to specific injured cohorts, and are not directly 
translatable to general trauma populations.  
Study Medication Trauma Population Effect on Outcome 
(M. Martin, 2005) Beta-blockers Critically injured Improved survival 
(Cotton, 2007) Beta-blockers Severe head injuries Improved survival 
(Arbabi, 2007)  Beta-blockers Patients on beta-blockers 
(initiated in hospital or pre-
morbid) 
Improved survival 
(most notable in severe 
head injury) 
(Riordan, 2007) Beta-blockers Severe head injuries with 
heart rate monitoring for 
first 24 hours on ICU 
Non-significant 
association with survival 
(Neideen, 2008) Beta-blockers Patients aged >65 years  Increased mortality in 
patients without head 
injury 
No difference in those 
with head injury 
(Salim, 2008) Beta-blockers Severe head injuries with 
Troponin I measurement 
Improved survival 
(Inaba, 2008) Beta-blockers Isolated head injury Improved survival 
(especially in head 
injuries >55 years) 
(Ferraris, 2010) Beta-blockers Patients aged >20 years Increased mortality 
(Schroeppel, 
2010) 
Beta-blockers Blunt traumatic brain 
injuries 
Improved survival 
(Hadjizacharia, 
2011) 
Beta-blockers Critically injured Improved survival in 
patients with AA treated 
with beta-blockers 
(Bukur, 2012) Beta-blockers Surgical ICU admissions 
without severe head injury 
Improved survival 
(Efron, 2008) Statins Patients with at least one 
severely injured body region 
Improved survival only in 
those >65 years with no 
cardiovascular disease  
(Neal, 2009) Statins Patients aged >55 years  No difference in survival 
Higher risk of MODS in 
statin users 
(Schneider, 2011) Statins Patients aged >65 years with 
severe head injury 
Improved survival and 
functional recovery at 
one year 
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Although papers describe the class of drugs investigated, they fail to 
mention the specific type of medication used, despite the variety of 
pharmaceutical effects that the family of beta-blockers have.  Doses are not 
reported, and the timing of administration variable.   
Finally, the literature has not yet established whether the pre-morbid use 
of these medications is associated with differing outcomes in trauma 
patients when compared to their initiation in hospital following injury. 
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1.9 Summary  
Trauma is an important cause of death and disability worldwide.  
Nonetheless, it is a poorly funded field characterised by a lack of research.  
The relationship of trauma with the heart is an area of study particularly 
neglected.   
Experimental evidence has demonstrated that trauma and haemorrhage 
may provoke a profound systemic inflammatory response characterised 
by increased levels of pro-inflammatory factors, with subsequent cardiac 
injury and dysfunction.  However, the experimental evidence is limited 
and not directly translational to clinical practice.  
Only a handful of dedicated clinical studies have investigated whether 
trauma can lead to secondary cardiac injury and dysfunction.  Although 
some of the studies are suggestive, findings lack unanimity (Table 1.3).  In 
addition, the outcomes associated with secondary cardiac injury in trauma 
remain uncertain.  
Much of the clinical evidence is derived from retrospective studies, and 
primarily limited to small numbers of critically injured patients only.  
Clinical manifestations of secondary cardiac injury are restricted to 
isolated diagnoses, whilst biomarker studies have investigated single 
markers, despite evidence in the non-trauma literature that multiple 
biomarker panels might be more effective (McCann et al., 2009).  
Furthermore the timings of biomarker sampling in relation to injury 
chronology have not been described precisely.   
The relationship between pre-existing heart disease and outcome in 
trauma is inconclusive.  Studies are conflictive and have relied on existing 
diagnoses of heart disease using database analyses.  Only one paper has 
reported the effect of heart disease specifically in isolation on survival. 
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Table 1.3.   Summary of Dedicated Clinical Studies of Secondary Cardiac Injury and Dysfunction in Trauma 
Study  Design (n) Trauma Population  Variable Incidence (%) Risk Factors Evidence of 
Secondary Cardiac 
Injury? 
(Edouard, 1998) Prospective cohort 
(17) 
Critically injured  Troponin I 35 Not identified  Yes 
(Moosikasuwan, 
2000) 
Retrospective 
cohort (11,866) 
All  MI 0.04 Not identified No 
(Edouard, 2004) Prospective cohort 
(728) 
Critically injured  Troponin I 12 Not identified  No 
(Ismailov, 2005) Retrospective 
cohort (1,051,081) 
All  MI 3.10 Chest/abdominal/pelvic 
trauma 
Yes 
(M. Martin, 2005) Retrospective 
cohort (1,081) 
Critically injured  Troponin I 29 Base excess 
ISS 
Deranged physiology  
Yes 
(Seguin, 2006) Prospective cohort 
(293) 
Critically injured  AF 5.5 Age >40 years 
>3 body regions injured 
Catecholamine use 
SIRS 
Deranged physiology 
Yes 
(Lagi, 2008) Prospective cohort 
(106) 
Mildly injured & no pre-
morbid cardiac disease  
Troponin I 16 Not identified No 
(Kirchhoff, 2008) Prospective cohort 
(26) 
Critically injured  BNP 100 Not identified Yes 
(Hadjizacharia, 
2011) 
Retrospective 
cohort (3,499) 
Critically injured  AA 6 Age >55 years Yes 
(Sangha, 2012) Prospective cohort 
(59) 
Severely injured children  Troponin I 27 Chest injury and ISS No 
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In conclusion, no study has attempted to link all clinical manifestations of 
secondary cardiac injury with multiple biomarker evidence.  In the event 
of the existence of this condition, the outcomes associated with it are not 
yet fully understood.   
The pathological processes, notably inflammation, together with the risk 
factors that might lead to secondary cardiac injury have been not 
investigated.  The trauma populations at risk of the condition have not 
been identified. 
Finally, the true incidence and effect of coronary heart disease on survival 
requires dedicated investigation.   
Consequently the theme of trauma associated cardiac injury and 
dysfunction represents an important and novel target for investigation. 
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1.10 Project Aims  
The overall research objective was to investigate the relationship between 
trauma and the heart.  Specifically, this project aimed to: 
1) Identify the existence of a trauma induced secondary cardiac injury 
(TISCI) and determine its impact on the outcome of severely 
injured patients 
2) Establish if there is an association between inflammation and the 
development of a trauma induced secondary cardiac injury, and 
determine whether inflammation combined with cardiac injury is 
associated with poorer survival 
3) Describe the features of a trauma induced secondary cardiac injury, 
and identify its risk factors in all adult trauma patients 
4) Identify the overall incidence of coronary heart disease in older 
trauma patients, and establish its association with survival after 
injury 
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CHAPTER TWO 
Trauma Induced Secondary Cardiac 
Injury 
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2.1 Introduction 
Direct trauma to the heart is known to lead to cardiac injury and 
dysfunction (Amino et al., 2009, Ismailov et al., 2007).  It remains 
controversial, however, if trauma may cause secondary cardiac injury, and 
if it does, whether this results in adverse outcomes for patients. 
There is circumstantial evidence to support the existence of indirect injury 
to the heart following trauma, and a few studies have described secondary 
cardiac events in injured patients.  In a retrospective review of over a 
million individuals, the risk of post-traumatic MI was found nearly to 
double following pelvic or abdominal trauma (Ismailov et al., 2005).  This 
observation was independent of confounding factors.  The development of 
AA has been reported in trauma patients, irrespective of the severity of 
thoracic injury.  AA occurred in six percent (n=210 of 3499) of injured 
patients on a critical care unit, and were independently associated with 
higher mortality (Hadjizacharia et al., 2011).  The only significant risk 
factor for developing an arrhythmia was age (>55 years).  Seguin found 
similarly that the incidence of AF was just over five percent in critically 
injured patients, and identified age, catecholamine use, the presence of 
SIRS and the severity of overall injury and physiological derangement as 
the contributing risk factors for AF (Seguin et al., 2006).  Patients with AF 
suffered a higher death rate, but in contrast to the aforementioned study, 
this was not statistically significant. 
In the trauma literature, heart specific biomarkers have also been 
investigated in research attempting to identify both the severity and 
significance of secondary cardiac injury in trauma. 
Troponin I, found in heart muscle, is a specific biomarker of myocardial 
injury.  Raised levels of Troponin I have been identified in patients after 
trauma and may be associated with both an increased risk of ACEs and 
death (Lagi et al., 2008, M. Martin et al., 2005).   
NT-proBNP is secreted primarily by the ventricles of the heart in response 
to excessive stretch.  It is a sensitive biomarker of cardiac injury.   
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Measured 24 hrs after trauma, NT-proBNP levels have been shown to 
correlate significantly with a decreased cardiac index and MODS 
(Kirchhoff et al., 2008).   
In experimental animal models, secondary cardiac injury and dysfunction 
have also been identified following trauma-haemorrhage.  Inflammation 
and ischaemia-reperfusion injury have been implicated repeatedly in their 
pathogenesis (Yang et al., 2004, Mizushima et al., 2000b, Li et al., 2007).  
In addition, there is a growing body of indirect, non-trauma related 
clinical evidence to suggest that cardiac dysfunction is associated with 
deranged physiological states.  Myocardial injury has been demonstrated 
after post-partum haemorrhage, critical illness and sepsis and is related to 
poorer outcomes, including higher death rates (Karpati et al., 2004, Lim et 
al., 2006, Post et al., 2008, Quenot et al., 2005, Wu et al., 2004).   
Although these studies are suggestive of post-traumatic secondary cardiac 
injury and dysfunction, no research has yet investigated the development 
of cardiac events in trauma patients in combination with biochemical 
evidence of cardiac injury.  
Previous biomarker studies have measured isolated markers only, and 
these have been done later in the clinical course, when elevations might 
have been caused by mechanisms other than trauma.  Moreover, many of 
these analyses have calculated a threshold level of the biomarker for 
prediction of outcome, despite the fact that associations between 
biomarkers and outcome are usually continuous.  Reporting of 
inaccurately large effect sizes may have thus resulted.   
Additional research is further limited by studies including only small 
numbers of patients, examining isolated cardiac diagnoses (such as MI) or 
by virtue of using retrospective database analyses.  Lastly, few 
investigations have reported outcomes.   
The existence and clinical relevance of TISCI, therefore, continues to 
remain in doubt. 
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2.2 Study Aims 
The overall study objective was to determine the existence of TISCI and if 
present, to establish whether it was associated with worse clinical 
outcomes. 
Specifically, the first aim was to identify the incidence of post-traumatic 
ACEs in a group of severely injured patients.   
Second, to ascertain whether there was biochemical evidence of myocardial 
injury early after trauma and if present, establish whether this was 
associated with the development of ACEs.   
Third, to identify which factors correlated with the development of a TISCI 
in terms of injury characteristics and degree of shock on admission.   
Finally, to assess whether a TISCI was associated with higher mortality in 
trauma patients.  
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2.3 Materials and Methods 
The research project complied with the Declaration of Helsinki.  It was 
reviewed and granted ethical approval by East London and the City 
Research Ethics Committee 1.  
2.3.1 Study Design and Setting 
A retrospective cohort study of severely injured patients admitted to an 
ITU.  The project was performed at The Royal London Hospital, a major 
urban trauma centre in the UK (Davenport et al., 2009). 
2.3.2 Study Population 
All adult trauma patients (>15 years) who had an abnormal primary 
survey were eligible for inclusion, and were prospectively recruited into 
the Activation of Coagulation and Inflammation in Trauma 2 (ACIT 2) 
study when research personnel were present (08:00-20:00 daily) 
(Davenport et al., 2011).   
Exclusion criteria were arrival in the ED more than two hours after injury, 
the administration of over 2000 millilitres (mls) of intravenous fluid prior 
to ED arrival, and transfer from another hospital.  Patients were 
retrospectively excluded if they declined to give consent to use research 
samples collected.    
Patients recruited into ACIT 2 and subsequently admitted to the ICU 
between January 2008 and January 2010 were retrospectively selected and 
enrolled into this study.  
2.3.3 Data Collection 
Data were prospectively collected on patient demographics, injury time 
and mechanism, time of arrival in the ED, baseline vital signs and daily 
physiological data, body regions AIS, ISS and survival.   
Each participant was retrospectively reviewed for the presence of ACEs 
using inpatient notes, critical care charts, pathology records and the 
hospital trauma registry.  
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2.3.4 Outcomes  
The two study outcomes were ACEs and in-hospital death and patients 
were followed up from admission until death or discharge.  An ACE was 
defined as any of the following diagnoses; cardiac death, myocardial 
infarction, angina, arrhythmia and cardiogenic shock.  Diagnoses were 
based on a combination of ECG, echocardiogram or other specialist 
cardiac investigations. 
Death was recorded as 28-day mortality of any cause, and patients 
discharged from hospital before 28 days were assumed to be alive at day 
28. 
2.3.5 Blood Collection  
Five millilitres of blood was drawn from either the femoral vein or the 
antecubital fossa along with standard trauma laboratory tests.  Baseline 
blood (0 hr) was drawn prior to any hospital intervention and taken 
within 20 minutes (mins) of arrival to the ED, and inside of two hours 
from injury.  Further samples were collected at 24 and 72 hrs thereafter.   
Blood was drawn into a 4.5 ml citrated vacutainer (0.109M + buffered 
sodium citrate 3.2%, Becton Dickinson, Plymouth, UK).  The citrated blood 
was centrifuged for ten minutes at 1750 g (relative centrifuge force) within 
one hour of collection.  Plasma was removed and then further spun for ten 
minutes at 1750 g before being transferred into 0.6 ml Eppendorf tubes 
and subsequently frozen at -80 degrees Celsius (°C) until ready for 
processing. 
2.3.6 Biomarker Assays  
2.3.6.1  Selection of Biomarkers 
Plasma was collected to measure levels of H-FABP, BNP and Troponin I as 
evidence of cardiac injury.  A panel of biomarkers was selected based on 
research that this may be more effective than single assays in the diagnosis 
and prognosis of cardiac damage (McCann et al., 2009).   
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Furthermore, such novel methodology sought to improve upon the 
limitations of prior relevant literature restricted to the study of single 
isolated markers. 
H-FABP may be the earliest and most sensitive biomarker to rise 
following myocardial cell damage (McMahon et al., 2012).  It is a predictor 
of poor outcomes including mortality and risk of future adverse events in 
non-trauma states (Viswanathan et al., 2010, Jo et al., 2012).  In trauma, H-
FABP has only been described in the experimental literature (Clements et 
al., 2010), where it was found to be a good early marker of cardiac injury.  
Consequently, its use in the clinical setting is a novel but clinically 
relevant and appropriate method for the detection of secondary cardiac 
damage in injured patients. 
BNP was selected as this is a sensitive indicator of cardiac injury, and has 
prognostic value in the prediction of both ACEs and survival in non-
traumatic conditions (Post et al., 2008, Meyer et al., 2007, Choi et al., 2009, 
Charpentier et al., 2004, Kistorp et al., 2005).  It is used frequently in the 
clinical setting and may be easily measured in hospital.  In addition, BNP 
has been described in the trauma literature (Stewart et al., 2007, Friese et 
al., 2007) and has also been investigated in the context of secondary 
cardiac injury (Kirchoff et al., 2008).  As such, its inclusion into this study 
enabled validation of its results and contrast with previous work. 
Troponin I was chosen because it is currently the most heart specific 
biomarker in use in clinical practice.  Moreover, the bulk of research on 
second cardiac injury in trauma has been undertaken using Troponin I 
(Lagi et al., 2008, M. Martin et al., 2005, Monaghan et al., 2012, Edouard et 
al., 1998, Edouard et al., 2004, Sangha et al., 2012).  Again this facilitated 
comparison and assessment of this study’s findings with the existing 
literature in this field.  
Individual biomarker ELISA (Enzyme-Linked Immunosorbent Assay) kits 
were selected based on a number factors.  These included practical 
protocols, with optimisation procedures compatible with the resources 
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available and the nature of blood collection and storage.  Existing 
validation of each kit prior to selection was sought in the published 
literature, and the assays were further opted for based on their sensitivity 
to the substrate and their precision (Tables 2.1-2.3). 
2.3.6.2  Inter- and Intra-Coefficients of Variation of Each Biomarker Kit  
Table 2.1.  Heart-type Fatty Acid Binding Protein (Hycult biotech Cat No. 
HK402) 
Inter  Intra 
OD CV (%) OD CV (%) 
0.097 7.3 0.106 4.5 
0.216 6.5 0.243 2.2 
0.499 5.3 0.556 6.1 
1.145 4.7 1.232 5.0 
2.160 3.2 2.298 4.6 
2.914 1.9 2.996 3.2 
 
OD=optical density 
Table 2.2.  B-type Natriuretic Peptide (BNP Fragment EIA Biomedica Cat No. 
BI-20852) 
Inter  Intra 
BNP (fmol/ml) CV (%) BNP (fmol/ml) CV (%) 
320 4.4 320 6.5 
666 3.8 666 4.0 
 
Table 2.3.  Troponin I (Troponin I [human cardiac-specific] Life Diagnostics, Cat 
No.2010) 
Inter  Intra 
Troponin I 
(ng/ml) 
CV (%) 
Troponin I 
(ng/ml) 
CV (%) 
5.88 4.8 5.93 3.7 
24.56 4.7 24.3 5.6 
48.91 4.6 44.9 4.0 
85.81 4.4 89.80 2.8 
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2.3.6.3  Materials 
 Cardiac biomarker ELISA kits (detailed below) 
 Distilled water 
 Alarm clock 
 Vortex stirrer 
 Plate mixer 
 Plate washer (automatic) 
 Polyprolene tubes 
 Calibrated ELISA plate 
 Calibrated micropipettes and disposable tips 
 
2.3.6.4  Assay Protocols 
Heart-type Fatty Acid Binding Protein (Hycult biotech Cat No. HK402) 
96 microtitre wells coated with antibody unspecified by manufacturer. 
1. Plasma samples selected and thawed for five minutes in water bath at 37 
C 
2. 96-well plate schematic/template and polyprolene tubes labelled 
accordingly (blank/standards/samples/control) 
3. Tracer diluted to either 1:5 or 1:10 using kit dilution buffer  
4. 50 microlitres (l) of duplicate standard/sample/control added to 
relevant wells in plate  
5. Adhesive cover placed over plate and incubated at room temperature for 
60 mins 
6. Plate washed x4 with wash buffer using plate washer 
7. 100 l Tetramethylbenzidine substrate added to each well 
8. Plate covered with aluminium foil and left at room temperature for 15 
mins 
9. 100 l of stop solution (oxalic acid) added to each well 
10. Absorbance of each well read at 450 nanometre (nm) within 30 mins of 
step 9 
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Calculation of results: 
The absorbance (OD) at 450 nm was measured using a spectrophotometre.  
A standard curve was obtained by plotting absorbance versus 
corresponding concentrations of H-FABP standards.  Concentrations of 
the samples were determined from the standard curve using GraphPad 
PRISM v5 (GraphPad Software Inc, San Diego, CA, USA) in accordance 
with both the manufacturer and GraphPad Prism instructions.   
Mean absorbance was converted to picogram per millilitre (pg/ml) using 
non-linear regression.  This was then corrected for dilution and final 
results reported in nanogram per millilitre (ng/ml). 
B-type Natriuretic Peptide (BNP Fragment EIA Biomedica Cat No. BI-20852) 
96 microtitre wells coated with polyclonal anti-BNP fragment. 
1. Plasma samples selected and thawed for five minutes in a water bath at 
37 C 
2. 96-well plate schematic/template and polyprolene tubes labelled 
accordingly (blank/standard/sample/control) 
3. 200 l assay buffer added to blank well 
4. 200 l added to standard/diluted sample/diluted control, in duplicate 
into respective wells.  (Standard=synthetic human BNP fragment). 
5. 50 l of conjugate (synthetic BNP fragment-HRPO) added to each well 
(except blank)  
6. Plate covered and incubated at 4 C in dark for 24 hrs 
7. Plate washed x5 with wash buffer 
8. 200 l of Tetramethylbenzidine added to each well 
9. Plate covered with aluminium foil and left at room temperature for 20 
mins 
10. 50 l of stop solution (sulphuric acid) added to each well 
11. Absorbance of each well read at 450 nm immediately 
Calculation of results: 
Results were calculated using the same methods described for H-FABP 
(above), although mean absorbance was converted to femtomole per 
milliliter (fmol/ml) using non-linear regression. 
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Troponin I (Troponin I [human cardiac-specific] Life Diagnostics, Cat No.2010) 
96 microtitre wells coated with mouse monoclonal anti-Troponin I. 
1. Plasma samples selected and thawed for five minutes in water bath at 37 
C 
2. 96-well plate schematic/template and polyprolene tubes labelled 
accordingly (blank/standard/sample/control) 
3. 100 l dispensed of standards, samples and controls in duplicate to each 
well 
4. 100 l dispensed of enzyme conjugate reagent (mouse monoclonal anti-
Troponin I conjugated to horseradish peroxidase in Tris Buffer solution 
with preservatives) in each well 
5. Mixed thoroughly for 30 secs 
6. Incubated at room temperature for 90 mins 
7. Plate washed x5 with distilled water 
8. 100 l of Tetramethylbenzidine added to each well and mixed for five 
seconds 
9. Incubated at room temperature for 20 mins 
10. 100 l of stop solution (hydrochloric acid) added to each well 
11. Gently mixed for 30 secs 
12. Absorbance of each well read at 450 nm within 15 mins  
Calculation of results: 
Data were collected as absorbance (OD) in duplicate at 450 nm, plotted 
against the dose and a standard curve fitted by 2nd order polynominal fit 
analysis using GraphPad PRISM v5 (GraphPad Software Inc, San Diego, 
CA, USA) in accordance with both the manufacturer and GraphPad Prism 
instruction manual.  Mean absorbance was converted to ng/ml. 
2.3.7 Statistical Analysis 
All statistical analyses were performed using GraphPad PRISM v5 
(GraphPad Software Inc, San Diego, CA, USA).   
Normal-quantile plots were used to test for normality.  Non-parametric 
data are expressed as medians with interquartile (IQR) ranges unless 
otherwise specified. 
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These were compared using Mann-Whitney U and Kruskal-Wallis.  
Proportions were assessed using Fisher’s exact test and Chi Squared test 
for trend.   
Spearman correlation coefficient was used to examine the linear 
relationship between head AIS and BNP and Troponin I levels, and 
biomarker levels and thorax AIS, ISS, lactate and SBP.   
A two-sided p value of less than 0.05 was considered significant. 
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2.4 Results 
One hundred and thirty five patients were included into this study and 
characteristics are described in Table 2.4 overleaf.   
2.4.1 Incidence and Features of Adverse Cardiac Events  
Eighteen patients (13.3%) had twenty ACEs during admission, of which 
the majority (65%) were supra-ventricular arrhythmias (Figure 2.1).   
 
Figure 2.1.  Numbers of adverse cardiac events by diagnosis  
Patients with ACEs were older (64 years vs. 37, p<0.001) and more likely 
to have known heart disease (22% vs. 1.8%, p=0.003, Table 2.4).  However, 
five patients (28%) who sustained an ACE were below the age of 50, and 
13 (72%) had no previous history of heart disease, and were not on any 
regular medication.   
The presence of pre-existing heart disease was related to the risk of a 
cardiac event in-hospital (Table 2.4).  In contrast, patients with heart 
disease were not placed at a significantly higher rate of death (p=1.000). 
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Table 2.4.  Patient Demographics, Characteristics and Outcomes 
 All No ACE  ACE  p Value 
Number 135 117 18   n/a 
Male, n (%) 106 (79) 92 (79) 14 (78)   1.000 
Age, years  40 (25-56) 37 (24-53) 64 (42-72) <0.001 
Pre-injury Diagnoses, n (%) 
    
Heart disease 6 (4.4) 2 (1.8) 4 (22)   0.003 
Diabetes 5 (3.7) 3 (2.6) 2 (11)   0.132 
Hypertension 8 (5.9) 7 (5.9) 1 (5.5)   1.000 
Hypercholesterolemia 5 (3.7) 4 (3.4) 1 (5.5)   0.517 
PVD 2 (1.5) 0 (0.0) 2 (11)   0.017 
CVA 2 (1.5) 1 (0.9) 1 (5.5)    0.249 
Pre-injury Medication, n (%)     
Aspirin 6 (4.4) 2 (1.8) 4 (22)   0.003 
Anti-hypertensives 4 (2.9) 3 (2.6) 1 (5.5)   0.439 
Statins 5 (3.7) 3 (2.6) 2 (11)   0.132 
Metformin 1 (0.7) 1 (0.9) 0 (0)   1.000 
Insulin 2 (1.5) 2 (1.7) 2 (11)   0.083 
Injury Characteristics     
Injury Severity Score  23 (13-30) 22 (13-30) 29 (19-35)   0.069 
AIS Body Regions     
Head and neck 1 (0-4) 1 (0-4) 2 (0-4)   0.469 
Face 0 (0-1) 0 (0-1) 0 (0-1)   0.182 
Thorax 3 (0-4) 3 (0-4) 3 (0-4)   0.348 
Extremity 2 (0-3) 2 (0-3) 3 (0-3)   0.395 
Abdomen/pelvis 0 (0-2) 0 (0-2) 0 (0-2)   0.433 
Admission Physiology      
SBP, mmHg  134 (62-220) 134 (62-220) 108 (63-160)   0.049 
SBP <90 mmHg, n (%) 26 (19.3) 19 (14.1) 7 (39)   0.047 
GCS 15 (14-15)  13 (7-15)  14 (11-15)   0.191 
Lactate, mmol/L  2.2 (1.3-3.5) 2.2 (1.3-3.5) 3.1 (1.4-3.6)   0.043 
Outcomes     
ICU stay, days  5 (2-10.5) 4 (2-8) 11 (4.5-18.5)   0.005 
Hospital stay, days  14 (5-28) 14 (5-27) 19.5 (5-37)   0.385 
Mortality, n (%) 28 (20.7) 20 (17) 8 (44.5)   0.008 
 
Data are presented as median (interquartile range) unless otherwise stated.  
Comparisons are between the No ACE and ACE cohorts.  PVD=Peripheral 
Vascular Disease, CVA=Cerebrovascular Accident, mmol/L=millimoles per litre.   
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2.4.2 Biomarkers and Adverse Cardiac Events  
Overall, H-FABP levels were highest on admission but by 72 hrs were 
below normal range.  BNP levels peaked at 72 hrs, with lowest values 
observed on admission.  Maximum Troponin I levels were observed at 0 
hr.  
Immediately on arrival to the ED, and hence within two hours of injury, 
patients showed elevations in plasma levels of the three cardiac 
biomarkers.   
Admission levels of H-FABP were 3.2 times higher in patients with ACEs 
compared to those without (104.4 ng/ml vs. 32.4, p=0.022, Figure 2.2 A).  
BNP levels were also greater in individuals who had a cardiac event (573.0 
fmol/ml vs. 407.0, p=0.004, Figure 2.2 B).  H-FABP and BNP remained 
higher at 24 and 72 hrs in patients who developed ACEs (Figure 2.2 A&B).   
Troponin I levels were no higher on admission blood samples.  At 24 and 
72 hrs, however, levels became significantly elevated in patients who 
suffered ACEs compared to those who did not (Figure 2.2 C).  
 
A 
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Figure 2.2  A-C.  Biomarker concentrations in patients without and with 
ACEs 
Box and whisker plots show median (horizontal line within box), interquartile range 
(box) and range (error bars).  A:  Patients with an ACE had higher concentrations of 
H-FABP at all three time points (hr 0 104.4 ng/ml [IQR 30.2-158.3] vs. 32.4 [IQR 
14.3-75.4]; hr 24 101.2 ng/ml [IQR 31.7-473.3] vs. 15.1 [IQR 6.6-29.9]; hr 72 49.9 
ng/ml [IQR 17.5-80.3] vs. 6.3 [IQR 3.7-11.9]).  B:  BNP in patients with ACEs was 
also higher at all time points (hr 0 573 fmol/ml [IQR 407-1111] vs. 453 [IQR 297-
818.7]; hr 24 840 fmol/ml [IQR 533.3-2725] vs. 567 [IQR 461.8-731.3]); hr 72 1175 
fmol/ml [IQR 831-2943.7] vs. 747 [IQR 287.5-1350]).  C:  Troponin I levels were 
significantly higher at 24 hrs (0 ng/ml [IQR 0-0.5] vs. 0 [IQR 0-0]) and 72 hrs (0 
ng/ml [IQR 0-0.9] vs. 0 [IQR 0-0]) in patients with ACEs, but were no different at 
hr 0 (0 ng/ml (IQR 0-0.2] vs. 0 [IQR 0-0], p=0.102).  *p<0.05, **p<0.01, ***p<0.001. 
 
B 
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2.4.3  The Relationship Between Adverse Cardiac Events and Injury 
There was no relationship between ACEs and injury to any specific body 
region (Table 2.4).  In particular, there was no association between chest 
trauma and the likelihood of developing ACEs.  The largest group of 
patients (n=6, 33%) who had a cardiac event had no injury to the thorax.  
This demonstrated that ACEs were not the product of direct trauma to the 
heart, and that a secondary process must be implicated (Figure 2.3).   
 
Figure 2.3.  The number of ACEs in each category of chest injury 
No relationship between ACEs and the severity of mechanical chest injury was 
observed, revealing ACEs were secondary in nature (p=0.392). 
There was a trend towards increasing numbers of ACEs with worsening 
ISS, and the largest group of patients with a cardiac event were critically 
injured and found in the highest ISS category.  Nonetheless, the 
relationship between ACEs and the severity of overall injury was not 
statistically significant (Figure 2.4).   
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Figure 2.4.  The relationship between ACEs and overall injury (ISS) 
There was a non-significant trend towards increasing numbers of ACEs 
with worsening ISS (p=0.052).  
2.4.4 Biomarkers and Injury 
H-FABP correlated to the severity of mechanical chest injury (Thorax AIS) 
on admission (r=0.47, 95% CI 0.32-0.61; p<0.001), at 24 hrs (r=0.40, 95% CI 
0.22-0.55; p<0.001) and once again at 72 hrs (r=0.29, 95% CI 0.08-0.47; 
p<0.01).   
There was no correlation, however, between thorax AIS scores and either 
BNP or Troponin I on admission (r=-0.05, 95% CI -0.23-0.12; p=0.535 and 
r=0.02 95% CI -0.17-0.20; p=0.862, respectively).  At 24 and 72 hrs, BNP 
continued to demonstrate no relationship to chest injury (r=-0.05, 95% CI -
0.13-0.25; p=0.535 and r=0.10 95% CI -0.11-0.29; p=0.324, respectively).  
Equally Troponin I at 24 hrs (r=-0.15, 95% CI -0.05-0.33; p=0.126) and 72 
hrs (r=0.06 95% CI -0.14-0.26; p=0.527) had no correlation to thorax AIS. 
H-FABP levels correlated with the overall severity of injury (Table 2.5).  
Conversely, neither BNP nor Troponin I exhibited such an association to 
ISS (Table 2.5). 
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Table 2.5.  Correlation between Biomarkers and ISS 
 Time Point (Hr) Spearman r (95% CI) p Value 
H-FABP 
0 0.37 (0.20 - 0.52) <0.001 
24 0.38 (0.20 - 0.54) <0.001 
72 0.33 (0.13 - 0.51)   0.001 
    
BNP 
0 0.05 (-0.13 - 0.22)   0.593 
24 0.12 (-0.07 - 0.31)   0.205 
72 0.12 (-0.09 - 0.31)   0.245 
    
Troponin I 
0 0.03 (-0.16 - 0.21)   0.790 
24 0.15 (-0.04 - 0.33)   0.112 
72 0.01 (-0.19 - 0.21)   0.968 
 
These results demonstrated that elevations in BNP and Troponin I were 
neither the product of direct chest injury, nor the total extent of injury. 
ACEs and both BNP and Troponin I release have been associated hitherto 
with traumatic brain injury (Kirchhoff et al., 2006, Stewart et al., 2007, 
Salim et al., 2008).  In this cohort of patients, however, there was no 
significant difference between the severity of traumatic head injury in 
individuals with or without ACEs (Table 2.4).  
Furthermore, no such association was observed between either of the two 
biomarkers with head trauma on admission, nor indeed at any subsequent 
time point (Table 2.6).   
Table 2.6.  Correlation between BNP and Troponin I and Head and 
Neck AIS 
 Time Point (Hr) Spearman r (95% CI) p Value 
 0  0.13 (-0.05 - 0.30) 0.149 
BNP 24 -0.01 (-0.28 - 0.09) 0.320 
 72 -0.08 (-0.27 - 0.13) 0.441 
    
 0  0.05 (-0.13 - 0.24) 0.569 
Troponin I 24 -0.07 (-0.26 - 0.11) 0.441 
 72 -0.03 (-0.23 - 0.16) 0.736 
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2.4.5  Adverse Cardiac Events, Biomarkers and Shock 
Shock showed an equivocal association with ACEs.  Half the patients 
(n=9, 50%) with ACEs presented with low systolic blood pressure (SBP 
<100mmHg), compared to nearly a quarter (n=25, 21%) of individuals 
without cardiac events.  As such, ACEs were associated with hypotension 
(SBP <100 mmHg 26% vs. 9% SBP ≥100 mmHg, p=0.017). 
The greatest number of cardiac events was found in the highest lactate 
quartile, and there was a vague trend towards higher numbers of ACEs 
with increasing lactate levels.   
Nonetheless the relationship between lactate and ACEs was not quite 
statistically significant (Figure 2.5).   
 
Figure 2.5.  Number of patients with ACEs per admission lactate 
quartile 
A pattern of increasing ACEs was observed with higher lactate values, although 
the association was not significant, p=0.053. 
The association between biomarkers and shock on admission was 
inconclusive (Table 2.7).  H-FABP correlated with lactate and showed an 
inverse relationship with SBP.  BNP exhibited no association with either 
marker of shock.  Troponin I showed a positive correlation to lactate only.  
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Table 2.7.  Correlation between Biomarkers and Admission Lactate and 
SBP 
 Biomarker Spearman r (95% CI) p Value 
 H-FABP  0.27 (0.07 - 0.43)   0.003 
Lactate BNP -0.02 (-0.19 - 0.16)   0.845 
 Troponin I  0.24 (0.06 - 0.41)   0.009 
    
 H-FABP -0.43 (-0.57 - -0.27) <0.001 
SBP BNP  0.02 (-0.16 - 0.19)   0.810 
 Troponin I -0.11 (-0.28 - 0.08)   0.256 
 
2.4.6  Adverse Cardiac Events, Biomarkers and Mortality 
Cardiac events were associated with significant mortality.  The incidence 
of death approached 50% in the ACE cohort, and was over double that of 
the group in whom no cardiac event occurred (Figure 2.6).   
 
Figure 2.6.  The relationship between ACEs and death 
ACEs were associated with significant mortality, **p<0.01. 
Median levels of H-FABP were higher in non-survivors at all three time 
points, although values did not reach statistical significance (Figure 2.7).   
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Figure 2.7.  The relationship of H-FABP with death 
Box and whisker plot shows median (horizontal line within box), interquartile range 
(box) and range (error bars).  H-FABP levels were lower throughout in survivors 
compared to non-survivors, although not statistically significant (hr 0 32.8 ng/ml 
[IQR 14.8-177.5] vs. 54.6 [IQR 16.3-142.8], p=0.315; hr 24 18.2 ng/ml [IQR 8.05-
65.0] vs. 18.8 [IQR 6.2-181.7], p=0.869; hr 72 6.8 ng/ml [IQR 3.9-17.8] vs. 10.2 [IQR 
6.5-34.4], p=0.312).  
BNP was associated with death at all three time frames (Figure 2.8). 
 
Figure 2.8.  The relationship of BNP with death 
Box and whisker plot shows median (horizontal line within box), interquartile range 
(box) and range (error bars).  BNP levels were significantly greater in non-survivors 
on admission (546 fmol/ml [IQR 191.7-1066.6] vs. 403 [IQR 167-920]) at 24 hrs 
(794 fmol/ml [IQR 420.8-1837.7] vs. 567 [IQR 275-962.5]) and at 72 hrs (977 
fmol/ml [IQR 684-2150] vs. 753 [IQR 475-1275]).  *p<0.05.  
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Admission Troponin I levels were associated with survival, but no 
differences between survivors and patients who died were observed on 
either 24 or 72 hrs blood samples (Figure 2.9). 
 
Figure 2.9.  The relationship of Troponin I with death 
Box and whisker plot shows median, interquartile range and range.  Hour 0 Troponin I 
levels were higher in non-survivors (0 ng/ml [IQR 0-1.9] vs. 0 [IQR 0-0], *p<0.05), 
although no further differences between the two groups were noted (hr 24 0 
ng/ml (IQR 0-0] vs. 0 [IQR 0-0], p=0.939; hr 72 0 ng/ml (IQR 0-0] vs. 0 [IQR 0-0], 
p=0.643).   
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2.5 Discussion 
There is evidence that cardiac injury and dysfunction occur as a result of 
critical illness states, and that their development is associated with poorer 
patient outcome.  Experimental research has shown that that the heart is 
susceptible to secondary injury following trauma-haemorrhage, whilst 
limited investigations in injured patients have hinted at a harmful and 
indirect relationship between trauma and the heart.   
This study is now the first in trauma to have shown both the clinical 
manifestations of cardiac dysfunction combined with a panel of 
biochemical evidence of cardiac injury.  The investigation is subject to 
robust methodology, including adherence to and guidance from the 
REMARK guidelines on biomarker studies (Mallett et al., 2010). 
Consequently, the results of this research add to the limited current 
evidence and knowledge by identifying the existence of a TISCI.  This 
analysis implied that TISCI might not be uncommon, and may be 
associated with both significant and increased mortality.  
Neither cardiac injury nor ACEs arose as a direct result of thoracic injury, 
thus demonstrating that trauma may have an indirect, secondary effect on 
the heart.  Previous studies (M. Martin et al., 2005, Edouard et al., 1998) 
have also shown that cardiac injury is not associated with thoracic trauma, 
whilst others have revealed that ACEs occur independent of chest injury 
(Hadjizacharia et al., 2011,  Ismailov et al., 2005, Seguin et al., 2006).  Taken 
all into account, the evidence indicates that pathological processes beyond 
direct myocardial damage are implicated in the cause of TISCI. 
ACEs demonstrated a trend towards worsening injury severity.  This 
relationship was not statistically significant, perhaps as a consequence of 
the relatively small survey population, but nonetheless remains an 
association that has been recognised previously (M. Martin et al., 2005, 
Seguin et al., 2006).   
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Severely injured patients are more likely to present with adrenergic stress, 
shock and reperfusion injury and generally experience a greater 
inflammatory response.   
They are therefore more susceptible to SIRS and subsequently MODS.  
Such pathological processes have been proposed in leading to cardiac 
dysfunction in non-trauma states, and so their role in driving TISCI 
requires investigation.   
Pre-existing cardiac disease was linked with the development of an ACE, 
but not associated with death.  However, only a minority of patients had a 
diagnosis of heart disease prior to injury and this association was seen in a 
very small number of individuals in this retrospective study.  
Accordingly, future larger analyses will need to clarify the true effect of 
pre-morbid heart disease on the outcomes of injured patients. 
Patients diagnosed with an ACE were significantly older and more 
shocked, but were well matched in terms of injury characteristics with 
those in whom no cardiac event was diagnosed.  Nonetheless, the 
difference in age may be a factor between the two groups, with older 
patients being at greater risk of asymptomatic heart disease.  The presence 
of this may have triggered an ACE, precipitated by the periods of 
physiological stress and haemodynamic disturbances caused by trauma 
(Sprung et al., 2000, Reich et al., 1999).   
Although neither the incidence nor sequelae of asymptomatic cardiac 
disease in trauma are known, the condition does not provide a likely 
explanation for ACEs seen in the younger patients among this cohort.  The 
development of a cardiac event, certainly amongst these individuals, is 
likely to be driven by alternative mechanisms.  
In experimental research, increased expression and levels of cardiac IL-6 
(Yang et al., 2004, Nickel et al., 2009) and TNFα (Cai et al., 2009) result 
from trauma-haemorrhage with a subsequently deleterious impact on 
cardiac function.  In mice, the daily administration of IL-18 leads to 
interstitial fibrosis and myocyte hypertrophy. 
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This causes increased ventricular stiffness (Platis et al., 2008).  
Furthermore, circulating TNFα in plasma taken from animals subject to 
mechanical trauma and given to normal cardiomyocytes from non-
traumatised animals has been shown to lead to cardiomyocyte apoptosis 
(Li et al., 2007).   
These findings support the notion that inflammation could be an 
aetiological factor in the clinical development of a TISCI.  The role of 
inflammation in TISCI warrants, therefore, detailed exploration in a 
dedicated clinical study.  
The analysis suggested a relationship between TISCI and shock, but was 
by no means conclusive.  ACEs were associated with low SBP, and 
demonstrated a non-significant trend towards higher lactate levels.  Both 
H-FABP and Troponin I were correlated to lactate levels, but only H-FABP 
showed any statistically relationship with SBP.  BNP was unrelated to 
shock.  Consequently, there remain unanswered questions regarding 
TISCI and shock, and further the associated pathogenic processes 
resulting from the integrated roles of ischaemia-reperfusion, free radical 
production and adrenergic stress as culprits in the development of this 
condition.   
There are potential implications of these results for clinical practice.  In 
general terms, cardiac dysfunction is amongst the most well recognised 
targets for therapeutic intervention, and beta-blockers are now 
recommended in selected elderly patients undergoing major elective 
surgery (Auerbach et al., 2002).  In some studies of trauma patients, the 
presence of pre-existing cardiac disease, and in particular congestive heart 
failure, has been linked to an increase in mortality (Ferraris et al., 2010).   
Research reporting the use of cardiac medication in injured patients has 
revealed conflicting results describing both increased and decreased 
mortality and morbidity rates following trauma (Arbabi et al., 2007, 
Cotton et al., 2007, Efron et al., 2008, Neal et al., 2009, Neideen et al., 2008).   
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Although most of the evidence regarding beta-blockers in injured patients 
is retrospective in nature, the majority of papers report a survival benefit 
in patients who are beta-blocked prior to trauma.  To date, this has been 
most evident in studies examining survival following head injury, where 
it is suggested that these drugs might exert their protective effects through 
the abrogation of the detrimental effects of catecholamine surges.   
In turn, this may also lead to a reduction in bone marrow dysfunction, 
systemic inflammation and myocardial oxygen demand (Elhassan et al., 
2011). 
This study provides additional evidence that a significant number of 
patients are at risk of ACEs after trauma.  In conjunction with other 
published data (M. Martin et al., 2005, Lagi et al., 2008, Hadjizacharia et 
al., 2011), this research also highlights the clinical relevance of TISCI by 
demonstrating the poorer outcomes associated with the condition.   
Accordingly, in the event that the pathways of TISCI are better 
understood and an “at risk” population identified, studies in the future 
might better elucidate the use of selected therapeutic intervention in 
certain individuals, and enable a consensus on the use of cardiac 
medication in trauma patients.  In particular, the benefit of beta-blockers 
in improving outcomes following trauma merits further investigation in 
larger prospective studies. 
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2.6 Limitations 
Although patients, blood samples and much of the information were 
collected prospectively, individuals enrolled into this analysis were 
retrospectively selected and assessed for ACEs.  It is possible, therefore, 
that the analysis was subject to measurement bias because the 
identification of ACEs was reliant on the events being accurately 
documented.  As a result, there is the potential for misclassification of 
ACEs, with the additional likelihood that the incidence of these amongst 
patients in this cohort is in fact higher.   
Furthermore, some patient data were not available, including individual 
left ventricular function prior to trauma.  Patients with ACEs were older, 
more often diabetic and on more medication.  Thus trauma may have in 
fact simply exposed pre-existing cardiac disease that was not identified 
pre-injury.  Although this could not have been discerned in this study, it is 
possible that ACEs were the manifestation of such a process.   
Injury to the heart was demonstrated through the abnormal elevation of 
cardiac biomarkers but without visualising the heart or assessing its 
function.  Echocardiograms or ECGs were not performed on admission in 
patients in this study, and hence this research was limited by an inability 
to rule out causes for biomarker rises such as pre-existing heart failure or 
an MI.  However, raised BNP has been shown in injured patients without 
heart failure, and a high incidence of pre-injury MI is very unlikely in this 
patient group.    
The exact cause of death in this cohort of patients was not known and 
therefore whether and how TISCI contributed to the mode of death 
remains unclear.  
Finally, the study looked only at a specific group, namely severely injured 
patients.  Accordingly results might not be representative of all trauma 
patients, and may not reflect the true incidence and outcomes associated 
with TISCI.   
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2.7 Conclusions 
This is the first study to have provided both clinical and multiple 
biomarker evidence identifying the existence of TISCI, and to have 
demonstrated its association with poorer outcomes. 
Future prospective studies are needed to characterise fully the exact 
nature, incidence, risk factors, and outcomes associated with TISCI.  In 
particular post-traumatic ACEs should be investigated in a larger 
prospective study.  Such research should be undertaken in all trauma 
patients, and not remain limited to the critically ill.   
The processes implicated in driving this condition should be investigated, 
and in particular, the role of inflammation, so that eventually targeted 
management strategies may be developed to lessen the burden of TISCI in 
trauma patients.  
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CHAPTER THREE 
Trauma Induced Secondary Cardiac 
Injury and Inflammation 
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3.1 Introduction  
In conjunction with the evidence presented in Chapter Two, a growing 
body of literature points to the existence and clinical significance of TISCI.  
The pathological mechanisms that lead to this condition have not yet been 
fully identified. 
Research in trauma patients has revealed associations between TISCI and 
the degree of injury and physiological stress (Edouard et al., 1998, M. 
Martin et al., 2005), age (Hadjizacharia et al., 2011), body region injured 
(Ismailov et al., 2005), catecholamine use and SIRS (Seguin et al., 2006).  
Although separate clinical entities, these factors are all linked together by 
inflammation.  Specifically, they either trigger it, or are the product of it.    
Injury provokes a systemic inflammatory response which may cause 
MODS, the leading cause of late death in trauma (Dewar et al., 2009).  In a 
prospective study of critically injured patients, a link between 
inflammation and secondary cardiac dysfunction was demonstrated 
(Seguin et al., 2006).  Individuals who developed AF were more likely to 
experience SIRS, in addition to other conditions associated with 
inflammation such as shock, sepsis and higher catecholamine use 
(Batistaki et al., 2008).  Most recently, an association between infection and 
cardiac injury was described in trauma, and implied the existence of 
infection-related, inflammatory driven cardiac dysfunction in critically 
injured patients (Monaghan et al., 2012).  
In SIRS and subsequently MODS, inflammation dominates and 
cardiovascular dysfunction is frequent (Jastrow et al., 2009, Maier et al., 
2007, Moore et al., 1996).  Inflammation is known to reduce cardiac 
function (Prabhu, 2004) and SIRS causes myocardial depression, 
contractile dysfunction and decreased afterload (Ungureanu-Longrois et 
al., 1995, R. S. Martin et al., 2005).   
Experimental research has identified that trauma-haemorrhage leads to 
secondary cardiac injury and dysfunction and has explored many of the 
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mechanisms implicated.  To date, the role of inflammation has been the 
predominant interest of most of these studies.   
Investigations have concentrated particularly on the relationship between 
the pro-inflammatory cytokines IL-6 and TNFα and cardiac damage, and 
explored the pathways through which these effects are exerted (Yang et 
al., 2004, Li et al., 2007, Sato et al., 2007).  Experiments designed to inhibit 
these damaging pathways have demonstrated that the suppression of 
inflammatory sequences leads to restored cardiac function (Nickel et al., 
2009, Mizushima et al., 2000a, Kan et al., 2008, Zou et al., 2008).  
Although the experimental literature is suggestive, it is not translational to 
the clinical setting.  The evidence is based on rodent data from small 
numbers of healthy animals, in models of tissue injury and shock 
specifically designed to lead to cardiac damage and dysfunction.  The 
experimental data is thus limited in its applicability to a heterogeneous 
cohort of injured patients. 
Currently in the trauma literature, only one study has described an 
association between rises in pro-inflammatory cytokines, namely TNFα, 
IL-6 and IL-8, with secondary cardiac injury (Jiang et al., 1997).  The 
analysis, however, was flawed by the inclusion of only small patient 
numbers, and through the use of an unreliable and dated biomarker of 
cardiac injury (CPK).  
The causes of TISCI have not been elucidated.  Based on existing 
experimental data, inflammation is most widely implicated.  
Consequently, the association between cytokines, inflammation and 
secondary cardiac injury and dysfunction represents an important and 
novel area for research.    
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3.2 Study Aims 
The overall objective of this study was to determine if there was an early 
association between inflammation and TISCI in trauma patients, and 
explore the impact of this relationship on survival.   
Specifically, the first aim was to investigate whether there was an 
association between acute markers of inflammation and subsequent 
development of ACEs.   
Second, to investigate if there was an early correlation between 
inflammatory markers and elevations in biomarkers of cardiac injury. 
Finally, to determine whether activation of inflammation combined with 
biomarker evidence of cardiac injury on admission was associated with a 
higher in-hospital mortality rate.  
 100 
3.3 Materials and Methods 
This project identified patients and used blood samples that were 
collected as part of the ongoing prospective ACIT 2 project.  ACIT 2 was 
granted ethical approval by East London and the City Research Ethics 
Committee 1.  All data and samples used in this study were consented for.  
3.3.1 Study Design and Setting 
A retrospective cohort study of severely injured patients admitted to an 
ICU.  The project was performed at The Royal London Hospital, a major 
urban trauma centre in the United Kingdom. 
3.3.2 Study Population  
This study is undertaken in the same cohort of patients described in 
Chapter Two (Section 2.3.2).  This selection was based on investigating the 
role of inflammation in a trauma population with established evidence of 
TISCI. 
3.3.3 Data Collection  
Data collection is detailed in Chapter Two (Section 2.3.3). 
3.3.4 Outcomes  
The two study outcomes were ACEs and in-hospital death.  An ACE 
included any one of the following diagnoses; supra-ventricular 
arrhythmias, ventricular arrhythmias, acute coronary syndrome (ACS) 
and cardiogenic shock.  Diagnoses were made and documented by a 
senior intensivist or cardiologist blinded to study outcomes.  
Death was recorded as 28-day mortality of any cause.  Patients discharged 
from hospital before 28 days were assumed to be alive at day 28. 
3.3.5 Blood Collection  
Blood collection is described in Chapter Two (Section 2.3.5). 
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3.3.6 Inflammatory Marker Analysis 
A panel of common cytokines which included TNFα, IL-6 and IL-8, 
together with interferon gamma (IFNγ), interleukin 10 (IL-10), interleukin 
12 (IL-12) and interleukin 1 beta (IL-1β) was selected in order to screen the 
association between inflammation and ACEs. 
Thereafter, the three pro-inflammatory cytokines TNFα, IL-6 and IL-8 
were isolated and investigated in further detail in order to translate 
experimental evidence into the clinical context.  Their selection was based 
on the existing literature demonstrating the role of these three in leading 
to cardiac injury and dysfunction in various disease states (Vallejo et al., 
2004, Emura et al., 2010, Li et al., 2007, Yang et al., 2006, Jiang et al., 1997). 
Plasma cytokine quantification was performed on participants’ blood 
using a commercially available Multiplex pro-inflammatory cytokine 
analysis platform on a SECTOR® Imager 2400 (Mesoscale Discovery, 
Maryland, USA).  Measurements were undertaken in accordance with the 
manufacturer’s protocol.  All samples were performed in duplicate.  A 
standard curve was prepared using the standard cytokine solution 
provided, to achieve a range from 0.6 – 2500 pg/ml.  This range was well 
within the detection limits of the apparatus.  Unknown concentrations 
were obtained from the standard curve using the inbuilt Mesoscale 
software.   
Cytokine analysis was performed by Joanna Manson, a fellow researcher, 
as part of an ACIT substudy. 
There is no defined normal range of these cytokines in a heterogeneous 
population such as trauma patients.  Accordingly, a control group was 
established and included individuals who had a normal base deficit (≤2 
mEq/L) with no or minimal evidence of injury (ISS ≤5).   
Eight patients were identified using these criteria (Table 3.1) and were 
excluded from any subsequent analyses.  Cytokines were deemed elevated 
when values exceeded the median values of the control group listed 
overleaf. 
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 TNFα  2.32 pg/ml, IQR 1.74-4.18 
 IL-6  10.45 pg/ml, IQR 1.41-55.02 
 IL-8  5.38 pg/ml, IQR 2.56-12.16 
Table 3.1.  Control Group Characteristics and Admission Cytokine 
Levels   
 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 
Gender F M M M M M M M 
Age, years 47 27 43 40 59 37 28 62 
Injury Characteristics 
Mechanism B B P B B B B B 
ISS 4 5 1 1 4 5 5 4 
Thorax AIS 0 0 0 0 0 2 0 0 
Admission Physiology 
SBP, mmHg 178 220 124 132 135 132 156 161 
Heart rate, bpm 69 118 121 82 120 88 130 100 
Base excess, mEq/L 2 1.5 1.2 -3.2 -0.4 0.6 0.1 1.2 
Admission Cytokine Levels (pg/ml) 
TNFα 2.01 2.27 2.36 1.46 3.27 1.65 4.48 5.48 
IL-6 38.62 1.06 5.68 0.32 60.48 2.44 15.22 90.38 
IL-8 4.29 2.58 1.84 2.55 12.33 6.48 24.01 11.63 
28 day Survival         
 Alive Alive Alive Alive Alive Alive Alive Alive 
 
Pt=patient, F=female, M=male, B=blunt, P=penetrating, bpm=beats per minute. 
3.3.7 Biomarker Assays 
H-FABP, BNP and Troponin I were selected as markers of cardiac injury.  
Biomarker analysis is detailed in Chapter Two (Section 2.3.6).  For the 
purposes of this study, elevated levels of H-FABP were defined as ≥20 
ng/ml, BNP as ≥300 fmol/ml and Troponin I as ≥0.03 ng/ml.   
These levels were based on a combination of the ELISA kit manufacturers’ 
guidelines and existing literature defining both normal and abnormal 
values of these biomarkers. 
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3.3.8 Statistical Analysis 
Data analyses were performed using SPSS version 20 (SPSS Inc., Chicago 
IL).  Statistical significance was set as a two tailed p value of <0.05. 
Data are presented as medians with interquartile ranges, unless otherwise 
specified.  Non-parametric data were compared using the Mann Whitney 
U test.  Correlation between biomarkers and cytokines was performed 
using Spearman correlation.  Proportions were analysed using Fisher’s 
exact test and Chi Squared test for trend.   
Simple univariate regression determined the correlation of cytokines with 
age.  To discover the independent association between H-FABP (as the 
earliest marker of cardiac injury) and inflammation on admission, 
multiple linear regression analysis was applied.  The enter method was 
used with the probability of F set at p<0.05 to enter and p>0.1 for removal.  
H-FABP represented the dependent variable, and age, ISS, base excess and 
hour 0 levels of TNFα, IL-6 and IL-8 were the predictor variables. 
The final aim was to investigate whether on admission, evidence of 
cardiac injury (defined by an elevated level of H-FABP, BNP or Troponin 
I) combined with activation of inflammation (demonstrated by an elevated 
level of TNFα, IL-6 or IL-8) was predictive of in-hospital death.  
Accordingly, patients were divided into four distinct groups:   
1. Patients with normal biomarker and normal cytokine values.   
2. Patients with an elevated biomarker value and a normal cytokine 
level.  
3. Patients with a normal biomarker level and an elevated cytokine 
value.   
4. Patients with both an elevated biomarker and elevated cytokine 
level.   
Group 1 was used as the control group (Relative Risk [RR]=1) and the 
relative risk of in-hospital death was calculated among the remaining 
three groups based on comparisons to the first.  
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3.4 Results 
One hundred and thirty five patients were recruited to the study.  
Eighteen (13.3%) individuals had an ACE during admission, and 28 
patients (20.7%) died.  Patient characteristics are summarised in Table 3.2.   
Table 3.2.  Patient Characteristics, Adverse Cardiac Events and 
Outcomes  
 All No ACE ACE p Value 
Number 135 117 18   n/a 
Male n (%) 106 (79) 92 (79) 14 (78)   1.000 
Age, years  40 (16-89) 37 (16-89) 64 (23-88) <0.001 
ISS  23 (13-30) 22 (13-30) 29 (19-35)    0.069 
Thorax AIS 3 (0-4) 3 (0-4) 3 (0-4)   0.348 
Admission SBP, mmHg 134 (62-220) 134 (62-220) 108 (63-160)   0.049 
Admission GCS 15 (14-15)  13 (7-15)  14 (11-15)    0.191 
Type of ACE, n (%)     
Supra-ventricular arrhythmia  13 (9.6) n/a 13 (65)   n/a 
Ventricular arrhythmia 1 (0.74) n/a 1 (5)   n/a 
Acute coronary syndrome 3 (2.2) n/a 3 (15)   n/a 
Cardiogenic shock 3 (2.2) n/a 3 (15)   n/a 
Outcomes     
ICU stay, days 5 (2-11) 4 (2-8) 11 (5-19)   0.005 
Hospital stay, days  14 (5-28) 14 (5-27) 20 (5-37)    0.385 
Mortality, n (%) 28 (21) 20 (17) 8 (45)   0.008 
 
Data are presented as median (interquartile range) unless otherwise stated. 
Comparisons are between the No ACE and ACE cohorts. 
3.4.1 Inflammation and Adverse Cardiac Events  
Amongst this cohort of severely injured patients, the cytokines TNFα, IL-6, 
IL-8 and IL-1β demonstrated an association with ACEs (Figure 3.1 A-D).   
Immediately on admission, and hence within two hours of injury, plasma 
levels of TNFα, IL-6 and IL-8 were all significantly higher in patients who 
subsequently developed an ACE in-hospital compared to those who did 
not (Figure 3.1 A-C).   
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Figure 3.1. A-D.  Relationship of TNFα, IL-6, IL-8 and IL-1β with adverse 
cardiac events 
Box and whisker plots show median (horizontal line within box), interquartile range 
(box) and range (error bars).  A:  Admission TNFα levels were higher in ACE 
patients (5.42 pg/ml [IQR 4.34-10.50] vs. 3.84 [IQR 2.86-9.28]), but no differences 
were noted at 24 hrs (5.01 pg/ml [IQR 1.95-58.05] vs. 5.62 [IQR 1.34-167.80], 
p=0.935) or 72 hrs (4.79 [IQR 3.95-11.11] vs. 2.56 pg/ml [IQR 1.76-8.67], p=0.119).  
B:  ACE patients had greater levels of IL-6 on admission (85.37 pg/ml [IQR 44.72-
308.94] vs. 24.39 [IQR 4.07-247.97]).  There were no differences between the two 
groups at 24 hrs (146.34 pg/ml [IQR 24.34-3762.05] vs. 126.02 [IQR 24.39-1159.79], 
p=0.390) and 72 hrs (96.46 pg/ml [IQR 66.19-186.00] vs. 51.80 [IQR 12.22-146.34], 
p=0.087).  C:  In patients with ACEs, admission (19.33 pg/ml [IQR 9.56-52.43] vs. 
9.18 [IQR 4.71-24.65]) and 72 hrs (14.50 pg/ml [IQR 8.87-36.81] vs. 5.85 [IQR 3.25-
19.44]) levels of IL-8 were higher.  24 hrs levels were no different (30.26 pg/ml 
[IQR 6.80-127.08] vs. 10.64 [IQR 5.29-36.81], p=0.098).  D:  Patients with a cardiac 
event had significantly higher levels of IL-1β at 72 hrs (0.55 pg/ml [IQR 0.29-5.94] 
vs. 0.19 [IQR 0.09-8.92]), but there were no significant differences between the 
two groups on admission (0.64 pg/ml [IQR 0.09-12.90] vs. 0.17 [IQR 0.05-29.81], 
p=0.130) or at 24 hrs (0.52 pg/ml [IQR 0.08-53.69] vs. 0.19 [IQR 0.07-36.78], 
p=0.333).  *p<0.05, **p<0.01. 
Although all cytokine values were highest at 24 hrs, there were no 
significant differences in levels between the two groups of patients at this 
time point.   
D 
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However, the median IL-8 level at 24 hrs was 2.8 times higher in patients 
with ACEs than in those without.  Moreover both IL-8 and IL-1β levels 
were statistically greater in ACE patients at 72 hrs (Figure 1 C&D). 
Conversely, there were no significant differences in IFNγ, IL-10 and IL-12 
levels between patients who experienced an ACE in-hospital compared to 
those who did not (Table 3.3). 
Table 3.3.  Levels of IFNγ, IL-10 and IL-12 and Adverse Cardiac Events  
 Time Point (Hr) No ACE ACE p Value 
IFNγ 
(pg/ml) 
0 0.74 (0.21-1.85) 1.79 (0.36-10.16) 0.185 
24 2.21 (0.31-11.11) 2.37 (0.08-20.24) 1.000 
72 0.47 (0.17-8.22) 0.85 (0.40-5.77) 0.284 
     
IL-10 
(pg/ml) 
0 48.52 (9.29-106.10) 30.15 (14.84-135.4) 0.603 
24 10.03 (2.33-29.08) 16.13 (5.30-78.28) 0.370 
72 3.88 (1.13-11.98) 8.33 (5.09-20.37) 0.113 
     
IL-12 
(pg/ml) 
0 1.06 (0.44-5.19) 0.79 (0.17-9.21) 0.296 
24 4.15 (0.13-36.01) 2.06 (0.577-70.39) 0.485 
72 0.67 (0.15-5.54) 2.63 (0.46-24.40) 0.152 
 
Data are presented as median (interquartile range). 
Patients with cardiac events were significantly older (Table 3.2).  
Univariate linear regression was performed, therefore, to determine 
whether age was a confounder for those cytokines associated with ACEs 
and age (Table 3.4).  
The analysis revealed that overall, age was not a confounder for higher 
cytokine levels.  Only 24 hr levels of IL-8 correlated significantly.  In 
patients with cardiac events, therefore, raised cytokine values were not the 
product of older age. 
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Table 3.4.  Relationship of Cytokines with Age   
 Time Point (Hr) Beta Coefficient p Value 
 0 -0.48 0.302 
TNFα 24 -0.01 0.617 
 72  0.86 0.140 
  
  
 0 -0.13 0.569 
IL-1β 24  0.03 0.084 
 72  0.40 0.507 
  
 
 
 0  0.07 0.376 
IL-6 24  0.02 0.100 
 72  0.09 0.649 
    
 0  0.48 0.408 
IL-8 24  0.01 0.019 
 72  0.13 0.060 
 
3.4.2 Inflammation and Cardiac Injury  
The relationship between levels of the pro-inflammatory cytokines TNFα, 
IL-6 and IL-8 with the biomarkers of cardiac injury was examined on 
admission, and again at 24 and 72 hrs.   
Admission levels of H-FABP correlated with admission levels of TNFα, IL-
6 and IL-8 (Figure 3.2 A-C).   
Within two hours of injury, therefore, incremental rises in each cytokine 
were associated with elevations in H-FABP, thereby providing evidence of 
a relationship between inflammation and cardiac injury. 
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Figure 3.2. A-C.  Correlation between admission levels of cytokines and 
H-FABP 
Box and whisker plots show median (horizontal line within box), interquartile range 
(box) and range (error bars).  A:  TNFα and H-FABP (24.70 ng/ml [10.40-39.53] vs. 
26.85 [15.58-46.18] vs. 44.60 [27.10-97.50] vs. 71.95 [20.40-149.90]).  B:  IL-6 and H-
FABP (17.90 ng/ml [10.30-27.75] vs. 25.70 [14.10-35.80] vs. 45.70 [25.13-118.80] vs. 
100.20 [48.40-175.80]).  C:  IL-8 and H-FABP (15.00 ng/ml [10.05-26.28] vs. 32.00 
[17.90-44.60] vs. 44.40 [22.95-109.40] vs. 89.95 [46.68-160.90]).  **p<0.01, 
***p<0.001. 
The correlation between all the cytokines and the biomarkers is shown in 
Table 3.5 overleaf.  IL-8 levels correlated with plasma levels of H-FABP at 
all time points.  IL-6 was associated with rises in H-FABP not only on 
admission, but also at 72 hrs.  TNFα correlated with H-FABP only at 0 hr.  
There was no correlation, however, between either TNFα, IL-6 or IL-8 and 
BNP at any point.  Similarly, the three cytokines demonstrated no 
association with Troponin I on admission, or at any subsequent time 
frame (Table 3.5).  
Early activation of inflammation was thus associated with release of H-
FABP into the plasma, and this relationship may persist for at least 72 hrs 
after injury. 
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Table 3.5.  Correlation between Cytokine Levels and Biomarkers 
 Time (Hr) H-FABP BNP Troponin I 
TNFα 
0 
0.41 (0.2 - 0.55) 
p<0.001 
0.14 (-0.07 - 0.34) 
p=0.174 
0.06 (-0.16 - 0.27) 
p=0.585 
24 
0.22 (-0.06 - 0.47) 
p=0.118 
-0.15 (-0.41 - 0.13) 
p=0.272 
0.14 (-0.14 - 0.4) 
p=0.318 
72 
0.27 (-0.02 - 0.52) 
p=0.062 
0.25 (-0.03 - 0.49) 
p=0.069 
-0.12 (-0.37 - 0.18) 
p=0.466 
     
IL-6 
0 
0.63 (0.48 - 0.74) 
p<0.001 
0.09 (-0.12 - 0.29) 
p=0.375 
0.07 (-0.14 - 0.3) 
p=0.491 
24 
0.25 (-0.03 - 0.5) 
p=0.073 
-0.07 (-0.34 - 0.21) 
p=0.613 
0.07 (-0.20 - 0.34) 
p=0.615 
72 
0.44 (0.17 -0.65) 
p=0.002 
0.01 (-0.27 - 0.29) 
p=0.920 
-0.03 (-0.31 - 0.25) 
p=0.842 
     
IL-8 
0 
0.62 (0.47 - 0.74) 
p<0.001 
0.16 (-0.05 - 0.36) 
p=0.114 
0.03 (-0.2 - 0.24) 
p=0.772 
24 
0.28 (-0.03 - 0.52) 
p=0.044 
-0.16 (-0.42 - 0.12) 
p=0.257 
0.05 (-0.23 - 0.32) 
p=0.716 
72 
0.40 (0.16 - 0.64) 
p=0.002 
0.26 (-0.02 - 0.51) 
p=0.059 
-0.02 (-0.29 - 0.27) 
p=0.909 
 
Data presented as Spearman r value (95% confidence intervals) with p values.   
In order to adjust for the positive relationship between H-FABP and 
inflammation on admission, multiple regression analysis was 
subsequently performed.  H-FABP was entered as the dependent variable 
and age, ISS, base excess, TNFα, IL-6 and IL-8 were examined as the 
covariates (Table 3.6).  The model was a fair fit (R²=0.342) and the overall 
association was significant (F[4,85]=11.030, p<0.001).   
Table 3.6.  The Relationship Between H-FABP and the Covariates 
Variable Beta Coefficient p Value 
Age  0.367 <0.001 
Base excess -0.131 0.198 
ISS  0.188 <0.05 
TNFα -0.234 0.539 
IL-6  0.206 <0.05 
IL-8  0.064 0.511 
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The analysis revealed that age, ISS and IL-6 were all independent 
predictors of an increased H-FABP.  In contrast, base excess, TNFα and IL-
8 were not associated with the biomarker.   
Thus in addition to older age and increasing tissue injury, evidence of 
inflammation on admission independently predicted cardiac injury (using 
H-FABP levels) in this cohort of trauma patients. 
3.4.3 Inflammation, Cardiac injury and Survival   
On admission plasma samples, patients who presented with an elevated 
H-FABP combined with an elevation in any of the three cytokines were 
not placed at an increased risk of in-hospital death (Figure 3.3 A-C).  
 
 
A 
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Figure 3.3. A-C.  The relationship between inflammation and H-FABP 
on admission with in-hospital mortality 
Relative risk of death (with 95% Confidence Intervals) is shown for each group 
(N=normal level, E=elevated level).  Hashed line indicates a relative risk of 1.  A:  H-
FABP and TNFα.  (E H-FABP and N TNFα, p=1.000, N H-FABP and E TNFα, 
p=1.000, E H-FABP and E TNFα, p=0.566).  B:  H-FABP and IL-6.  (E H-FABP and 
N IL-6, p=1.000, N H-FABP and E IL-6, p=1.000, E H-FABP and E IL-6, p=0.448).  
C:  H-FABP and IL-8.  (E H-FABP and N IL-8, p=0.618, N H-FABP and E IL-8, 
p=1.000, E H-FABP and E IL-8, p=0.526). 
On hour 0 plasma samples, patients who presented with an elevated BNP 
in combination with evidence of high levels of inflammation were not 
found to be placed at an increased risk of in-hospital death.   
In particular, a high BNP level combined with an elevated TNFα on 
admission was not associated with a higher risk of death in this patient 
population (Figure 3.4).   
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Figure 3.4.  The relationship between TNFα and BNP on admission 
with in-hospital mortality 
Relative risk of death (with 95% Confidence Intervals) is shown for each group 
(N=normal level, E=elevated level).  Hashed line indicates a relative risk of 1.  E BNP 
and N TNFα, p=1.000, N BNP and E TNFα, p=1.000, E BNP and E TNFα, 
p=0.493.   
Similarly, neither the combination of an elevated BNP with elevated IL-6, 
nor a raised BNP and raised IL-8 produced significantly higher relative 
risks of in-hospital death compared to the other groups in the analysis 
(Figure 3.5 A&B). 
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Figure 3.5. A & B.  The relationship between IL-6 and IL-8 with BNP on 
admission with in-hospital mortality 
Relative risk of death (with 95% Confidence Intervals) is shown for each group 
(N=normal level, E=elevated level).  Hashed line indicates a relative risk of 1.  A:  BNP 
and IL-6.  (E BNP and N IL-6, p=1.000, N BNP and E IL-6, p=1.000, E BNP and E 
IL-6, p=0.768).  B:  BNP and IL-8.  (E BNP and N IL-8, p=1.000, N BNP and E IL-8, 
p=1.000, E BNP and E IL-8, p=0.605). 
Furthermore, no differences between any of the groups were elucidated.  
No single BNP and cytokine combination was associated with an 
increased risk of in-hospital mortality. 
However, when demonstrated by an elevated Troponin I concentration, 
early evidence of cardiac injury combined with evidence of hyperacute 
activation of inflammation was associated with a significantly greater 
relative risk of in-hospital death in this severely injured trauma 
population.   
Specifically, patients with an elevated Troponin I and an elevated TNFα 
on admission were placed at the highest risk of death when compared to 
the other groups (Figure 3.6). 
B 
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Figure 3.6.  The relationship between TNFα and Troponin I on 
admission with in-hospital mortality 
Relative risk of death (with 95% Confidence Intervals) is shown for each group 
(N=normal level, E=elevated level).  Hashed line indicates a relative risk of 1.  E 
Troponin I and N TNFα, p=0.091, N Troponin I and E TNFα, p=0.546, E Troponin 
I and E TNFα, p=0.015. 
Patients with a raised Troponin I and either a raised IL-6 or IL-8 were also 
placed at the greatest risk of death (Figure 3.7 A&B). 
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Figure 3.7. A & B.  The relationship between IL-6 and IL-8 with 
Troponin I on admission with in-hospital mortality 
Relative risk of death (with 95% Confidence Intervals) is shown for each group 
(N=normal level, E=elevated level).  Hashed line indicates a relative risk of 1.  A:  
Troponin I and IL-6.  (E Troponin I and N IL-6, p=0.871, N Troponin I and E IL-6, 
p=0.297, E Troponin I and E IL-6, p=0.001).  B:  Troponin I and IL-8.  (E Troponin 
I and N IL-8, p=0.002, N Troponin I and E IL-8, p=0.176, E Troponin I and E IL-8, 
p=0.008). 
Critically injured patients who presented on admission with both an 
elevated Troponin I and an elevated cytokine were found to have at least a 
ten fold greater risk of death compared to patients in the other groups.  
Individuals with a raised Troponin I and a normal IL-8 on 0 hr plasma 
samples level also had a significantly higher risk of death. 
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3.5 Discussion 
Increasingly there is evidence to suggest that trauma may lead to the 
development of cardiac injury and dysfunction in the absence of direct 
damage to the heart.  The condition, TISCI, may be associated with worse 
clinical outcomes, although the pathological mechanisms that cause it are 
not known.  As such, the purpose of this study was to be the first to 
identify the relationship between TISCI and acute inflammation. 
The project completed all its aims, and revealed that in severely injured 
patients, clinical and biochemical evidence of secondary cardiac injury 
was associated with inflammation.  Specifically, activation of 
inflammation within two hours of injury was associated with the 
subsequent development of ACEs, and was correlated with H-FABP 
release.  Finally, this study demonstrated that on admission, the 
combination of inflammation and cardiac injury may place trauma 
patients at a higher risk of in-hospital death.     
These new findings are corroborated by existing clinical evidence.  Studies 
have shown that trauma leads to activation of inflammation, including the 
production of IL-6, IL-8 and TNFα (Moore et al., 1996, Maier et al., 2007, 
Jastrow et al., 2009, Spielmann et al., 2001).  This may in turn lead to SIRS 
and MODS.  In injured patients, an association between AF and SIRS has 
been previously demonstrated, as well as relationships with other 
conditions related to high levels of inflammation (Seguin et al., 2006).   
However, while supportive of the link between inflammation and post-
traumatic cardiac dysfunction, the study referenced above examined only 
a single cardiac diagnosis, and did not investigate the association with 
secondary cardiac injury.  Furthermore, the aim of their analysis was to 
investigate the incidence and risk factors associated with AF exclusively, 
and hence inflammation was only measured in terms of clinical correlates 
(e.g. SIRS, higher catecholamine use).   
In contrast to previous research, this study is therefore not only 
strengthened by investigating the association of inflammation with all 
 119 
manifestations of cardiac dysfunction, but is also the first to combine this 
with a panel of specific markers of cardiac injury.   
Further, through the measurement of both cytokines and biomarkers, the 
link between inflammation and cardiac injury in this project was 
demonstrated objectively and quantitatively. 
The findings of an association between inflammation and cardiac injury 
are substantiated by a Japanese review of autopsy cases of patients with 
MODS (Emura et al., 2010).  High levels of IL-6, IL-8 and TNFα were 
found in blood taken directly from the heart and this was associated with 
evidence of cardiac myocyte necrosis.  None of the patients in the Japanese 
study were trauma victims, but these results nevertheless support an 
association between MODS, inflammation and cardiac injury. 
Furthermore, the Japanese study mitigates a weakness of this project.  
Because only peripheral blood was sampled, the cytokines measured in 
this analysis were within the systemic circulation and were not localised to 
any specific organ or tissue.  The postmortem investigation demonstrated 
that in MODS, inflammation occurs within the heart itself and causes 
cardiac injury.  It provided, therefore, evidence that the associations 
revealed in this study have a direct pathological basis. 
As such, the results of this analysis combined with the autopsy findings 
lead to the hypothesis that cardiac dysfunction might be implicated in the 
late deaths observed in trauma patients with MODS.  Future projects 
should establish whether this is the case.     
Non-trauma based research further supports the results of this study, and 
inflammation has been widely implicated in cardiac disease and failure 
(Chen et al., 2008, Hohensinner et al., 2011).  C-reactive protein (as a 
marker of systemic inflammation), for example, may be independently 
associated with AF, and levels might also be predictive of future episodes 
(Aviles et al., 2003).   
The findings presented in this study of early differences in cytokine levels 
in patients with cardiac dysfunction contrasted to those without are not 
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new.  Individuals with acutely decompensated heart failure have been 
shown to have significantly higher admission IL-6, TNFα and IL-1β levels 
compared to controls without cardiovascular disease (Suzuki et al., 2005).  
Moreover, IL-6 values may correlate significantly with the severity of the 
disease, and TNFα levels are higher in decompensated patients.  However, 
such differences have not been demonstrated previously in injured 
patients.  Consequently, this study adds new evidence to the existing body 
of literature in this narrow field of trauma research.   
Experimental models have investigated the role of inflammation and the 
mechanisms through which it leads to cardiac injury following trauma-
haemorrhage (Vallejo et al., 2004, Mizushima et al., 2000, Nickel et al., 
2009, Li et al., 2007, Yang et al., 2004, Sato et al., 2007).  These have 
revealed in animals almost identical cytokine responses to trauma over 
parallel time frames.  
Specifically, TNFα levels peak an hour and a half after non-lethal 
mechanical trauma, and lead to cardiomyocyte apoptosis through 
overproduction of cytotoxic reactive oxygen and nitrogen species (Li et al., 
2007).  In addition, the upregulation of IL-6 in cardiomyocytes may occur 
within two hours of trauma-haemorrhage and is associated with 
decreased cardiac output, stroke volume and left ventricular performance 
(Yang et al., 2004, Yang et al., 2007, Yang et al., 2006).  Myocardial damage 
may occur within three hours of ischaemia-reperfusion, and results in the 
subsequent activation of inflammasomes and IL-1β production 
(Kawaguchi et al., 2011). 
Although the basic science research ratifies the results of this study, it also 
highlights a weakness of this project, namely its failure to demonstrate the 
precise mechanistic processes leading to TISCI.  At this stage, only 
inferences can be drawn from the experimental evidence, which suggests 
that inflammation causes mainly functional and not structural changes to 
the heart.  These cause decreased contractility and myocardial depression.   
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Because cytokines also generate cardiomyocyte injury and apoptosis 
through oxidative and nitrative stresses, these in turn may generate or 
further compound existing cardiac dysfunction.  Notwithstanding, further 
investigation is required in patients to determine the precise mechanisms 
through which inflammation causes TISCI.  
This study has provided new understandings regarding the interaction of 
early cardiac injury, inflammation and in-hospital mortality.  Prior 
investigation of inflammation in injured individuals has shown that 
certain cytokine profiles in trauma may be predictive of death (Hranjec et 
al., 2010), whilst Troponin I is a recognised predictor of poor outcome in 
many disease states (Kim et al., 2002, King et al., 2005, Wu et al., 2004).  
Similarly, improved prediction of in-hospital mortality has been 
demonstrated when the inflammatory status is added to a model designed 
to predict death in trauma patients (Park et al., 2008).  In Park’s study this 
was combined with coagulation, but it suggests that the synergism of 
inflammation with organ injury or body system failure might be a risk 
factor for increased mortality. 
Although the result of a preliminary retrospective analysis, the findings of 
this research may provide some potential explanations to the survival 
benefits observed in patients on certain cardiac medications.  Both statins 
and beta-blockers have been associated with improved function and 
survival in selected studies (Efron et al., 2008, Schneider et al., 2011, 
Arbabi et al., 2007, Cotton et al., 2007, M. Martin et al., 2005).  Although 
most widely used for preserving cardiac function and lowering 
cholesterol, both have significant anti-inflammatory properties.  In 
addition, severely injured younger females have been shown to have a 
lower incidence of MODS, sepsis and lesser plasma cytokine levels 
compared to male counterparts (Frink et al., 2007).  This observation has 
been postulated to be the result of the protective effects of oestrogen on 
the immune response, and further suggests the detrimental effect of 
inflammation on organ function. 
 
 122 
Animal data has also shown both increased survival (Cai et al., 2009) and 
restoration of cardiac function (Tsai et al., 2011) when downregulating the 
inflammatory response to trauma-haemorrhage.  Furthermore, TNFα 
blockade in pigs may attenuate or even prevent myocardial dysfunction in 
those animals with significant increases in plasma TNFα following 
resuscitation after cardiac arrest (Niemann et al., 2010).   
In combination with the evidence presented above, this study generates an 
additional hypothesis of an association between survival with 
preservation of cardiac function and attenuation of inflammation, and 
encourages further research in this area. 
Finally, the analysis revealed that early activation of inflammation was 
associated with H-FABP release, but not Troponin I or BNP.  Although the 
reasons behind this discordance are uncertain, these results might be a 
reflection of both the different kinetics and mechanisms of release of the 
biomarkers, particularly in the acute stages.  H-FABP appears in the 
circulation more rapidly than Troponin I and BNP following damage to 
the heart, and is the earliest, most sensitive biomarker to rise following 
cardiac injury (McMahon et al., 2012 ).  It follows, therefore, that this 
marker was most likely to show an association with inflammation on 
admission blood samples, which were taken within two hours of injury.   
Troponin I, however, is the most specific indicator of myocardial injury 
(Babuin et al., 2005), and so perhaps heart damage may not have always 
been present in spite of elevated H-FABP levels.  This might also explain 
why only a combination of Troponin I with the cytokines was predictive 
of survival, given that a rise in this biomarker was most likely to have 
indicated cardiac injury.  H-FABP and BNP elevations may have been less 
specific to the heart. 
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3.6 Limitations  
The study is subject to a number of limitations.  Firstly, because of the 
retrospective identification of ACEs, the reported incidence and nature of 
the cardiac events in this project may have been inaccurate.  Such 
methodology will most likely have led to the under-reporting of ACEs, 
and this in turn may have altered the statistical accuracy of the results 
presented.  
Cardiac dysfunction was described in terms of ACEs, but was not 
demonstrated in each individual case by imaging or functional studies 
such as echocardiography.  In future research, the use of such modalities 
should be employed to characterise more accurately not only the nature 
but also the degree of the cardiac abnormalities induced by trauma.   
All ACEs were grouped together, in spite of the observation of multiple 
cardiac diagnoses.  Nonetheless, it was the aim of this study to describe all 
the events witnessed in this cohort of critically injured patients, and 
investigate their overall association with inflammation.  It is possible, 
however, that specific cardiac events are associated with different 
initiating factors, and so the involvement of inflammation may be greater 
or lesser according to each individual diagnosis. 
Only the acute relationship between inflammation and TISCI was 
examined.  Although the bulk of evidence has investigated primarily the 
early relationships and characteristics of the inflammatory response to 
trauma, future research would benefit from identifying the more 
protracted relationship between inflammation and TISCI. 
It is possible that many of the inconsistencies between H-FABP, BNP and 
Troponin I were a consequence of the study being underpowered by too 
few patients in the analysis, given that many of the trends are similar but 
lack statistical significance. 
A further limitation of the study is that whilst it demonstrated an 
association between inflammation and TISCI, the mechanistic, 
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pathological link between the two was not demonstrated, and requires 
further characterisation.  
Moreover, the findings of an association between inflammation and post-
traumatic cardiac injury and dysfunction were demonstrated using a 
handful of cytokines, despite the fact that there exists greater numbers of 
inflammatory markers.  However, the purpose of this study was to 
examine this association using the markers of inflammation most 
commonly referenced to in the existing literature, which are those that 
have been shown to rise following trauma and are associated with cardiac 
damage. 
These results are specific to a cohort of critically injured patients.  Such 
individuals are in all likelihood more susceptible to cardiac injury, and 
exposed to higher levels of inflammation.  Consequently, the association 
described between inflammation and TISCI in this cohort is potentially 
subject to other confounding variables, including higher ISS scores and 
greater inotrope use for example.  As such, these findings might not be 
applicable to less seriously injured trauma patients.   
Lastly, although the relationship between cardiac injury (using H-FABP) 
and inflammation (IL-6) was demonstrated in an adjusted multivariate 
regression analysis model, the R2 value was relatively low, and few 
predictor variables were included.  Future research would benefit 
correspondingly from larger studies designed to collect prospective data 
on all potentially confounding variables. 
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3.7 Conclusions 
This study of critically injured trauma patients has revealed an acute 
association between inflammation and clinical and biochemical evidence 
of secondary cardiac injury.  In addition, this project has provided 
evidence that on admission, patients who presented with a combination of 
elevated cytokine levels and cardiac injury were at increased risk of in-
hospital death.  
This research will serve as a base for future work.  These include larger 
prospective studies undertaken to understand better the relationship 
between inflammation and TISCI over a longer time period.  Additionally, 
analyses are required of the mechanistic pathways leading to secondary 
cardiac injury and dysfunction that are driven by inflammation.  
Ultimately, this work should lead to trials of therapeutic avenues designed 
to minimise the morbidity and mortality associated with TISCI.  In the 
first instance, these should be directed at downregulating inflammation 
and preserving cardiac function. 
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CHAPTER FOUR 
Adverse Cardiac Events in a 
General Trauma Population:   
A Prospective Study 
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4.1 Introduction 
Clinical evidence suggests that trauma can lead to secondary cardiac 
injury and dysfunction (TISCI) which may be associated with poorer 
patient outcomes (Kirchhoff et al., 2008, Hadjizacharia et al., 2011, 
Moosikasuwan et al., 2000, Ismailov et al., 2005, Seguin et al., 2006, M. 
Martin et al., 2005, Lagi et al., 2008, Edouard et al., 1998). 
The evidence supporting the existence of TISCI is limited, however.  Much 
of the research is retrospective in nature, and conducted in specific 
populations, such as critically injured patients (M. Martin et al., 2005) or 
individuals with mild trauma (Lagi et al., 2008).  Although certain studies 
are prospective, they have included relatively small numbers of 
individuals (Edouard et al., 1998, Kirchhoff et al., 2008), or have 
investigated the features of a single diagnosis (AF) in a selected patient 
cohort (Seguin et al., 2006).  Larger studies are mainly constrained to 
retrospective database reviews which have only examined specific 
diagnoses in isolation, such as AA (Hadjizacharia et al., 2011) or MI 
(Ismailov et al., 2005).   
In Chapter Two, the existence of TISCI was further identified.  Nonetheless, 
the detection of ACEs was performed retrospectively, and remained 
limited to a selected group of patients, namely those admitted to an ICU. 
On the basis of previous research, therefore, it remains inconclusive as to 
whether a general trauma population is susceptible to ACEs following 
injury.  If so, the epidemiology, clinical features and outcomes of these 
events are uncertain, and the risk factors for their development poorly 
determined. 
Moreover, the precise nature of ACEs in all categories of trauma patients 
has not been fully established hitherto.  In particular, no research has 
examined whether there is a correlation between ACEs in injured patients 
and a stress induced cardiomyopathy, commonly referred to as 
Takotsubo’s.   
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Currently in trauma, Takotsubo’s cardiomyopathy has only been 
described in a couple of case reports (Vergez et al., 2009, Morita et al., 
2010).   
It is an acute and reversible cardiac disorder characterised by left 
ventricular dysfunction and is usually triggered by stressful physical or 
psychological events (Prasad et al., 2008).  Although the pathophysiology 
is not known, dysfunctional metabolism of fatty acids, mitochondrial 
disturbances, stress-induced catecholamine release with subsequent 
cardiac stunning and vasoconstriction of the coronary arteries leading to 
microvascular dysfunction have all been proposed (Akashi et al., 2008).   
Takotsubo’s may well be implicated in trauma patients who develop 
cardiac events, given these individuals are exposed to significant physical 
and psychological stress following injury.  H-FABP levels are increased 
after trauma (Chapter Two), and this may mirror derangement of fatty acid 
metabolism in the heart.  In addition, trauma causes mitochondrial 
changes (Zhang et al., 2010) and injured patients are exposed to high 
levels of both circulating endogenous and exogenous catecholamines.  
Finally, trauma can lead to shock, which results in systemic 
haemodynamic changes including vasoconstriction.   
Patients with Takotsubo’s may present with symptoms of an ACS or be 
asymptomatic.  The disorder may manifest with arrhythmias, heart 
failure, ECG changes, cardiogenic shock or death, likening the 
presentation of many of the patients with ACEs in Chapter Two.  
The most characteristic feature of the syndrome is apical ballooning of the 
left ventricle in association with diminished left ejection fraction.  
Although there is no consensus on the diagnostic specifications for 
Takotsubo’s cardiomyopathy, the Mayo criteria are commonly referred to 
(Table 4.1). 
In spite of the possible association between Takotsubo’s syndrome and 
post-traumatic ACEs, the relationship connecting the two has yet to be 
formally established. 
 129 
Table 4.1.  Mayo Criteria for a Diagnosis of Takotsubo’s 
Cardiomyopathy 
 
1 Transient hypokinesis, akinesis, or dyskinesis of left ventricular mid segments with or 
without apical involvement; regional wall motion abnormalities extend beyond a single 
epicardial vascular distribution; stressful trigger is often, but not always present 
2 Absence of obstructive coronary disease or angiographic evidence of acute plaque 
rupture 
3 New electrocardiographic abnormalities (either ST-segment elevation and/or T-wave 
inversion) or modest elevation in cardiac Troponin 
4 Absence of Phaeochromocytoma or Myocarditis 
 
For a diagnosis of Takotsubo’s, all four criteria must be met (Taken from Prasad 
et al., 2008). 
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4.2 Study Aims  
The overall study objective was to confirm the existence of TISCI and 
further define the features of ACEs in a general trauma population.   
The first aim was to determine the epidemiology and clinical features of 
ACEs in a non-specific cohort of injured patients.   
Second, to determine whether post-traumatic ACEs were the manifestation 
of Takotsubo’s syndrome.   
Third, to compare the characteristics of patients with and without ACEs.   
Fourth, to examine the outcomes associated with ACEs in a general cohort 
of injured patients.   
Finally, to identify the risk factors associated with the development of 
ACEs in all injured patients.  
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4.3 Materials and Methods  
This study is an analysis of data generated from the Trauma Associated 
Cardiac Injury and Dysfunction A (TACID A) research programme.  TACID 
is a large observational study created and designed to investigate TISCI in 
detail, including its longer-term outcomes.   
TACID received ethical approval from the Cambridgeshire 3 Research Ethics 
Committee the 3rd of September 2010 (REC reference number: 10/H0306/47).  
4.3.1 Study Setting 
This study was performed at the Royal London Hospital, a major trauma 
centre in the United Kingdom.  
4.3.2 Study Design 
A prospective cohort study of all injured patients admitted to the hospital 
in the 16 months between the 15th September 2010 and 31st December 2011. 
4.3.3 Study Population 
The inclusion criteria incorporated all adult trauma patients (>15 years) 
who initiated trauma team activation (Table 4.2) and presented with an 
abnormal primary survey.   
Individuals suitable for inclusion were prospectively recruited to TACID 
when research personnel were present (08.00 hrs to 21.00 hrs daily). 
Exclusion criteria included the following: 
 Patients transferred from other hospitals 
 Not expected to survive >72 hrs  
 Pregnant 
 Patients <16 years of age 
 Prisoners 
 Trauma team leader deemed recruitment inappropriate 
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Table 4.2.  Trauma Team Activation Criteria 
History of 
Person hit by train  
Person trapped under vehicle 
Fatality in same vehicle as occupant 
Occupant ejected from vehicle 
Fall from >2 metres 
Presentation with 
Amputation proximal to wrist or ankle 
Spinal trauma with altered neurology 
Chest trauma with altered physiology 
Polytrauma with burns 
GCS <14 or Respiratory Rate <10 or >29 or Systolic BP <90 
Penetrating trauma from neck to groin or proximal to elbow or knee 
Clinical suspicion of 
Open or depressed skull fracture 
Pelvic fracture 
Major haemorrhage 
 
4.3.4 The Process of Consent  
On admission, most severely injured patients present unconscious either 
as a result of trauma or as a consequence of intubation.  Conscious 
individuals may be temporarily incapacitated due to anxiety, pain, 
psychological distress or as a result of alcohol or drug intoxication.   
Accordingly, a hierarchy of consent was established and approved by the 
Cambridgeshire 3 Research Ethics Committee to enable recruitment of 
trauma patients to this study.  
On admission to the ED, trauma team leaders (ED Consultants or 
Registrars), all of whom were independent to this study, acted as the 
patient's advocate and were thus appointed their Professional Legally 
Appointed Representative (PLAR).   
If consent was granted by the PLAR and the individual recruited, 
continued participation was sought from the patient as a priority.  
Participants were examined daily to determine capacity.   
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Until such time as the patient had capacity, next of kin acted as the 
Consultee (Legally Appointed Representative), and were asked to 
consider the wishes of the patient.   
Patients and Consultees were provided with detailed information sheets 
and time to consider involvement in the study.  If consent was refused or 
retracted by either the patient or Consultee, then participation was 
withdrawn.   
If a patient died before personally giving consent, the Consultee was 
approached for permission to continue the use of samples and patient data 
for the study.  In cases where no Consultee was identified, and the patient 
either died or suffered such disability that they remained incapacitated, 
samples and data remained in the study.  If the patient was not identified 
or no next of kin were found, samples and data also remained in the 
study.   
A record was kept on a secure database of all consent procedures and 
patient reviews.  Conversations with participants and Consultees, together 
with consent were documented in the patient’s medical notes. 
4.3.5 Data Collection 
Data were prospectively collected on patient demographics, injury time 
and mechanism, time of arrival in the ED, baseline vital signs and daily 
physiological data, ISS, AIS and survival.   
Each participant was reviewed daily for the presence and timing of ACEs 
until either death or discharge.  In patients in whom an ACE was 
diagnosed, Troponin T levels were measured according to standard 
hospital protocols (normal value <30 ng/L) and further ECGs performed.  
Where possible, echocardiograms were undertaken.  In addition, the 
TACID study protocol dictated the collection of an admission ECG (within 
a maximum of two hours of injury), followed by further examinations at 
24 and 72 hrs after admission.   
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4.3.6 Study Definitions 
An ACE included any of the following diagnoses; MI, new onset left or 
right bundle branch block (LBBB or RBBB), ACS, cardiac death, 
arrhythmia or cardiogenic shock. 
Diagnoses were made and documented by senior intensivists or 
cardiologists based on a combination of clinical evidence, cardiac 
biomarker (Troponin T) values, ECGs, echocardiograms or other specialist 
cardiac investigations.  These clinicians were both independent of the 
study and blinded to its outcomes. 
Death was recorded as 28-day mortality of all causes.  Patients discharged 
from hospital before 28 days were assumed to be alive at day 28. 
4.3.7 Statistical Analysis 
Statistical analyses were performed using SPSS version 20 (SPSS Inc., 
Chicago IL).  Data are presented as medians with interquartile ranges, 
unless otherwise specified.  Non-parametric data were analysed using 
Mann-Whitney U and Kruskal-Wallis.  Student’s t-test was used to 
compare parametric data.  Fisher’s exact test, chi-square, or chi-squared 
test for trend was used to compare categorical data.  Pearson’s correlation 
coefficient was used to correlate ejection fraction with death.   
A binary logistic regression model was created to identify patient risk 
factors for the development of ACEs.  Initial analysis examined 
unadjusted effects of possible predictor variables using univariate 
statistics.  Thereafter, a binary logistic model was undertaken and 
contained both categorical and continuous predictor variables.  Variables 
were added in a stepwise regression analysis with significance levels set at 
p<0.05 to enter and p>0.1 for removal.  The following variables were 
included: age, SBP, thorax AIS, lactate, base excess, the presence of either 
cardiac disease, diabetes or hypertension pre-injury, ISS and pre-hospital 
administration of Tranexamic Acid. 
A two-sided p value of less than 0.05 was considered significant. 
 135 
4.4 Results 
One hundred and ninety nine patients were recruited during the 16 month 
study period.  Characteristics are described in Table 4.3. 
Table 4.3.  Patient Demographics, Injuries and Admission Physiology  
 All  No ACE  ACE  p Value 
Number 199 169 30   n/a 
Male, n (%) 164 (82.4) 143 (84.6) 21 (70)   0.068 
Age, years  37 (26-52) 36 (24-49) 50 (30-61)   0.010 
Mechanism, Blunt n (%) 158 (79.4) 130 (76.9) 28 (93)   0.049 
Injury Characteristics     
Injury Severity Score  18 (9-30) 16 (9-26) 31 (25-42) <0.001 
Head and neck AIS 0 (0-3) 0 (0-2) 3 (0-4)   0.004 
Face AIS 0 (0-1) 0 (0-1) 0 (0-2)   0.516 
Thorax AIS 2 (0-3) 1 (0-3) 3 (3-4) <0.001 
Extremity AIS 2 (0-3) 2 (0-3)  3 (0-3)   0.016 
Abdomen/pelvis AIS 0 (0-2) 0 (0-2) 0 (0-2)   0.339 
Admission Physiology     
SBP, mmHg  125 (109-144) 129 (114-145) 102 (77-124) <0.001 
SBP <90 mmHg, n (%) 30 (15) 16 (9.5) 14 (46) <0.001 
GCS  15 (11-15) 15 (12-15) 11 (5-14) <0.001 
Lactate, mmol/L  2.1 (1.3-3.7) 2 (1.3-3.4) 3.7 (1.8-7.7)   0.003 
Outcomes     
ICU stay, days 0 (0-5) 0 (0-2) 12 (6-17) <0.001 
Hospital stay, days  8 (3-21) 7 (2-15) 27 (14-46) <0.001 
Mortality, n (%) 17 (8.5) 11 (6.5) 6 (20)   0.026 
 
Data are presented as median (interquartile range) unless otherwise stated.  
Comparisons are between the No ACE and ACE cohorts. 
4.4.1  Epidemiology and Clinical Features of Adverse Cardiac Events 
Thirty (15%) individuals had an ACE in hospital.  Of these, arrhythmias 
were the most frequently observed.  In most cases, these were supra-
ventricular in nature (Figure 4.1). 
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Figure 4.1.  Numbers of adverse cardiac events by diagnosis  
The median time from admission to the development of an ACE was three 
days (IQR 2-5 days), and the majority (n=24, 80%) occurred within five 
days of admission (Figure 4.2). 
 
Figure 4.2.  Percentage of ACEs occurring each day post admission 
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For the most part, admission ECGs (n=18, 60%) were normal in patients 
who subsequently developed an ACE in-hospital (Figure 4.3).  Moreover, 
the nature of ECG changes was not predictive of the type of ACE 
subsequently observed. 
 
Figure 4.3.  Admission ECG findings in patients who developed an ACE 
Twenty one (70%) patients who had an ACE had an echocardiogram 
(transthoracic n=19, transoesophageal n=2).  Of the remaining nine 
individuals, echocardiograms were not performed acutely following their 
ACE because of either death shortly after the cardiac event (n=3), or 
individuals were in theatre or undergoing intervention (n=2).  In the last 
four cases, chest wounds or dressings prohibited transthoracic 
examination.  Findings of these investigations are summarised in Table 4.4 
overleaf.   
In only two cases, a small reactive pericardial effusion was diagnosed but 
not a single patient had evidence of blunt cardiac injury or contusion.  In 
addition, in no case was left apical wall ballooning observed (Table 4.4).   
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Table 4.4.  Echocardiogram Findings in Patients with Adverse Cardiac 
Events 
Findings Frequency, n (%) 
Ejection Fraction  
Normal  
Reduced  
18 (86) 
3 (14) 
Left Ventricle 
 
Appearance 
Normal 
Hypertrophied (mild) 
Function 
Normal 
Dyskinetic 
Hyperdynamic 
 
16 (76) 
5 (24) 
 
15 (71) 
4 (19) 
2 (10) 
Right Ventricle 
 
Appearance 
Normal 
Dilated (mild) 
Not visualised 
Function 
Normal 
Decreased  
Hyperdynamic 
 
18 (86) 
2 (10) 
1 (4) 
 
14 (67) 
5 (24) 
1 (4) 
Septum 
 
Normal 
Hypertrophied 
Hypokinetic (Basal) 
Dyskinetic 
Not reported 
15 (71) 
1 (4) 
3 (14) 
1 (4) 
1 (4) 
Pericardium  0 (0) 
Normal 
Effusion (small) 
19 (90) 
2 (10) 
Traumatic Valve Injury 0 (0) 
  
Left Ventricular Ballooning 0 (0) 
  
Contusion 0 (0) 
 
Ten patients (48%) had an entirely normal study and no individual who 
had an ACE had a markedly abnormal echocardiogram.   
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The majority of those who had an ACE retained normal cardiac function 
on echocardiography (mean ejection fraction=65%, standard deviation 
[SD] 9.6).   
Furthermore, there were no differences in the type of cardiac events 
between those with completely normal studies in comparison to those 
with abnormalities.  
Based on Pearson’s correlation coefficient, ejection fraction was not 
correlated with death (r2=0.015, 95% CI -0.56-0.36).  
In eight patients (38%), the echocardiogram was reported as a limited 
study.  This was either due to poor subcostal views (n=4, 50%), inadequate 
apical views (n=3, 37%) or positioning (one patient in a Rotorest, 13%). 
Troponin T levels were measured in 25 (83%) patients following their 
diagnosis of an ACE.  Figure 4.4 shows a scatter plot of the values.  Seven 
patients (28%) had a normal Troponin T value after their event, although 
the median Troponin T value in this group was mildly raised above the 
normal range (61 ng/L, IQR 10-160).   
There was no difference in Troponin T values in those with or without an 
abnormal echocardiogram (median Troponin T 21 ng/L, IQR 10-194.7 vs. 
97.95 ng/L, IQR 45.75-192.0, p=0.411 respectively). 
 
Figure 4.4.  Scatter plot of Troponin T values in patients with ACEs   
Each graduation on the x axis represents a single patient. 
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4.4.2 Adverse Cardiac Events and Takotsubo’s Syndrome 
Based on the Mayo diagnostic criteria (Table 4.1), there was evidence in 
four of the patients (13%) with ACEs that post-traumatic cardiac events 
could have been the manifestation of Takotsubo’s Syndrome.  These 
individuals had left ventricular wall dyskinesis (criterion 1), although in 
no cases was the classical left apical ballooning observed.  No patient had 
an angiogram, and hence obstructive coronary disease was not ruled out 
in this study (criterion 2).   
All of these individuals developed new ECG changes (two patients with 
ACS and two with arrhythmia) and all four had rises in Troponin T 
(criterion 3).  No patient had a diagnosis of myocarditis and although 
phaeochromocytomas were not actively ruled out, not a single individual 
exhibited evidence of the condition (criterion 4). 
4.4.3 Characteristics of Patients With and Without Adverse Cardiac 
Events 
The ACE cohort was more severely injured compared to the non-ACE 
group (ISS 31 vs. 16, p<0.001) and had higher thorax AIS scores (3 vs. 1, 
p=0.006).  Patients with cardiac events were older, and were more shocked 
on admission with lower GCS scores (Table 4.3).   
In terms of co-morbidity, only the incidence of diabetes and hypertension 
were significantly greater in the ACE population.  There was, however, no 
significant difference in the incidence of pre-morbid heart disease between 
the ACE and no ACE cohorts (Table 4.5).   
The pre-morbid use of anti-platelet therapy and insulin was higher in 
those patients who had a cardiac event.  There were no further significant 
differences in documented medication use pre-injury between the two 
populations (Table 4.5). 
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Table 4.5.  Pre-morbid Diagnoses and Medications 
 All  No ACE  ACE  p Value 
Number 199 169 30   n/a 
Pre-morbid Diagnoses      
Heart disease 9 (5) 7 (4) 2 (7)   0.627 
Diabetes 8 (4) 6 (3.5) 2 (7) <0.001 
Hypertension 21 (10.5) 14 (8.3) 7 (23)   0.022 
Hypercholesterolemia 15 (7.5) 10 (6) 5 (17)   0.055 
PVD 1 (0.5) 0 (0) 1 (3)   0.151 
CVA 3 (1.5) 3 (1.7) 0 (0)   1.000 
Pre-morbid Medications     
Anti-platelet 7 (3.5) 3 (1.7) 4 (13)   0.012 
Anti-hypertensives 18 (9) 13 (7.6) 5 (17)   0.158 
Statins 15 (7.5) 10 (6) 5 (17)   0.055 
Diuretics 3 (1.5) 1 (0.6) 2 (7)   0.061 
Anticoagulants 2 (1) 1 (0.6) 1 (3)   0.279 
Vasodilators 2 (1) 2 (1) 0 (0)   1.000 
Anti-arrhythmics 0 (0) 0 (0)  0 (0)   n/a 
Oral Hypoglycaemics 4 (2) 3 (1.7) 1 (3)   0.483 
Insulin 2 (1) 0 (0) 2 (7)   0.022 
 
Data are presented as absolute number (percentage).  Comparisons are between 
the No ACE and ACE cohorts.  PVD=Peripheral Vascular Disease, 
CVA=Cerebrovascular Disease.   
Patients who developed an ACE were more likely to have been 
administered Tranexamic Acid pre-hospital (OR 2.5, 95% CI 1.1-6.2), and 
in general required significantly more cardiac medication during their 
admission (Figure 4.5).   
Individuals who had a cardiac event needed more pressure support 
through the use of inotropes and vasopressors.  These patients also had 
higher glycaemic control requirements, and were more often prescribed 
hypoglycaemics such as insulin.   
Indeed, only the in-hospital prescription of anti-platelet agents such as 
Aspirin was no different between the two groups (Figure 4.5). 
 142 
 
Figure 4.5.  Medication requirements of the No ACE and ACE cohorts 
Tranexamic Acid was administered pre-hospital by a dedicated trauma 
physician.  All other medications were prescribed according to clinical 
requirements during admission.  *p<0.05, **p<0.01, ***p<0.001. 
4.4.4 Adverse Cardiac Events and Outcomes 
ACEs were associated with poorer outcomes in this population of general 
trauma patients.   
Cardiac events were related to nearly a four fold longer length of hospital 
stay (27 days vs. 7, p<0.001).  Moreover, 26 patients with ACEs (87%) 
required an intensive care admission compared to 36 individuals (21%) 
from the cohort in whom no cardiac events occurred (p<0.001).  ACEs 
were also associated with a significantly increased length of ICU stay 
(Table 4.3). 
ACEs were related to higher mortality and patients who had a cardiac 
event were three times more likely to die (OR 3.6, 95% CI 1.2-10.6) 
compared to the group in whom no ACE was observed (Figure 4.6). 
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Figure 4.6.  The mortality rate in patients with and without ACEs 
*p<0.05.  
There was a clinical difference between the timing of death in the 
deceased ACE and no ACE individuals.  Overall, patients who had a 
cardiac event died much later during their admission, although the 
discrepancy was not statistically significant (p=0.149, Figure 4.7).   
 
Figure 4.7.  Timing of death of the deceased patients  
There was, however, a significant difference between the two groups’ 
median date of death (ACEs: day 11 of admission, IQR 6-17 vs. no ACE: 
day 2, IQR 2-5, p=0.026). 
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4.4.5 Adverse Cardiac Events and Risk Factors 
Table 4.6 shows crude and adjusted odds ratios for each of the predictors 
of ACEs in this cohort of injured patients.  The R2 value was 42% 
(Nagelkerke R Square 0.416) which suggested that the risk model was a 
good forecaster of cardiac events amongst this trauma cohort. 
Table 4.6.  Crude Odds Ratios and Adjusted Multivariate Predictors of 
Adverse Cardiac Events in 199 Trauma Patients 
Variable Crude OR  
(95% CI) 
p Value Adjusted OR  
(95% CI) 
p Value 
Mechanism, blunt 4.07 (0.92 - 17.89)   0.064 2.84 (0.39 – 20.64)   0.301 
Age, years 1.03 (1.01 - 1.05)   0.011 1.02 (1.01 – 1.04)   0.019 
SBP, mmHg 0.97 (0.95 - 0.98) <0.001 0.99 (0.99 – 1.01)   0.190 
Thorax AIS 1.59 (1.24 - 2.04) <0.001 1.24 (0.85 – 1.82)   0.264 
ISS 1.07 (1.04 - 1.11) <0.001 1.06 (1.02 – 1.09)   0.001 
Lactate, mmol/L 1.26 (1.11 - 1.44) <0.001 1.21 (0.89 – 1.63)   0.219 
Base excess, mEq/L 0.84 (0.78 - 0.91) <0.001 0.87 (0.81 – 0.94) <0.001 
Cardiac disease 0.41 (0.10 - 1.69)   0.218 0.48 (0.66 – 3.39)   0.468 
Hypertension 3.17 (1.16 - 8.70)   0.028 3.88 (0.88 – 17.04)   0.072 
Diabetes 1.83 (0.35 - 9.55)   0.614 4.99 (0.46 – 53.86)   0.186 
Tranexamic Acid 2.58 (1.08 - 6.13)   0.041 2.27 (0.56 – 8.33)   0.259 
 
Three predictors of post-traumatic ACEs were identified.  These were 
increasing age, worsening severity of injury (ISS) and decreasing base 
excess (indicating tissue hypoperfusion or shock). 
Based on this model, however, the cardiac events that developed in this 
cohort of patients were not associated with the severity of chest injury. 
This demonstrated that post-traumatic ACEs were the not the result of 
direct, primary heart damage, and hence were secondary in nature.  
Furthermore, cardiac events were unrelated to the presence of heart 
disease pre-injury, revealing that the ACEs observed in this study 
population were not the product of trauma merely exacerbating existing 
cardiac disease. 
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4.5 Discussion 
The identification and description of ACEs that occurred in all categories 
of injured patients was undertaken in this prospective cohort study.  In 
conjunction with limited prior research, these results demonstrated that 
trauma leads to secondary cardiac events, and that these are associated 
with poorer patient outcomes.  Accordingly, this study confirmed the 
existence of TISCI. 
Although undertaken prospectively in a more general cohort of patients, 
this investigation mirrored the findings of Chapter Two, namely that 
cardiac events occur in approximately 15% of all trauma admissions.  It 
also substantiated the observation that post-traumatic ACEs are most 
commonly supra-ventricular arrhythmias.   
Echocardiograms performed in individuals with ACEs demonstrated that 
no single patient had evidence of blunt cardiac injury, such as myocardial 
contusion, traumatic valve injury or septal rupture, for example.  These 
findings demonstrated that ACEs in this injured population were thus the 
product of a secondary process, and not the result of direct chest trauma.  
Additionally, when adjusted for in multivariate analysis, thoracic injury 
was not found to be a risk factor for ACEs, thereby reinforcing the 
secondary nature of these cardiac events. 
Takotsubo’s cardiomyopathy causes secondary cardiac dysfunction 
following stressful triggers, and may lead to arrhythmias, ECG changes, 
Troponin rises and symptoms of ACS (Akashi et al., 2008, Prasad et al., 
2008).   
It is possible that secondary cardiac events in trauma could have been the 
result of Takotsubo’s, although the findings of this study are suggestive in 
only a handful of cases.  Four patients demonstrated left ventricular 
dyskinesis in conjunction with ECG changes and Troponin rises, although 
none had echocardiographic evidence of left apical ballooning.  In 
addition, in no individual was a comment on the state of the coronary 
arteries possible.   
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As such, this study provided limited evidence for Takotsubo’s leading to 
ACEs in injured patients, and in the event, only in a minority of cases. 
Given that the echocardiogram findings did not support any evidence of 
significant macrostructural changes to the heart, and ACEs were not due 
to mechanical disruption of cardiac tissue, other pathological factors must 
have been at play.  The processes leading to cardiac dysfunction must 
therefore occur on a microstructural level, be it cellular, molecular or both.  
These conclusions are supported by the findings of Chapter Three, 
indicating the role of inflammation in the pathogenesis of TISCI. 
Furthermore, in Chapter Three, the relationship between TISCI and 
inflammation was demonstrated in the acute setting.  The significance of 
the acute nature of this association is reaffirmed in this study given that 
80% of ACEs had occurred within five days of admission. 
Injury severity and shock on admission were identified as risk factors for 
the development of ACEs.  This was established in a robust regression 
model, based on a significant R2 value and the inclusion of over ten 
outcomes in the analysis (Harrell et al., 1996).   
These findings are supported by previous clinical studies (M. Martin et al., 
2005, Seguin et al., 2006, Ismailov et al., 2005) and animal models which 
both have demonstrated cardiac injury and dysfunction following trauma 
and shock.  Such clinical states are known to stimulate an inflammatory 
response, and higher ISS and shock are risk factors for the development of 
SIRS, a state of systemic inflammation.   
SIRS may lead to MODS, the leading cause of late death in the critically 
injured, and most of the individuals with TISCI died later in hospital.  
These patients also had a higher incidence of ICU admission, with a longer 
length of stay.  As such they were also more likely to experience MODS.  
Taken these observations into consideration, this investigation thus 
further suggested the association of inflammation with TISCI, and leads 
again to the hypothesis that post-traumatic secondary cardiac dysfunction 
may be implicated in the significant mortality related to MODS.   
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In trauma patients, age as a risk factor for ACEs has been shown in 
previous research, (Seguin et al., 2006, Hadjizacharia et al., 2011, Ismailov 
et al., 2005) and is again supported by the findings of this study.   
Age is a significant predictor of cardiovascular events based on the 
Framingham Risk Score, and is associated with poorer survival following 
injury (Tornetta et al., 1999, Taylor et al., 2002).  Although the precise 
mechanisms for these worse outcomes in elderly trauma patients are not 
known, this study implied that cardiac dysfunction might be a relevant 
factor.   
In accordance with the findings of Chapter Two together with previously 
published literature on the subject, this investigation revealed both the 
existence of a cohort of injured patients at risk of TISCI, coupled with its 
association with poorer outcome.  Consequently, this evidence supports 
the need for further research investigating interventions aimed at 
mitigating the harmful effects of secondary cardiac injury and dysfunction 
in trauma.   
Beta-blockers, for example, have largely been shown to confer a survival 
advantage to older patients (Arbabi et al., 2007, Bukur et al., 2012).  This 
evidence is mostly in traumatic head injury (Cotton et al., 2007, Inaba et 
al., 2008), and the result of multivariable regression analyses of 
retrospective database reviews.  Nonetheless, these drugs may represent a 
suitable first line of inquiry.  In the first instance, older, shocked and more 
severely injured patients should be targeted, and investigated in large 
randomised trials.  
Patients with ACEs had a higher incidence of ICU admission which was 
combined with a longer length of intensive care stay compared to non-
ACE patients.  Individuals with cardiac events also had significantly 
greater requirements for vasoactive drugs, and were more often 
prescribed cardiac medications and insulin.  The higher incidence and 
degree of critical illness following injury in individuals with ACEs 
indicated that although this study was performed in a general cohort of 
 148 
trauma patients, TISCI remains a condition primarily limited to the 
critically injured.  Whilst critical illness might not be a risk factor per se, it 
appears to be a useful marker of those patients at risk of secondary cardiac 
damage after injury. 
The majority of patients who developed ACEs had a normal ECG on 
admission, and hence suggested that unless blunt cardiac injury is 
suspected, ECGs may be of limited value in the initial assessment of the 
patient.  Even if they provided evidence of heart disease, this study 
showed that pre-morbid cardiac disease did not predict patients at risk of 
in-hospital ACEs.  This observation has been noted previously in the 
literature (Seguin et al., 2006, Hadjizacharia et al., 2011).   
As such the study revealed that trauma is in itself an entity that 
precipitates cardiac events.  Post-traumatic ACEs are not, perhaps 
contrary to expectation, simply the result of injury aggravating pre-
existing cardiovascular disease.  Although in Chapter Two heart disease 
was associated with ACEs, this relationship was identified in much 
smaller numbers and was not adjusted for, thereby representing a 
limitation of that study. 
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4.6 Limitations 
There are several limitations to this study.  In the first instance, the 
investigation substantiated the existence of TISCI through the 
demonstration of trauma induced ACEs, but did not provide evidence of 
cardiac injury through biomarker rises.  However, blood samples had 
been acquired prospectively in Chapter Two, and were analysed accurately 
using ELISA techniques.   
ACEs, conversely, were recorded retrospectively and hence were more 
likely subject to recall error.  As such, prospective and contemporaneous 
documentation of ACEs was necessary to demonstrate the existence of 
TISCI, given that cardiac injury through biomarker rises had already been 
reliably demonstrated in Chapter Two. 
In over a third of patients, the echocardiogram views were noted as 
limited, and therefore could not have provided comprehensive 
information on cardiac function and appearance.  In addition, few 
transoesophageal examinations were carried out, despite this modality 
providing more accurate and detailed information on the heart and 
vessels.  However, ultrasonographers documented only that which they 
could accurately see, and solely these findings were reproduced in the 
results section of this chapter, giving a reliable overview of the heart in 
trauma. 
Diagnostic criteria for Takotsubo’s require evidence of normal coronary 
arteries in the presence of the other signs and symptoms of the disorder.  
None of the study patients underwent coronary angiography or detailed 
coronary imaging, so the diagnosis of this syndrome amongst this cohort 
could neither be conclusively ruled in or out.   
In spite of this, coronary angiography for the purposes of this research 
would not have been appropriate because there are serious potential risks 
associated with the procedure.  Given many patients were active and 
young, however, it is unlikely they would have pre-existing coronary 
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artery disease.  Nonetheless, the incidence of atherosclerosis in trauma 
populations is not known, and requires investigation. 
Since most of the patients were unconscious on the ICU when ACEs were 
diagnosed, none were able to report any symptoms including chest pain, 
thus restricting the ability to further diagnose cardiac events or 
Takotsubo’s syndrome. 
Finally, the influence of smoking in leading to cardiac disease is well 
documented.  This investigation failed to record a history of smoking 
amongst the study population, despite the fact it may be a relevant risk 
factor for the development of ACEs.  Its effect on outcome and its 
relationship to secondary cardiac events in trauma should be determined 
by other studies. 
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4.7 Conclusions 
This is the first prospective study to have investigated the epidemiology 
and features of all ACEs in all categories of injured patients.  It confirmed 
the existence of TISCI. 
Cardiac events occurred in about 15% of trauma patients, primarily in 
those who were critically ill.  ACEs were associated with worse outcomes, 
including higher death rates, and risk factors for their development 
included older age, shock on admission and severity of injury.  Cardiac 
events were not the product of pre-existing cardiac disease, but in some 
cases may have been a manifestation of Takotsubo’s syndrome. 
Future research should examine the appearance and function of the heart 
following post-traumatic ACEs using more detailed imaging, such as 
transoesophageal echocardiography or cardiac magnetic resonance 
imaging (MRI).  The latter would also enable an assessment of the 
coronary arteries.  A smoking history should be elucidated from all 
patients. 
Because an “at-risk” population for TISCI has been identified, studies 
should examine therapeutic interventions such as beta-blockers aimed at 
improving the poor outcomes associated with this condition. 
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CHAPTER FIVE 
Coronary Artery Calcium and 
Trauma 
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5.1 Introduction 
Both coronary heart disease (CHD) and trauma are leading causes of 
death internationally.  Trauma accounts for nearly six million fatalities 
annually (WHO, 2009), whilst CHD is the commonest cause of death 
worldwide (WHO, 2007).  In the US around 16.3 million people have 
symptomatic CHD (Roger et al., 2011).  In the UK, over two million live 
with the disease (BHF, 2011).  Previous chapters in this thesis have focused 
on the effect of trauma on the heart.  Yet research on trauma associated 
cardiac injury and dysfunction must also consider the effect of pre-morbid 
heart disease on outcome following injury.   
Existing evidence in trauma has described the effect of co-morbidity on 
survival and has shown that both the presence and number of pre-injury 
conditions may lead to higher death rates (Bamvita et al., 2007).  The 
impact of pre-existing heart disease on post-traumatic survival has been 
the subject of only a handful of limited studies, however, and remains 
uncertain still. 
Several retrospective analyses in trauma patients, for instance, have 
shown associations between pre-morbid heart disease and poorer survival 
(Morris et al., 1990, Perdue et al., 1998, Wutzler et al., 2009, Milzman et al., 
1992).  Conversely, conflicting evidence has suggested that the presence of 
cardiac disease pre-injury has no influence on mortality (Grossman et al., 
2002, Horst et al., 1986, Smith et al., 1990), or has only a limited effect in 
selective patient cohorts (Mcgwin et al., 2004, Hollis et al., 2006, Shoko et 
al., 2010).  
To date, just one single study in trauma has focused on the relationship 
between cardiac disease in isolation and survival (Ferraris et al., 2010).  In 
addition, the impact of CHD on post-traumatic mortality has been 
measured solely in those with a documented cardiac diagnosis, and 
therefore predominantly symptomatic patients.  A significantly higher 
number of injured individuals are likely to present with asymptomatic, 
subclinical heart disease, although studies have so far neglected to 
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investigate this category of patients.  Consequently, the true incidence of 
CHD in a trauma population is not known.  
Moreover, research has yet to reveal the impact of CHD in trauma and 
include all documented cases of the disease, including those with 
asymptomatic or subclinical CHD.  If subclinical heart disease, combined 
with symptomatic disease, does indeed lead to higher death rates, its 
presence would require screening for as part of the assessment of the older 
trauma population.  Thereafter, studies would be required designed to 
improve the poorer survival seen in such patients, including trials of 
therapeutic intervention. 
Currently the difficulty with measuring both the epidemiology and 
impact of all types of CHD in trauma is that individuals with 
asymptomatic disease are unlikely to present with an established 
diagnosis.  Moreover, injured patients are very frequently admitted 
unconscious or unable to give a history.  Markers of CHD that include 
subclinical disease must therefore be determined. 
On Computerised Tomography (CT) scans of the chest, the presence of 
calcium in the coronary arteries is an indicator of subclinical CHD (Wexler 
et al., 1996).  It directly correlates with atherosclerotic plaques on 
histological examination (Rumberger et al., 1995).  Furthermore, an 
absence of coronary artery calcium (CAC) tends to rule out luminal 
obstructive disease (Simons et al., 1992).   
Thirteen years ago, Agatston (Agatston et al., 1990) demonstrated that 
CAC can be easily and accurately scored on CT scans, and subsequent 
studies have demonstrated an association between high coronary artery 
calcium scores (CACS) with an increased risk of ACEs, in both 
symptomatic and subclinical presentations of heart disease (Keelan et al., 
2001, Arad et al., 1996, Arad et al., 2000, Detrano et al., 2008, Polonsky et 
al., 2010, Lamonte et al., 2005).  More recently, there is evidence that CACS 
(CACS=Agatston score) are predictive of all cause mortality in patients 
with heart disease (Ostrom et al., 2008, Raggi et al., 2008, Budoff et al., 
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2007) and may provide valuable screening assessments of the heart in 
non-cardiac illnesses such as HIV (D’ettorre et al., 2011) and aortic 
aneurysms (Stolzmann et al., 2009). 
Accordingly, CACS represents a suitable marker of CHD in trauma.  Until 
now, however, CACS have been calculated using dedicated software.   
No studies have attempted to estimate CACS both in the absence of 
dedicated cardiac scanning and in the context of non-cardiac related 
disease.   
Therefore the true incidence and impact on mortality of pre-morbid CHD 
in injured patients, determined by the extent of CAC on CT scans of the 
chest, represents a significant and original target for research. 
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5.2 Study Aims 
The overall objective of this study was to determine the global incidence of 
CHD in older trauma patients, and to investigate its association with 
survival after injury.   
Specifically, the first aim was to establish the feasibility of using trauma 
triage CT scans performed on admission to assess the quantity and 
severity of CAC.   
Second, to describe the incidence of CHD using CACS in a trauma 
population aged 45 years or over.   
Third, to compare the general features and characteristics of injured 
patients with and without CAC on their trauma CT scans of the chest.   
The final aim was to determine whether either the presence or extent of 
CAC, as a marker of both subclinical and symptomatic CHD, was 
associated with increased in-hospital mortality in older injured patients. 
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5.3 Materials and Methods-Part A 
This study was conducted in two stages, namely parts A and B.  Part A 
was a training and validation exercise.  In the first instance, the burden of 
calcium was examined on existing non-trauma CT scans with an 
established formal calcium score.  This was followed by a validation 
assignment, whereby the investigators’ capacity to interpret and agree on 
the CACS was measured.  On completion of part A, Part B was 
undertaken.  This second stage was designed to investigate the study 
aims, and involved the assessment of calcium on CT scans of injured 
patients and its association with mortality. 
To ensure the scientific validity of this study, a second researcher (Kathryn 
Oakland) was invited to interpret the scan images in both Parts A and B.   
5.3.1 Training 
Both investigators reviewed and familiarised themselves with the features 
of 200 CT scans of the heart with formal calcium scores (Agatston scores) 
performed in patients with known coronary atherosclerosis.  These images 
were obtained by the cardiology team and were undertaken 
independently for the purpose of assessment of the coronary arteries in 
patients with symptomatic heart disease.  These 200 scans were selected at 
random from the list of patients found in the cardiology database. 
The scans were undertaken using a second generation dual-source CT 
scanner (SOMATOM Definition Flash, Siemens, Forchheim, Germany).  
These heart scans were performed at the London Chest Hospital, and were 
acquired with a prospectively ECG-triggered technique at 40% of the 
cardiac cycle when the patient's heart rate was higher than 75 beats per 
minute, otherwise with a high pitch spiral technique.   
Scan parameters were as follows: collimation 0.6 mm, x-ray tube voltage 
120 kilovolts (kV), x-ray tube current 250 milliamperes (mA).  Three 
millimetre thick images were reconstructed at an increment of 1.5 mm.   
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MSCT datasets were analysed using a dedicated workstation (syngo 
MultiModality Workplace, Siemens, Erlangen, Germany) and specific 
software (syngo Calcium Scoring, Siemens, Germany) was used to 
measure calcium score on non-enhanced images.  
5.3.2 Validation 
Once familiar with the characteristics of the 200 formal CT calcium scores, 
a different set of 50 cardiac CT scans were then selected at random from 
the database to validate the ability of each observer to estimate accurately 
a CACS.   
These 50 scans had also been undertaken previously to evaluate non-
trauma patients with symptomatic heart disease and each had already 
been ascribed a formal Agatston score.  The two investigators assessed 
these scans independently, and whilst blinded to both one another’s 
estimates and the formal Agatston score.   
Each investigator gave both a numeric score (estimated CACS) based on 
the quantity of calcium in the coronary arteries and a grade.  Grades were 
awarded on the basis of the calcium score (Table 5.1).  
Table 5.1.  Grades of Calcium Based on Corresponding Calcium Score 
Calcium Score Calcium Grade 
0 None 
1-100 Mild 
101-400 Moderate 
401-1000 Severe 
1001≤ Extensive 
 
These grades were based on the American College of Cardiology 
Foundation/American Heart Association guidelines (Greenland et al., 
2007).  
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5.3.3 Inter-observer Agreement  
In this validation exercise, the agreement between the two observers was 
excellent for both grade (kappa coefficient, ĸ=0.82) and score (Figure 5.1).   
 
Figure 5.1.  Bland Altman plot of inter-observer agreement in validation 
exercise   
There was excellent agreement between the two observers’ scores in the 50 
patients selected at random with formal Agatston scores (Bias=-10.6, SD of bias 
71.67). 
Agreement between the first observer and grade based on the formal 
Agatston score was excellent (ĸ=0.80) and between the second observer 
and formal grade was good (ĸ=0.64).  
These statistics revealed that observers could independently and reliably 
estimate the score and grade of coronary artery calcium.  Consequently, 
the ability to interpret the CTs was validated, and Part B of the study 
could be undertaken robustly. 
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5.4 Materials and Methods-Part B  
Based on guidance from the National Research Ethics Service, ethical 
approval for this study was not required (NRES, 2011).  
5.4.1 Study Design and Setting 
A single centre retrospective cohort study performed at the Royal London 
Hospital. 
5.4.2 Study Population 
Inclusion criteria were all trauma patients aged 45 years or over who 
presented to the hospital between 1st January 2009 and 1st January 2011.  
The age selection was based on Framingham Data describing the 
respective contribution of age to cardiovascular risk in men and women 
(Grundy et al., 1999).  The only exclusion criterion was individuals 
without a CT scan of the chest.    
Patients were identified retrospectively from the hospital trauma registry.  
This has been prospectively collecting detailed and contemporaneous data 
on every trauma patient who has presented to the Royal London Hospital 
since 2003.   
5.4.3 Indication for CT in Study Patients 
Scans had been performed as part of the initial and emergency assessment 
of patients following trauma, and were formulated to diagnose and 
qualify the severity of traumatic injures.   
CTs were indicated in patients who presented with severe injuries, 
abnormal physiology or with a significant traumatic mechanism.  Reasons 
for not performing a CT included patients deemed too physiologically 
unstable to scan, or those not for further treatment because of anticipated 
and imminent death.  The trauma team who were both independent and 
blinded to this study’s outcomes requested all scans.  All CTs were 
undertaken within three hours of arrival to the ED and were performed by 
the hospital radiology department.  
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5.4.4 CT Scan Protocol in Trauma 
All CT scans were performed on a Siemens SOMATOM Sensation 64 slice 
scanner (Siemens Medical Solutions, Forchheim, Germany).   
Patients were placed supine and entered the scanner head first with arms 
above their heads whenever possible.  The scans covered from above the 
lung apices to below the pelvis.   
The delay between the start of contrast medium administration and the 
start of scanning was obtained using an automated bolus triggering 
technique (CARE bolus, Siemens Medical Solutions).  In all patients, 80 
mls of Visipaque contrast was used (Visipaque 270, GE Healthcare, 
Milwaukee, WI, USA) and injected at a rate of 2-3 mls/sec with a scan 
delay of 50 secs.   
Data were acquired in a cranio-caudal direction with the following 
scanning parameters:  120/260 kV tube voltage, collimation 24 x 1.2 mm, 
0.5 secs rotation time and 5 mm increment and 5 mm reconstructed section 
thickness.  A smooth reconstruction thickness (B31f) was used for initial 
reconstruction, followed by reconstructions using the settings of soft tissue 
fine, lung, bone fine, coronal lung, coronal thorax and abdomen, coronal 
spine/pelvis and sagittal spine. 
5.4.5 CT Scan Interpretation  
All patients who met study inclusion and exclusion criteria were 
identified and their admission CT scans were located and reviewed using 
the NHS Picture Archiving and Communication System (PACS). 
Thereafter, both authors reviewed each CT scan independently and a 
CACS was estimated.  Based on the CACS, a grade of calcium in the 
coronary vessels was then awarded (between none and extensive). 
CAC was defined as an intra-coronary artery plaque of a minimum of 
three millimetres of high attenuation.  The total score was calculated from 
the sum of the estimated calcium content of the three major coronary 
arteries. 
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These were the left, including the main and anterior descending (LAD), 
the circumflex (Cx), and the right coronary (RCA, Figure 5.2).  Both the 
number (0-3) and identity of vessels containing calcium plaques were also 
documented in each patient.   
   
Figure 5.2.  Axial views of the heart on a trauma CT scan  
The presence of coronary artery calcium in the LAD, the Cx and the RCA is 
demonstrated.   
Interpretation of the scans was performed with observers blind to all 
patient characteristics, outcomes and each other’s measurements until 
assessment of the CT scans was complete in its entirety.   
5.4.6 Data Collection 
Data on patient demographics and baseline physiology, injury 
characteristics, ISS and mortality were collected from the hospital trauma 
registry and from individual patient clinical records. 
5.4.7 Study Outcome 
The study endpoint was death, defined as death of any cause occurring in-
hospital.  For the purposes of analysis, patients surviving to hospital 
discharge were assumed to have survived.  
5.4.8 Statistical Analysis   
All data analyses were performed using SPSS version 20 (SPSS Inc., 
Chicago IL).  Normal-quartile plots were used to test for normality.   
LAD 
Cx RCA 
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Non-parametric continuous data are reported as median with interquartile 
range and categorical data reported as absolute number and percentage.   
Mann-Whitney U or Kruskal-Wallis tests were used to compare numerical 
data and Fisher’s exact test, chi-square, or chi-squared test for trend was 
used to compare categorical data.  
Regression analysis was used to identify the risk factors for death in this 
patient group.  Initially, univariate statistics were performed to examine 
the unadjusted effects of potential predictor variables.  A subsequent 
binary logistic model containing both categorical and continuous 
predictor variables was conducted, and variables were added in a 
stepwise regression analysis.  Significance levels were set at p<0.05 to 
enter and p>0.1 for removal.  The following variables were included: age, 
gender, base excess, GCS, the presence of pre-morbid disease, mechanism 
of injury, SBP, ISS and the CACS. 
Using Fisher's exact test, univariate analyses were conducted for mortality 
rates based on the grade of coronary artery calcium.  To adjust for age and 
injury severity, patients were divided into two age categories (<65 years 
and ≥65 years, in accordance with existing literature) and analyses were 
performed after stratification of ISS into four subgroups (≤5, 6-15, 16-24, 
25≤). 
Kappa coefficient was used to test inter-observer reliability for nominal 
data (http://justusrandolph.net/kappa, accessed 24/10/12) and Bland-
Altman plots were used to interpret inter-observer agreement for 
continuous data.   
Statistical significance was set as a two tailed p value of <0.05. 
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5.5 Results 
Over the two year study period, 880 trauma patients met the inclusion 
criteria.  Four hundred and five (46%) of these patients did not have a CT 
scan of the chest, and were excluded from any further analyses.   
The medical records of one patient who had had a CT thorax could not be 
traced, and therefore that individual was also disqualified from any 
further analysis (Figure 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.  Flow diagram depicting selection of study population  
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5.5.1 Feasibility of Trauma CT scans in Determining Calcium Score  
Of the 474 patients who had a CT scan of the thorax on admission, 432 
(91%) had sufficiently clear images of the heart and coronary arteries to 
enable reliable assessment of calcium score and grade.   
The interpretation of the remaining 42 scans was not possible due to 
artefact from chest drains, other external devices or movement, and so 
these patients were further excluded.   
Authors were independently unanimous in their agreement (ĸ=1) in 
identifying those images that could and could not be assessed further for 
the purposes of this study.  In just over 90% of trauma CT scans, therefore, 
an assessment of calcium score and grade was feasible.  
5.5.2 Study Population  
The study population comprised of some 432 patients.  In total, 41 (9.5%) 
individuals died.  Overall, patients were severely injured but were not 
shocked on admission.  Patient characteristics are described in Table 5.2. 
Table 5.2.  Study Population Characteristics 
  
Number 432 
Male n (%) 345 (80) 
Age, years  56 (45-94) 
Injury Characteristics  
Blunt mechanism n (%) 392 (91) 
Injury Severity Score  16 (8-25) 
Admission Physiology  
SBP, mmHg  134 (138-154) 
HR, bpm mean (SD) 84 (68-99) 
GCS  14 (8-15) 
Base Deficit, mEq/L 1.6 (4 - -1) 
Outcomes  
Hospital stay, days 4 (1-17) 
Mortality, n (%) 41 (9.5) 
 
Data presented as median (interquartile range) unless otherwise stated.  
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One hundred and seventy eight patients (41%) presented with one or 
more documented co-morbidities on admission.  Of these, hypertension 
was the most common diagnosis amongst the study population (Table 5.3). 
Table 5.3.  Documented Patient Co-morbidities on Admission 
Diagnosis Frequency, n (%) 
Hypertension 55 (12.7) 
Hypercholesterolemia 23 (5.5) 
Diabetes 27 (6.5) 
Coronary Heart Disease 26 (6) 
Valve Disease 3 (0.7) 
PVD including AAA 11 (2.5) 
Cerebrovascular Accident 16 (3.7) 
Renal Disease 6 (1.5) 
Respiratory Disease 22 (5) 
Mental Illness 30 (7) 
Malignancy 10 (2.5) 
Neurological Disease 21 (4.9) 
Gastro-Intestinal & Liver Disease 8 (1.8) 
Orthopaedic 13 (3) 
Musculoskeletal 3 (0.7) 
Blood Disorders 3 (0.7) 
Thyroid Disorders 2 (0.5) 
Chronic Infection 2 (0.5) 
 
PVD=Peripheral Vascular Disease, AAA=Abdominal aortic aneurysm. 
5.5.3 Incidence of Coronary Artery Calcium on Trauma CT 
One hundred and thirty seven patients (32%) had no calcium in their 
coronary arteries (Ca0 group), whilst the remainder (n=295, 68%) had 
evidence of CHD with a calcium score of one or greater (Ca+ group).  The 
Ca+ group was older (60 years, IQR 45-94 vs. 50 years, IQR 45-76, p<0.001) 
and included higher numbers of patients with co-morbidities (132 patients 
vs. 46, p=0.035, respectively).  
Total lengths of hospital stay were not significantly different between the 
Ca+ and Ca0 groups (12 days IQR 3-25 vs. 6 days IQR 2-25, p=0.08 
respectively). 
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5.5.4 Characteristics of Patients with Coronary Artery Calcium  
The median overall CACS was 53 (range 1-1250), and the largest group of 
patients had a grade of mild coronary artery calcium (Table 5.4). 
Table 5.4.  Patient Characteristics Based on Coronary Artery Calcium 
Grade 
 None Mild Moderate Severe Extensive p Value 
Number (%) 137 (31.2) 139 (32.2) 75 (17.4) 64 (14.8) 17 (3.9) <0.001 
Age, years 50 (47-56) 53 (45-89) 64 (45-94) 70 (46-91) 77 (58-91) <0.001 
Gender, male 
n (%) 
107 (78) 115 (83) 56 (75) 51 (80) 16 (94)   0.568 
Co-morbidities  
n (%) 
46 (33) 38 (27) 43 (57) 42 (66) 9 (53) <0.001 
ISS 13 (2-25) 12 (5-28) 17 (9-29) 15 (9-27) 20 (3-32)   0.268 
GCS 15 (12-15) 15 (11-15) 14 (11-15) 14 (10-15) 14 (12-15)   0.754 
BP, mmHg 
mean (SD) 
135 (37) 137 (34) 136 (28) 147 (41) 123 (34)   0.059 
Base Excess, 
mEq/L 
1.3 (-0.8-4) 1.1 (-1.3-
3.8) 
2.3 (-0.05-
4) 
2.1 (-1.9-
5.5) 
1.4 (-0.9-
2.8) 
  0.578 
CACS 0 (0-0) 45 (20-70) 190 (130-
290) 
617.5 
(500-763) 
1100 (1048-
1150) 
<0.001 
Vessels 0 (0-0) 1 (1-2) 2 (2-3) 3 (3-3) 3 (3-3) <0.001 
Hospital stay, 
days 
6 (2-25) 8 (2-20) 17 (5-30) 16 (4.5-25) 14 (1.5-
48.5) 
  0.008 
 
Data presented as median (interquartile range) unless otherwise stated.  
Comparisons are made across all groups.  
The median number of calcified vessels was two.  The artery most 
commonly affected was the Circumflex and calcium was seen in this 
vessel in 229 (53%) patients.   Calcification was observed in the LAD in 219 
(51%) and the RCA in 162 (38%) individuals. 
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5.5.5 Coronary Artery Calcium and Mortality 
5.5.5.1  Overall Study Mortality  
Patients with evidence of CHD had a higher mortality rate compared to 
those without, but differences were not significant (p=0.597, Figure 5.4).  
 
Figure 5.4.  Death rate based on the absence or presence of coronary 
artery calcium  
No significant difference in the overall death rate between patients without CAC 
(Ca0 group) compared to those with evidence of CHD (Ca+ group) was observed. 
The death rate in each coronary artery calcium quartile is shown in Figure 
5.5.  
 
Figure 5.5.  Death rate per coronary artery calcium score quartile (p=0181) 
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The death rate was greatest in patients in the highest CACS quartile, and 
there was a trend towards poorer survival with increasing calcium score.  
The differences were not, however, statistically significant (Figure 5.5). 
In order to identify the clinical variables independently associated with 
mortality in this study population, a binary logistic regression model was 
created (Table 5.5).  The model was a good predictor of death amongst this 
cohort with an R2 value of 48% (Nagelkerke R Square 0.481).  
Table 5.5.  Predictors of Death in Trauma Patients Over the Age of 45 
Variable Crude OR            
(95% CI) 
p Value Adjusted OR    
(95% CI) 
p Value 
Age, years 0.95 (0.93-0.98) <0.001 0.93 (0.89-0.97)   0.012 
Gender, male 0.39 (0.19-0.78)   0.007 0.95 (0.33-2.67)   0.092 
ISS 0.93 (0.91-0.96) <0.001 0.96 (0.94-1.01)   0.180 
BE, mEq/L 1.19 (1.11-1.27) <0.001 1.13 (1.04-1.22)   0.004 
GCS 1.29 (1.20-1.39) <0.001 1.29 (1.16-1.44) <0.001 
SBP, mmHg 1.01 (1.00-1.02) <0.001 1.00 (0.99-1.01)   0.356 
Pre-morbid disease 1.74 (0.91-3.32)   0.092 1.25 (0.48-3.23)   0.655 
Mechanism, blunt 0.23 (0.03-1.69)   0.147 1.34 (0.34-6.54)   0.967 
CACS 0.99 (0.99-1.00)   0.282 1.00 (0.99-1.01)   0.757 
 
Three predictors of death were identified amongst the patients in this 
study.  These were age, base excess and GCS.  Based on both univariate 
and multiple regression analysis, however, the CACS was not 
independently associated with mortality.  This revealed that in this 
population of older trauma patients, CHD was not a risk factor for in-
hospital death. 
5.5.5.2  Mortality and Coronary Artery Calcium Grade 
The mortality rate in each individual CAC grade group was around 10% 
or less.  Only patients with evidence of severe CAC had markedly higher 
death rates, although the differences were not statistically significant 
(p=0.157, Figure 5.6).  
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Figure 5.6.  Death rates according to grade of coronary artery calcium 
In addition, only a grade of severe CAC on admission trauma CT was 
associated with significantly higher odds of death.  Those with otherwise 
mild, moderate or extensive CAC were found to have no significant 
differences compared to those patients without evidence of calcification 
(Figure 5.7). 
 
Figure 5.7.  Odds ratios of death (with 95% CI) according to grade of 
coronary artery calcium   
Only patients with severe CAC were placed at significantly higher odds of in-
hospital death. 
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5.5.5.3  Coronary Artery Calcium Grade and Mortality Adjusted for Age 
and ISS  
The CAC grade, even after adjusting for age and ISS, was not associated 
with higher mortality in this study population.   
Amongst the younger patients, there was no statistical or clinically 
relevant pattern of mortality according to the calcium grade even after ISS 
was adjusted for (Table 5.6). 
Table 5.6.  Odds Ratio of Mortality per Calcium Grade Stratified by 
Injury Severity Score in Patients Aged <65 Years 
 ISS <5 ISS 6-15 ISS 16-24 25≤ ISS 
None 
1.28 (0.17-9.52) 
p=1.000 
0.54 (0.02-13.55) 
p=1.000 
0.85 (0.05-14.40) 
p=1.000 
0.56 (0.14-2.24) 
p=0.529 
Mild 
0.14 (0.01-2.71) 
p=0.136 
4.83 (0.19-121.9) 
p=0.389 
2.33 (0.14-39.85) 
p=0.525 
0.97 (0.29-3.29) 
p=1.000 
Moderate 
3.08 (0.28-33.26) 
p=0.363 
2.07 (0.08-53.66) 
p=1.000 
1.65 (0.07-39.13) 
p=1.000 
1.58 (0.37-6.69) 
p=0.683 
Severe 
13.33 (0.93-191.3) 
p=0.135 
2.86 (0.11-74.41) 
p=1.000 
2.71 (0.11-68.30) 
p=1.000 
4.00 (0.59-26.75) 
p=0.176 
Extensive n/a n/a n/a 
0.54 (0.03-10.62) 
p=1.000 
 
Data presented as odds ratio (95% confidence intervals) with p values.  n/a=There 
was no patient <65 years with an extensive calcium grade and an ISS <25 in this 
cohort. 
Within the older population, there were no patients within the mild injury 
category (ISS <5).  Only those with severe injuries (ISS 16-24) 
demonstrated a non-significant pattern of increasing odds of death with 
higher grades of calcification.   
In all other respects, however, there was similarly no evidence of a 
relationship between the grade of CAC and death.  This remained true 
irrespective of the degree of injury (Table 5.7). 
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Table 5.7.  Odds Ratio of Death per Calcium Grade Stratified by Injury 
Severity Score in Patients Aged 65≤ Years 
 ISS <5 ISS 6-15 ISS 16-24 25≤ ISS 
None n/a 
6.33 (0.17-231.3) 
p=1.000  
1.24 (0.04-34.23) 
p=1.000 
3.90 (0.56-26.94) 
p=0.303 
Mild n/a 
1.48 (0.05-41.58) 
p=1.000 
1.34 (0.07-35.07) 
p=1.000 
1.10 (0.28-5.31) 
p=1.000 
Moderate n/a 
0.72 (0.03-19.36) 
p=1.000 
1.43 (0.08-26.91) 
p=1.000 
0.33 (0.06-1.78) 
p=0.276 
Severe n/a 
4.87 (0.18-128.9) 
p=0.400 
1.83 (0.10-34.87) 
p=1.000 
1.11 (0.26-4.67) 
p=1.000 
Extensive n/a 
2.52 (0.08-74.87) 
p=1.000 
2.20 (0.07-70.48) 
p=1.000 
1.08 (0.09-13.15)  
p=1.000 
 
Data presented as odds ratio (95% confidence intervals) with p values.  n/a=There 
was no patient ≥65 years with an ISS <5 in this study population. 
5.5.5.4  Mortality According to Vessel Involvement 
Patients with calcium in all three coronary arteries had the highest 
incidence of death, although this was not significant (p=0.173, Figure 5.8). 
 
Figure 5.8.  Mortality according to number of calcified vessels observed   
Moreover, increasing numbers of coronary vessels with calcium 
involvement was not associated with higher odds of death (Figure 5.9). 
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Figure 5.9.  Odds ratios of death (with 95% CI) according to number of 
calcified coronary vessels.   
No significant differences in the odds of death were observed based on the 
number of calcified vessels involved. 
Finally, there was no association between mortality and any one particular 
vessel with calcification (Table 5.8). 
Table 5.8.  Relationship of Each Coronary Artery with Mortality 
Vessel Mortality Rate OR of Death (95% CI) p Value 
Left Anterior Descending 11.5% 0.61 (0.32-1.18) 0.165 
Circumflex 11.8% 0.53 (0.26-1.07) 0.078 
Right Coronary Artery 12.3% 0.78 (0.41-1.51) 0.507 
 
5.5.6 Inter-observer Agreement 
The results of the inter-observer agreement analyses revealed that the 
estimation of the CAC load on the CT scans of the study patients was both 
reliable and reproducible.   
There was good agreement between the CACS of the two observers with 
399 (92%) of estimates falling within the 95% Confidence Intervals (Figure 
5.10).   
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Where there was disagreement, this was predominantly in patients with a 
lower CACS and as the score increased, so did the inter-observer 
concordance (Figure 5.10). 
 
Figure 5.10.  Bland Altman plot of inter-observer agreement of estimated 
coronary artery calcium scores 
There was good inter-observer agreement in the scores of the 432 trauma 
patients’ CT scans (Bias=30.5, SD of bias 82.18). 
There was substantial agreement between observers when analysing 
grade of CAC (ĸ=0.74).  Where discrepancies existed between observers, 
only in seven patients (1.6%) was the difference by more than one 
estimated grade. 
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5.6 Discussion 
This study is the first to have demonstrated that an estimation of the 
CACS on CT is feasible, not only in the absence of dedicated cardiac 
scanning but also in the context of trauma.  Using these assessments, this 
research indicated the true incidence of CHD in a trauma population aged 
45 years or over approaches nearly 70%.  Finally, and perhaps contrary to 
expectations, an increase in the distribution and severity of CAC was not, 
for the most part, associated with an increased in-hospital mortality 
following injury. 
Although scan interpretation was subjective in nature, this study revealed 
that estimated scores and grades correlated appropriately with expected 
patient characteristics of increasing levels of coronary calcium, such as 
older age and greater numbers of co-morbidities (Wexler et al., 1996, 
Budoff et al., 2007).  Furthermore, CAC assessments were possible in just 
over 90% of trauma patients with a CT scan of the thorax, and substantial 
agreement between the two observers’ scores and grades was 
demonstrated, thus validating this technique.   
This novel finding has implications for future work not only in trauma, 
but also in other specialties.  Using these estimates, patients having a CT 
chest for non-cardiac related disease could be screened for the incidence 
and severity of CHD.  Additionally, because the measurements did not 
rely on patients presenting with signs and symptoms of heart disease, 
calcium estimates could be used to detect the true incidence of 
atherosclerotic heart disease in any given population. 
CAC was present in over two thirds of the study cohort.  Whilst this is a 
considerably higher incidence compared to much of the existing published 
data on incidental findings on trauma CTs (Van Vugt et al., 2011, Barrett et 
al., 2009, Devine et al., 2010), these previous studies have also included 
much younger patients who will not have developed signs of coronary 
artery disease.   
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Other research, including those examining the role of statins and beta 
blockers on outcome in trauma (Schneider et al., 2011, Neideen et al., 2008, 
Neal et al., 2009, Efron et al., 2008, Cotton et al., 2007, Arbabi et al., 2007) 
have described the incidence of a number of cardiac diseases in trauma 
populations, although only a single investigation has described heart 
disease in isolation (Ferraris et al., 2010).  In all cases, however, these 
studies have identified pre-morbid cardiac diagnoses only, but none have 
acknowledged either the incidence or additional contribution to outcome 
of patients with subclinical CHD.  Accordingly, these papers have 
reported fewer cases of heart disease amongst their populations.  
It is particularly useful in the trauma setting to screen for cardiovascular 
disease, given that patients are mostly unable to give a full medical history 
or are unconscious on arrival to hospital.  To demonstrate evidence of 
underlying cardiac disease, therefore, may be a useful adjunct to enable 
appropriate allocation of resources and the subsequent planning of 
relevant management strategies, such as the early involvement of 
cardiology specialists.   
Although survival was the study outcome, it is worth noting that patients 
with higher CACS and evidence of CHD tended to have longer lengths of 
hospital stay.  By association, it is probable that these patients were more 
unwell and consumed greater hospital resources.  In selected studies, 
injured patients on beta-blocker therapy have improved outcomes, 
notably survival (M. Martin et al., 2005, Hadjizacharia et al., 2011, Arbabi 
et al., 2007, Cotton et al., 2007).  Although this protective effect is most 
apparent following head injury, it is possible that a secondary and 
previously unrecognised benefit of these drugs is the treatment and 
stabilisation of patients with subclinical CHD, which in turn might lead to 
improved outcomes.  Future studies should therefore determine whether 
the treatment of subclinical CHD in trauma is beneficial overall. 
In contrast, isolated levels of CAC were not generally predictive of 
survival and only patients with severe CACS were placed at an increased 
odds of death.   
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These findings not only support results presented in Chapter Two, but are 
corroborated by much of the literature demonstrating patients with 
cardiac disease are not exposed to a higher risk of death following injury 
(Shoko et al., 2010, Bamvita et al., 2007, Smith et al., 1990, Oreskovich et 
al., 1984, Horst et al., 1986).  This finding may have been a consequence of 
survival bias, however.  Patients who will have died in the acute setting 
will not have had a CT scan, and older patients with higher CACS may 
have been exposed to higher death rates on admission.  They will not have 
been included into this study therefore (Meisler et al., 2011).   
Given the disproportionately fewer numbers of individuals with extensive 
CAC in this analysis, it is also likely that patients with very high CACS are 
older and die from cardiac related disease, and are perhaps less likely to 
be exposed to trauma.   
The study did reveal that patients with evidence of severe CAC were at a 
higher odds of death, but it is possible that the study was underpowered 
given the findings are otherwise contrary to some of the other published 
data on survival with heart disease in trauma (Ferraris et al., 2010, Morris 
et al., 1990, Perdue et al., 1998, Wutzler et al., 2009, Milzman et al., 1992).   
Furthermore, evidence on the prognostic value of CACS on mortality has 
often followed up patients over the course of several years (Ostrom et al., 
2008).  It would be valuable in future studies, therefore, to analyse 
whether the estimated CACS is more predictive of the higher longer-term 
death rates seen in trauma patients. 
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5.7 Limitations 
In the first instance, the study could have been subject to inaccurate 
documentation of patient characteristics and outcomes because of its 
retrospective nature.   
Secondly, survival was the primary endpoint examined amongst this 
trauma cohort.  In order to achieve a clearer insight into the effects of pre-
existing heart disease on the outcomes of injured patients, additional 
endpoints should be studied in future, including the risk of ACEs, given 
that that is where the bulk of evidence on calcium scoring currently lies.   
Conclusions of this study were derived from calcium score estimates and 
not objectively calculated values.  In addition, calcium scores were not 
formally computed using dedicated software to verify the estimates.  
Although it was one of the aims of this study to determine whether 
calcium score estimates could be made and usefully applied, it does mean 
that at this stage that the findings of this study can only be generalised.  
Formal calcium scoring of non-cardiac CTs is also not possible, however, 
and so it would not be feasible to objectively measure Agatston scores for 
the purposes of a study such as this. 
While the agreement between observers was substantial, in a few cases 
where there was disagreement, certain scores led to grades moving from 
one category to another.  Accordingly, patients may have been categorised 
incorrectly to a group, and thus inappropriately influenced the numbers 
and outcomes associated with each calcification grade (e.g. mild CAC 
incorrectly labelled moderate or vice versa).   
There is evidence within the statistical analyses that the study may have 
been underpowered.  This was perhaps most apparent when determining 
the odds ratio for death in each calcium score grade after adjusting for age 
and ISS. 
The confidence intervals were very wide in places, and suggested this 
investigation lacks sufficient numbers of patients to achieve statistical 
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significance.  Indeed, although a large overall study population, there 
were only 17 patients in the group with extensive CAC, for example.  
There were also no patients in certain categories, such as deceased patients 
≥65 years with an ISS <5, and this will have led to incomplete data 
analyses.  As a result of all these, the statistical validity of the results may 
have been undermined, and thus the strength of the overall study 
conclusions weakened.   
Nonetheless, because findings from this pilot study were novel and 
designed in part to assess the global incidence of CHD, including those 
subclinical cases, a power calculation to estimate the study population size 
could not have been undertaken.  As a consequence of this work, future 
research will now be able to compute a sufficiently well powered study. 
Finally, the median ISS in this patient cohort was 16 demonstrating this 
analysis was undertaken in predominantly severely injured patients.  
Moreover, no older patient with an ISS <5 died.  It is difficult, therefore, to 
draw conclusions from this investigation on the influence of pre-morbid 
cardiac disease on survival in mild trauma.   
In spite of the fact that the findings of this study are supported by some 
prior research in the field, much of the previous evidence that has 
revealed a negative impact of cardiac disease on survival has shown that 
this effect is most marked in less injured patients.  The high overall ISS of 
this study population meant that the findings of these latter studies could 
neither be confirmed nor refuted.  Future analyses should therefore 
include more patients with mild injury. 
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5.8 Conclusions 
Trauma CT scans performed on admission in older injured patients may 
be used to estimate the CACS and grade.  These estimates suggested that 
the incidence of CHD, inclusive of all presentations, approaches 70% in 
injured patients aged 45 years or over.  Finally, the presence and extent of 
CAC, and therefore CHD, was generally neither predictive nor associated 
with all cause in-hospital mortality in an older trauma cohort. 
Further studies should ensure sufficient statistical power, and examine not 
only in-hospital mortality but also longer term survival.  Furthermore, the 
presence of CAC should be assessed as a risk factor for ACEs in trauma. 
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CHAPTER SIX 
Conclusions 
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6.1 Summary of Findings 
This thesis has achieved all the aims described in Chapter One, and has led 
to significant and novel contributions to the body of knowledge on trauma 
associated cardiac injury and dysfunction.   
Chapter Two identified the existence of a “Trauma Induced Secondary 
Cardiac Injury-TISCI”, and demonstrated its association with poorer 
outcomes.  This included significantly higher death rates.   
Chapter Three revealed a relationship between TISCI and acute 
inflammation.   It also demonstrated that on admission, evidence of 
cardiac injury combined with high levels of inflammation may be 
associated with an increased risk of in-hospital mortality in trauma.   
Chapter Four confirmed both the existence of TISCI and its link to 
increased mortality.  Detailed characteristics of ACEs were reported, 
including evidence that cardiac events were not a manifestation of a stress 
induced (Takotsubo’s) cardiomyopathy.  In addition, the chapter revealed 
the risk factors associated with the development of ACEs, namely 
increasing age and ISS and shock (worsening base excess).  Finally, the 
study showed that pre-morbid heart disease was not an independent 
predictor of secondary ACEs in trauma.   
Lastly, Chapter Five reported that CT scans of the chest undertaken in 
trauma patients may be assessed for the presence and degree of coronary 
artery calcium, as a surrogate marker of CHD.  Although the incidence of 
this disease in an older trauma population approached 70%, its presence 
did not significantly impact on survival outcomes. 
A summary of the principal findings of this thesis is illustrated in Figure 
6.1. 
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Figure 6.1.  Trauma associated cardiac injury and dysfunction: an 
illustrative summary of the principal findings of this thesis 
Full arrows show the associations, or when crossed the non-associations 
demonstrated in this dissertation.  Dashed arrows show putative relationships 
not examined by this research project. 
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6.2 Strengths and Limitations 
6.2.1 Strengths of the Research Project 
There are several key strengths to this research project, which is believed 
to be the largest dedicated global study of trauma associated cardiac 
injury and dysfunction to date.   
This work is the only investigation to have identified TISCI through the 
combination of clinical and multiple biomarker evidence.  Previous work 
has focused on either isolated clinical diagnoses (Hadjizacharia et al., 2011, 
Moosikasuwan et al., 2000, Ismailov et al., 2005, Seguin et al., 2006) or 
single biomarker studies (M. Martin et al., 2005, Edouard et al., 2004, 
Edouard et al., 1998, Lagi et al., 2008), but none have yet combined the 
two. 
The prospective evidence gathered from a larger, unrelated cohort of 
injured patients in Chapter Four mirrored the retrospective findings of 
Chapter Two.  Consequently, perhaps the single greatest strength of this 
work is to have presented conclusive verification of TISCI, a relevant and 
important clinical entity. 
In contrast to prior research in the field (Hadjizacharia et al., 2011, 
Ismailov et al., 2005, Seguin et al., 2006), this thesis contains currently the 
only prospective data examining all ACEs in a general trauma population.  
Using multivariate analysis in a robust statistical model, the project 
identified the risk factors for post-traumatic secondary cardiac events in 
trauma.  These findings not only build upon the limited current 
knowledge of the field, but more importantly will now enable clinicians to 
identify those patients at risk of TISCI following trauma. 
This research project includes the first clinical study to investigate fully 
the role of inflammation in TISCI, and thus begin to translate the findings 
of existing experimental evidence (Yang et al., 2006, Nickel et al., 2009, 
Horton et al., 2000, Liu et al., 2011) into the wider clinical context. 
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By means of a novel and innovative technique, this is the only study to 
examine the epidemiology of CHD in trauma and encompass all 
spectrums of the disease.   
Furthermore, the method evolved and developed is one that may be 
replicated and used to assess CHD in other medical specialties in the 
future.   
A significant achievement of this project is to have set up the single largest 
ongoing prospective study of its kind.  Using robust methodology and 
effective recruitment procedures “Trauma Associated Cardiac Injury and 
Dysfunction-TACID” continues to examine all aspects of the secondary 
effects of trauma on the heart.  In conjunction, a further key strength of 
this work was the development and application of an ethical and 
functional process of consent in injured patients.  Although notoriously 
difficult to undertake and traditionally prohibitive to research in trauma, 
this system remains in place and enables ongoing data collection.  
The chief legacy of this thesis is to have produced translational and 
clinically applicable data that reveals significant and tangible 
opportunities for future research, most conspicuously in targets for 
therapeutic intervention in TISCI.  This project provides novel insights 
and thus represents an important step in leading potentially to a reduction 
in the burden of morbidity and mortality associated with trauma. 
6.2.2 Limitations of the Research Project 
There are, however, notable limitations to the work presented in this 
dissertation.  Most of the studies were dependent on retrospective data 
collection.  Accordingly, there existed the potential for misclassification of 
cardiac events which may have led to subsequent inaccuracies in the 
diagnoses of post-traumatic ACEs.  Furthermore, such methodology may 
have resulted in an inaccurate estimation of the incidence of such 
occurrences.   
Nonetheless, whilst it is possible that ACEs were more widespread, the 
prospective findings in Chapter Four suggested that the retrospective data 
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capture was a comprehensive and accurate reflection of the epidemiology 
of post-traumatic cardiac events. 
The diagnosis of cardiac injury and dysfunction were based 
predominantly on clinical and biomarker evidence.  Few patients with 
TISCI were investigated with detailed imaging studies, which would have 
provided additional and more complete information on cardiac 
morphology and function.  As such this represents another limitation of 
the research methodology. 
The measurement of coronary artery calcium on CT in Chapter Five was 
based on subjective assessments using a non-validated technique.  
Consequently, there would have been inevitable errors in reporting the 
extent of cardiac calcification in patients.  Based on the Bland-Altman 
charts demonstrating the discrepancies between observers, these were 
most likely in individuals with lower calcium scores. 
Finally, many of the conclusions of this thesis are based on associations in 
relatively small study populations.  Although larger than many previous 
investigations, the existing data would benefit from substantiation in 
future studies with greater statistical power. 
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6.3 Future Work 
The research presented in this thesis revealed the existence of a trauma 
induced secondary cardiac injury that is associated with poorer outcome.  
Although an association with inflammation was shown, the 
pathophysiological mechanisms driving this condition are not fully 
understood.  Future work should investigate the cellular structure of the 
heart in TISCI, and identify which organelles and microscopic processes 
are disrupted in leading to such cardiac damage.  Mitochondria and 
endoplasmic reticulum together with apoptosis and autophagy represent 
appropriate targets for preliminary investigation.  Whilst initially 
performed in animal studies, corroboration in human hearts should be 
undertaken pending ethical approval.  Furthermore, postmortem analyses 
would determine if and how TISCI leads to the death of injured patients.  
Prospective experimental and clinical research should also conduct 
detailed cardiac imaging studies such as MRI and positron emission 
tomography (PET) to yield further information on the appearance, 
structure and function of the heart in TISCI.   
Investigations should examine why increased age, shock and tissue injury 
are independent predictors of TISCI.  They should determine which 
pathological processes responsible for cardiac injury they initiate.  
Further outcomes associated with TISCI require exploration, including 
longer-term end points (such as one, five and ten year mortality and 
economic cost, for example).  This would also establish if TISCI is a 
chronic condition, and implicated in the higher protracted death rates seen 
in trauma patients. 
The novel technique used to assess coronary artery calcium should be 
validated.  This could be done using existing cardiac scanning software 
designed to measure calcification objectively in the heart.  In addition, this 
research did not reveal the impact of CHD on other outcomes in trauma, 
such as the development of ACEs.  Indeed the influence of CHD on long-
term survival remains unknown.  Future work should establish these. 
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Ultimately, the aim of the research both presented and generated in this 
thesis will be to identify opportunities to reduce the mortality and 
morbidity associated with trauma.   
These include the trial of therapeutic interventions such as cardiac 
medication.  Beta-blockers are recommended agents in the treatment of 
life threatening conditions such as MI, and the evidence presented in this 
thesis might represent the first step in the eventual justification and 
initiation of a future randomised clinical trial of such medication in 
trauma. 
Finally, increasing age, shock and tissue injury were found to be the risk 
factors linked to TISCI.  None of these aspects, however, are exclusive to 
trauma, and indeed they are common to a number of other medical 
specialties.  As such, this thesis justifies research in non-trauma fields 
(such as all major surgery) to determine whether secondary cardiac injury 
and dysfunction exists in such areas, and whether it is also responsible for 
negative impacts on outcome. 
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6.4 Conclusions 
This thesis has completed all the study aims.  It has revealed that trauma 
induces a secondary cardiac injury and that this is related to poorer 
outcome.  Increasing age, shock and tissue injury are independent 
predictors, whilst inflammation is associated with TISCI.  Although 
coronary heart disease is widespread in older trauma patients, it has no 
significant impact on in-hospital mortality. 
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Synopsis 
“Trauma Associated Cardiac Injury and Dysfunction” (TACID) is a 
programme designed to investigate cardiac-specific outcomes following 
major trauma.  Trauma and heart disease are two of the world’s most 
prevalent conditions and are the leading causes of death and disability.  
There is emerging evidence that trauma may have adverse effects on the 
heart, leading to long-term cardiac dysfunction and poor outcomes.   
Furthermore, as the elderly remain active for longer, they are more likely 
to sustain serious injury.  Elderly patients are known to have worse 
outcomes following injury and pre-existing cardiovascular disease may 
contribute to this.   Early identification of at-risk patients and cardiac 
dysfunction may allow targeted therapeutic intervention and reduce death 
and disability associated with major trauma. 
We will assess the effect of trauma on the healthy heart; looking at the 
independent impact of direct cardiac trauma, extra-thoracic trauma and 
systemic hypotension on short and long term cardiac function.  We will 
also investigate the influence of trauma on the diseased heart, 
investigating the contribution of pre-morbid cardiovascular disease on 
short and long-term outcomes in trauma patients.  We hope to identify the 
optimal investigations for screening and delineation of post-traumatic 
cardiac injury.  Finally, we wish to determine a reliable, sensitive and 
specific biomarker of cardiac trauma which may be used alone or in 
conjunction with other simple investigations to screen for cardiovascular 
risk following injury.   
The initial investigations are structured as observational (A) and 
feasibility (B) studies to inform the design and conduct of subsequent 
larger cohort studies.   Patients at risk of cardiac dysfunction will be 
enrolled into the study.  These patients will have significant chest trauma, 
major extra-thoracic trauma, systemic shock or have risk factors for pre-
existing cardiac disease.  Patients expected not to survive the first 72 hours 
will be excluded. 
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In TACID (A), initially and at 24 hours, patients will have an ECG and a 
blood sample taken for markers of cardiac injury.   
Patients with an adverse cardiac event will receive a transthoracic 
echocardiogram within the first 3 days.   
Individuals will be followed up during the course of their admission for 
any cardiac-related morbidity.  At discharge patients will have their 
current and premorbid disability and quality of life assessed using 
validated scoring systems.  Patients who are alive at 12 months will be 
contacted to ascertain their current general and cardiac-specific health and 
quality of life. 
A smaller subset of the above patients, in the order of 50, will be enrolled 
into TACID (B), a feasibility study to examine the role of more detailed 
cardiac investigations in the screening and diagnosis of cardiac injury and 
dysfunction.  In addition to the above investigations patients will have a 
cardiac MRI scan.  These patients will also undergo cardio-pulmonary 
exercise testing (CPEx) prior to discharge.  At twelve months they will 
undergo further 24-hour Holter monitoring, Echo, MRI and CPEx testing 
and blood samples. 
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Study Aims & Hypotheses 
Aim 1:  To identify the effect of trauma on the healthy heart. 
Hypothesis:  1A 
Direct chest injury results in cardiac dysfunction.  These patients 
have significant long-term cardiac dysfunction and worse 
outcomes.   
Hypothesis:  1B 
Severe tissue injury results in cardiac dysfunction.  These patients 
have significant long-term cardiac dysfunction and worse 
outcomes. 
Hypothesis:  1C 
Systemic shock results in cardiac dysfunction.  These patients have 
significant long-term cardiac dysfunction and worse outcomes. 
Aim 2:  To determine the effect of trauma on the diseased heart. 
Hypothesis:  2A 
The presence of pre-morbid cardiac disease results in worse 
outcomes in trauma patients. 
Hypothesis:  2B 
The presence of atherosclerotic disease, or its individual risk 
factors, results in worse outcomes in trauma patients. 
Hypothesis:  2C 
Pre-morbid cardiac medical therapy improves outcomes following 
trauma in at-risk patients. 
Aim 3:  To identify useful screening and diagnostic investigations for 
the presence of post-injury cardiac dysfunction. 
Hypothesis:  3A 
ECG is the most appropriate screening test for significant cardiac 
dysfunction following injury. 
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Hypothesis:  3B 
Echo is the most appropriate screening test for significant cardiac 
dysfunction following injury. 
Hypothesis:  3C 
Echo is the most appropriate diagnostic tool of significant cardiac 
dysfunction following injury and its associated prognosis. 
Hypothesis:  3D 
CPEx testing is the most appropriate diagnostic tool of significant 
cardiac dysfunction following injury. 
Hypothesis:  3E 
Cardiac MRI is the most appropriate diagnostic tool of significant 
cardiac dysfunction following injury. 
Aim 4:  To identify the most reliable biomarker of cardiac trauma and 
subsequent cardiac dysfunction 
Hypothesis:  4A 
Troponin I is a sensitive biomarker of cardiac trauma and levels are 
predictive of the extent of cardiac dysfunction and subsequent 
cardiac complications. 
Hypothesis:  4B 
Heart type fatty acid binding protein (H-FABP) is a more sensitive, 
specific and reliable assessor of the presence of cardiac trauma and 
longer term outcomes. 
Hypothesis:  4C 
Brain Natriuretic Peptide (BNP) is a more sensitive, specific and 
reliable assessor of the presence of cardiac trauma and longer term 
outcomes. 
Hypothesis:  4D 
A combination of biomarkers, ECG and/or Echo is an effective 
screening tool for cardiac dysfunction following trauma. 
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Background 
Trauma and heart disease are two of the world’s most prevalent 
conditions and are leading causes of death and disability.  There is 
emerging evidence that trauma may have adverse effects on the heart, 
leading to long-term cardiac dysfunction and poor outcomes.  
Furthermore, as the elderly remain active for longer, they are more likely 
to sustain serious injury.  Elderly patients are known to have worse 
outcomes following injury and pre-existing cardiovascular disease may 
contribute to this.  Early identification of at-risk patients and cardiac 
dysfunction may allow targeted therapeutic intervention and reduce death 
and disability associated with major trauma. 
Trauma is the leading cause of death in those aged between one and forty.  
For every death due to injury, there are approximately two patients left 
with serious permanent disabilities1.  Trauma is a serious financial burden 
to the NHS with a mean hospital cost per blunt trauma patient estimated 
at £9,530, and penetrating at £7,9832,3 .  Cardiovascular disease is the 
world’s leading cause of death.  In the UK, coronary heart disease is the 
single biggest killer with approximately 110,000 deaths in England alone4. 
Despite occurring together with increasing frequency, very little is known 
about the combination of trauma and cardiovascular disease.  There is also 
a paucity of clinical evidence on the effect of trauma on the healthy heart.  
There is a reasonable body of laboratory evidence to suggest that trauma 
and its consequences have a significant detrimental effect on cardiac 
function, even when the heart is not directly injured in the event.   
Studies have shown that trauma patients’ risk of death following 
discharge is approximately twice as high as age and sex matched 
uninjured cohorts for up to ten years post injury5.  Amongst the former, 
cardiovascular disease may account for nearly 25% of these deaths6.  Most 
often, these are young active members of society with little or no 
associated background illnesses.  Prior to injury, these patients typically 
lead healthy lives with normal life expectancies.   
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The reasons why this cohort is more likely to die once they have recovered 
from the acute injury are therefore crucial to establish.  Cardiac 
dysfunction as a result of trauma may contribute either wholly or in part 
to these poor outcomes and therefore may represent an important target 
for preventing post-injury death and disability. 
Certain retrospective studies suggest that patients with cardiovascular 
disease may have worse outcomes following injury.  Patients over the age 
of 45 have worse outcomes following trauma, which increases linearly as 
patients get older.  One study has shown that all cause mortality in trauma 
patients over 60 approached 20%7.  Moreover, those over 65 have a two to 
threefold higher risk of death and worse outcomes than younger 
individuals8.  These patients are presumed to have ‘less physiological 
reserve’ without a specific understanding on why they are less able to 
cope with trauma.  Roughly 22% of our annual trauma team activations 
comprise patients over 45 (n=230) and those over 60 nearly 10% (n=90). 
These patients are in large numbers and are representative of significant 
trauma case loads in society. The effects of trauma on a diseased heart 
may lead to increased early and late deaths or long-term cardiac-related 
disability.  Trauma-induced cardiac dysfunction may also have other 
systemic effects influencing outcomes in the elderly. 
Data on trauma patients with pre-existing coronary heart disease remains 
scarce in spite of the prevalence of this disease and its burden on the NHS.  
According to the British Heart Foundation, in 2006 the prevalence of 
Coronary Heart Disease rose from 3.6% in those aged 45 to 54 to 28.6% in 
those aged 75 or over.   
The true rate of asymptomatic cardiac disease is higher in all likelihood, as 
are risk factors such as diabetes and hypertension.  A better 
understanding of the impact of background coronary artery disease or 
heart failure in the context of injury may lead to improved survival and 
reduced disability in this increasing patient population.   
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There is circumstantial evidence that patients on cardiovascular 
medication (beta blockers, statins) may have an improved outcome 
following injury.  This data comes from very limited retrospective studies.   
Prospective studies are needed to assess whether this effect is real and 
whether they may hold therapeutic potential for patients after injury. 
The existence and severity of post traumatic cardiac disability is a poorly 
explored phenomenon in spite of the impact on both the individual and 
society.  Patients’ exercise tolerance and ability to return to their pre-injury 
existence are not well known.  Patients who remain inactive and unable to 
work are more susceptible to mental health problems and developing 
diseases at later stages in life.  They represent significant cost to the NHS 
yet the prevalence and extent of cardiac disability following injury has not 
been quantified.  The study will seek to identify the degree to which 
patients have cardiac dysfunction following trauma and the impact this 
has on their activities of daily living.  The assessment of post-traumatic 
cardiac physiology, through CPEx testing, imaging and patient surveys 
will enable a better understanding of the impact and significance of longer 
term abnormal cardiac function secondary to injury. 
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Background  
Aim 1:  To identify the effect of trauma on the healthy heart 
Trauma is the leading killer of young people.  There is evidence that chest 
injuries and haemorrhage can lead to longer term cardiac dysfunction. 
This might lead to a higher protracted risk of death in discharged trauma 
patients due to cardiovascular diseases and a reduction in function due to 
cardiac disability. 
Hypothesis 1A: 
 Clinical data have shown that direct blunt chest trauma results in 
cardiac injuries in up to a third of cases.  Longer term follow up of 
these subjects has shown a greater susceptibility to potentially fatal 
cardiac events and a decline in cardiac function in up to 50% of 
patients with injuries to the heart9.  In patients 65 or over, 
significant chest injuries were shown to cause adverse outcomes in 
16% of the cohort10. 
 The numbers in these studies are small, however, and the degree to 
which chest trauma affects cardiac function and the duration of this 
effect requires quantifying and qualifying.  It has also not been 
established whether cardiac function, if disrupted, ever returns to 
normal. 
Hypothesis 1B: 
 Cardiovascular and respiratory dysfunction account for over half 
the mortality of patients with severe traumatic brain injury where 
death is not neurological in origin11.  Multiply severely injured 
patients, as defined by an injury severity score (ISS) >15 are known 
to have worse short and long-term outcomes. 
 The impact, however, of severe tissue injury on the heart has not 
been fully explored and myocardial function of these patients 
following discharge has not been examined over the long term. 
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Hypothesis 1C: 
 In clinical studies, cardiac ischaemia occurs in over 50% of patients 
with postpartum bleeding and cardiac dysfunction occurs in sepsis 
and SIRS12,13.  Animal models have confirmed that trauma 
haemorrhage results in acute cardiac dysfunction through a variety 
of inflammatory and other pathways14,15,16, 17,18. 
 Few studies have verified this phenomenon in trauma and the 
duration and extent of cardiac dysfunction remains unknown. 
A small number of studies have examined the effect of both shock and 
severe generic trauma on the heart and little is known on longer term 
outcomes in these patients and the degree and length to which cardiac 
physiological function is affected.  Moreover, there remains a paucity of 
evidence on the effect of direct trauma to the heart.  There is a lack of data 
on why trauma patients are more susceptible to death at later stages and 
how this might be prevented.   It is not known who represents a high-risk 
patient for subsequent cardiac complications.   
Establishing these facts will result in a better understanding on the effect 
of trauma on the heart thereby potentially enabling in the future a 
significant reduction in both cardiac associated morbidity and mortality 
following trauma. 
Aim 2:  Assess the effect of trauma on the diseased heart 
There is some retrospective data to suggest that patients with pre-existing 
cardiovascular disease fare worse in trauma.  The presence of diabetes is 
associated with worse morbidity outcomes whilst there are suggestions 
that cardiovascular medications may have protective effects in trauma 
patients. 
Hypothesis 2A: 
 There is a little retrospective evidence that patients with pre-
existing heart disease have worse outcomes in trauma.   
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 Age, with greater associated co-morbidities is a risk factor for 
higher death rates, longer hospital stay and poorer outcomes. 
Detailed evidence on the impact of pre-injury cardiovascular 
disease is lacking including its true incidence, and the short and 
longer term outcome of this specific group of patients is not known. 
Hypothesis 2B: 
 There is evidence that diabetics have worse morbidity compared to 
age and injury severity matched counterparts19.  Furthermore, poor 
glycaemic control has been shown to result in poorer outcomes in 
SIRS and sepsis. 
 Few studies, however, have analysed in detail the impact that risk 
factors such as hypertension and hypercholesterolaemia have in 
trauma patients. 
Hypothesis 2C: 
 There may be a protective effect associated with pre-trauma B-
blockers.  Statins are associated with improved in-hospital survival 
amongst older patients following injury20,21. 
 There remain, however, many questions on the effect that 
cardiovascular medicines have on outcomes.  It has not been 
examined whether all severely injured patients should be 
prescribed any or a combination of cardiovascular medications. 
In spite of the massive health implications of both heart disease and 
trauma, very little is known on what effect pre-existing cardiac illness has 
on injured patient outcomes.  There is sparse evidence on both short and 
long term outcomes in patients with heart disease pre-injury, and whether 
outcomes are influenced by diabetic and cardiovascular medications.  
Identifying whether these patients are at greater risk of mortality and 
morbidity would then provide impetus for developing means of 
improving survival and minimising the longer term effects of injury.   
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It would also facilitate further studies identifying the role of cardiac and 
diabetic medications, and whether these have a role in all trauma patients 
and not just those with coronary artery disease or diabetes. 
Aim 3:  To identify useful screening and diagnostic investigations for 
the presence of post-injury cardiac dysfunction. 
ECGs and Echos are used in current clinical practice to detect cardiac 
injuries.  They are safe, cheap and reliable.  MRI perfusion scans are useful 
diagnostic investigations in trauma although seldom used.  CPEx has not 
been explored.   
Little is known on these investigations abilities’ to prognosticate or screen 
cardiac injuries. 
Hypothesis: 3A 
 ECGs have been shown in many studies to be a reasonable 
indicator of cardiac injury and may correlate with severity of injury 
and outcome.  Cheap, quick and safe to patients, ECGs are now 
commonly used in the detection of cardiac injuries, mostly 
following blunt chest trauma. 
 The extent to which ECGs are useful screening tools in post-injury 
cardiac dysfunction is vague.  Cardiac abnormalities following 
trauma may manifest on ECGs, and may continue to do so at least 
twelve months post injury.  The sensitivity and specificity of ECGs 
to independently screen for cardiac dysfunction needs 
confirmation. 
Hypothesis: 3B & 3C 
 There is good evidence that the diagnosis of cardiac injuries using 
echocardiograms is reliable.  Identification of cardiac function, 
volume status and wall abnormalities have been evaluated in the 
intensive care setting and the investigation is both safe and cheap22. 
 Echocardiograms have not been extensively used in the diagnosis 
of post traumatic cardiac dysfunction and evidence on the subject 
remains insufficient 
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Hypothesis: 3D 
 The use of CPEx to assess cardiopulmonary physiological function 
is now commonplace in patients planned for major elective surgery.  
Its ability to detect cardiac dysfunction to this end is well 
documented and relied upon. 
 The role of CPEx testing has not been assessed in trauma and 
therefore the extent to which patient’s exercise tolerance and 
cardiac function following trauma are compromised is not known. 
Hypothesis: 3E 
 MRI is safe and can discriminate between cardiac contusions and 
peri-traumatic myocardial infarctions.   
 There is also evidence to suggest that MR stress testing may 
indicate patients at risk of future cardiac events which might 
validate its use as a screening tool of cardiac dysfunction23. 
 The use of MRI as an investigation in the screening and diagnosis 
of cardiac dysfunction has not been attempted in trauma patients. 
In spite of the volume of evidence demonstrating that the above imaging 
modalities are effective in demonstrating cardiac damage, there is little 
evidence assessing their ability to detect cardiac dysfunction in trauma 
patients.  In addition, little is known on the optimal timing of undertaking 
these investigations, which is most reliable, and finally which would give 
the best indication of patients at risk of cardiac complications in the longer 
term. 
Aim 4:  To identify the most reliable biomarker of cardiac trauma and 
subsequent cardiac dysfunction 
Troponin I is used in clinical practice as a biomarker of cardiac injury, 
particularly in blunt chest trauma.  Studies have shown it to be specific 
but poorly sensitive.  Other cardiac biomarkers such as Troponin T and 
CK-MB have been demonstrated to be relatively invalid indicators of 
cardiac dysfunction and are discouraged in the literature24.   There is no 
significant current evidence on both BNP and H-FABP in trauma. 
 231 
Hypothesis:  4A 
 Troponin I has been shown to be a biomarker of cardiac damage 
both in studies of trauma and critical care25.  In critical care, 
following orthopaedic and vascular surgery and in sepsis, a rise in 
Troponin I may be suggestive of increased mortality and cardiac 
complications26,27,28. 
 The extent to which Troponin I is sensitive and the significance of 
its levels are still not fully known.  Objective parameters indicating 
prediction of death or likelihood of future adverse cardiac events 
have not been set. 
Hypothesis:  4B 
 There is mounting evidence that H-FABP is a reliable biomarker 
of myocardial infarction and other acute coronary syndromes.  
Furthermore, there is increasing data demonstrating its ability to 
detect long term mortality and cardiac events29,30,31. 
 H-FABP has not been investigated in trauma. 
Hypothesis:  4C 
 B type Natriuretic Peptide has been studied in sepsis and with 
regard to cardiac surgery and failure. On the one hand its use is 
discouraged whilst conversely other studies have endorsed its role 
in detecting myocardial injury32,33. 
 Little is known on its validity both in detecting myocardial injuries 
and as a prognostic indicator in trauma. 
Hypothesis:  4D 
 Studies have demonstrated that when used in combination 
Troponin I and ECGs are sensitive detectors of cardiac injury.  The 
grouping of Troponin I with other biomarkers is no more sensitive 
than the former in isolation. 
 The use of H-FABP/BNP/Troponin I together has not been 
assessed nor indeed has the use of routine screening Echos as a 
screening tool of cardiac damage.   
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Moreover, a sufficiently reliable combination of tests to indicate future 
adverse cardiac outcomes remains undetermined. 
A highly sensitive biomarker of cardiac trauma remains undiscovered.  
Furthermore, the extent to which Troponin I has prognostic value in 
subsequent cardiac events in patients following injury is not known.  A 
sensitive and specific combination of cardiac biomarkers and tests has not 
been elucidated. 
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Goals and Expected Outcomes 
Overall Goal 
Both the short and long term effects on the heart of severe trauma, shock 
and direct cardiac injury remain largely unknown.  By undertaking this 
study, we hope to identify what happens to patients following injury and 
whether clinical or subclinical cardiac dysfunction exists and contributes 
to poorer mortality and morbidity outcomes.  By following these patients 
over the course of a year, we will establish whether myocardial damage 
persists, and what, if any, consequence that has.  We will examine post-
traumatic exercise tolerance and cardiac disability and determine why 
patients die at later stages following injury, and whether the heart is 
implicated.   
This research will establish “at risk” groups of subsequent cardiac 
mortality and morbidity following trauma and which investigations will 
best ascertain risk and prognosis.  In undertaking this research, we aim to 
provide baseline data to enable future larger prospective studies to be 
undertaken.  Using this data, research could examine, as an example, the 
utility of cardiac medications in trauma and thus expand knowledge and 
improve care in this poorly understood area. 
Aim1: 
 Understand the long and short term effects of direct trauma to the 
heart 
 Determine the impact of shock on cardiac function 
 Establish the consequence of severe generic trauma on myocardial 
behaviour 
 Identify areas which require further research on the matter of 
preventable long term death and disability from trauma 
Aim 2: 
 Establish the effect of pre-morbid heart disease on trauma 
outcomes 
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 Establish the effect of hypertension, hypercholesterolaemia and 
diabetes and age on trauma outcomes 
 Encourage further research on the mechanisms behind why these 
patients have worse outcomes 
 Analyse means of reducing the impact of trauma on this cohort 
 Determine the impact of cardiovascular medications on trauma 
outcomes 
Aim 3: 
 Establish which investigation best assesses cardiac dysfunction and 
its prognosis 
 Determine the best time frame in which to undertake particular 
imaging modalities 
 Provide clinicians with universal guidance on the assessment of 
myocardial damage in trauma.   
 Highlight which patients need close follow up and cardiological 
supervision 
Aim 4: 
 Determine the sensitivity of Troponin I in detecting traumatic 
myocardial injury  
 Establish the reliability of Troponin I as a prognostic indicator  
 Determine the reliability of H-FABP in the detection and 
prognostication of cardiac injuries 
 Determine the reliability of BNP in the detection and 
prognostication of cardiac injuries 
 Improve the detection of cardiac injuries and better determine who 
is at risk of cardiac complications 
 Establish those who do not require admission for surveillance or 
cardiac monitoring and eventually reduce the cost of unnecessary 
inpatient stays 
 To validate a combination of biomarkers 
 235 
TACID (A) 
Prospective Cohort Study of Cardiac Dysfunction in Trauma (numbers 
anticipated = approx. 300) 
Inclusion criteria 
 Trauma patients meeting trauma team activation criteria  
Exclusion criteria 
 Not expected to survive > 72 hours 
 Pregnant 
 Prisoners 
 Patients under 16 years of age 
Interventions 
 Blood sampling: Baseline, 24 hours & 72 hours 
 ECG: Baseline, 24 & 72 hours 
 Echocardiogram in patients with adverse cardiac events 
 Premorbid cardiac risk factors, medications, cardiac-specific 
disability/Quality of Life 
Outcomes 
 Cardiac events during admission (arrythmias, infarctions, failure, 
angina and cardiac death) 
 Requirement for cardiac medication during admission (B-blockers, 
inotropes, diuretics, Ca channel blockers, ACE inhibitors, Angiotensin 
II inhibitors) 
 Mortality (30 day, six months and one year) 
 Length of hospital stay, length of ITU stay, ventilator free days 
 Cardiac-specific disability/ Quality of Life at discharge or 30 days 
(whichever is first) 
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TACID (B) 
Comprehensive Cardiac Assessment Feasibility Sub study 
In addition to the former, a subgroup of 50 patients from the cohort above 
will be recruited into a more comprehensive cardiac assessment sub study. 
Inclusion criteria 
Subset of patients from cohort above with one or more of the following: 
 Severe thoracic injury (AIS>3) 
 Severe extra-thoracic injury (ISS > 24) 
 Severe traumatic brain injury (AIS>2) 
 Severe systemic shock (Systolic BP < 80 during ED phase) 
 Age 60 or over 
 Known significant heart disease or cardiovascular risk factors 
 Evidence of cardiac injury on admission/24 hr ECG, cardiac enzymes, 
CT 
 Evidence of pre-existing cardiovascular disease on admission 
investigations  
Exclusion criteria 
 Patients without consent 
 Prisoners 
 Patients transferred from other hospitals 
 Patients likely to have difficulty with study related tasks 
Investigations (Table 1) 
 Echo – At 24 hours and again at 12 months 
 ECG – Admission, 24hrs, 72hrs and 12 months 
 Blood sampling - Admission, 24hrs, 72hrs and 12 months 
 CT Calcium score calculated if patient has a CT Chest on clinical 
grounds 
 Cardiac MRI - Within first 14 days and at 12 months 
 Cardiopulmonary Exercise testing Prior to discharge and at 12 months 
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 Patients with pre-existing cardiovascular disease and/or risk factors 
will have CT Coronary Angiography 
Outcomes 
 In-hospital cardiac events (arrythmias, infarctions, failure, angina and 
cardiac death) 
 Requirement for cardiac support/medication in-hospital 
 Discharge or 30-day cardiac disability/Quality of Life 
 12-month disability  
 Length of hospital stay, length of ITU stay, ventilator free days 
 Mortality (30 day, six months and one year) 
Table 1.  Summary of Cardiac Assessment Feasibility Sub study 
 
Admission 24 hours 72 hours 3-14 days Discharge 12 months 
Biomarkers    X X  
ECG    X X  
CT chest  X X X X X 
Echo  X  X X X  
MRI X X X  X  
CPEx X X X X   
Questionnaire X X X X   
 
Proposed Outcome Surveys  
1. Minnesota 
2. SF-36 
3. EQ-5D 
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Procedures 
All investigations, with the exception of the CT scan, will be performed at 
least twice in order to compare the results of the test in the acute and the 
longer term settings.  This will permit a comparison of cardiac 
morphology and function in these time frames, and indicate the best 
period in which to perform these investigations in future, outside the 
context of this study. 
Blood Samples  (TACID A&B) 
Trauma patients will have blood samples drawn to measure Troponin I, 
H-FABP and BNP levels.  Samples will be drawn on admission, at 24 and 
72 hours and thereafter at twelve months. 
There is discomfort associated with having blood taken and certain 
patients have needle phobia.  Whenever possible we will therefore 
coordinate our blood draws with those of clinical need, to reduce the 
number of needle-sticks.  Most major trauma patients have an arterial or 
central line placed and hence most blood draws will involve no pain.  
Electrocardiogram (ECG)  (TACID A&B) 
An ECG will be performed on admission, at 24 and 72 hours and at twelve 
months.  ECGs are performed on admission in trauma patients regardless 
of the study and the result of this initial investigation may be a 
determinant of whether the patient is enrolled in the research.  ECGs are 
cheap and safe and cause no distress to patients.  They can be performed 
very quickly and therefore impose minimal time delays on patients 
awaiting transfer to theatre, angiography or other investigations.  The 
purpose of repeating this test at various stages of seeing the patient is to 
determine whether ECG changes incurred as a result of traumatic damage 
to the heart reverse, and in the event, in what time frame.  In addition, in 
those who have abnormal ECGs prior to injury, we seek to determine 
whether any changes occur in their traces and over what period this may 
occur. 
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Computerised Tomography (CT) chest  (TACID A&B) 
A CT of the chest will be performed on admission in all trauma patients in 
whom it is clinically indicated.  This decision will be made by the trauma 
team leader, independent of this study.  If this scan is abnormal, the 
patient will be included in the project, on the basis that they either have 
evidence of pre-existent heart disease, or that changes incurred as a result 
of the traumatic episode are sufficient as to indicate significant chest 
trauma.  Only the CT scan performed on admission will be interpreted for 
the purposes of this research, although others may be undertaken during 
the patient’s admission if clinically required.  A CT chest is associated 
with large doses of radiation and this is why we will not request the 
investigation unless clinically warranted.  Transfer to the CT room and 
into the scanner itself is associated with time delays and is potentially 
hazardous to patients with spinal injuries.  Furthermore access to the 
patient during scanning can be problematic.   
Given the difficulties and potential dangers with CT, we will only request 
Calcium scores in patients who clinically require the investigation and will 
not undertake it independently for the purposes of the study only.  
There is evidence, however, in the literature that in spite of the radiation, a 
CT scan is usually indicated in severely injured patients given its 
sensitivity and superiority to chest radiographs and other imaging 
modalities in detecting abnormalities of the heart, lungs, great vessels and 
mediastinum. 
Echocardiogram (Echo)  (TACID A&B) 
A transthoracic Echo will be performed in patients with adverse cardiac 
events (A) or after 24 hours and at 12 months (B).  This investigation will 
provide a cheap, reliable and safe means of assessing the heart, both in 
terms of structure, appearance and function.  There can be discomfort to 
the patient when applying the probe to an injured chest wall, although the 
technician will ensure the patient has good analgesia and will undertake 
the study with due care to minimise this effect.   
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Echo will highlight new cardiac problems due to trauma, whilst also 
indicating patients with pre-existing heart disease with wall and valve 
defects, morphological abnormalities and lowered ejection fractions.  The 
investigation may be of clinical benefit to patients by giving their treating 
doctors information on cardiac function and volume status.  It will 
provide us with data on acute cardiac dysfunction and the structural 
changes that may occur as a result of both direct cardiac trauma and 
generic injury and shock.  Twelve months later, images can be compared 
with the admitting investigation and provide the study with information 
on what the long-term consequences of trauma are on heart appearance 
and function. 
Magnetic Resonance Imaging (MRI)  (TACID B only) 
MRI perfusion studies will be performed between 3 and 14 days and again 
at twelve months.  The purpose of the MRI will be to assess myocardial 
blood flow and the degree of cardiac injury.  The rationale for timing the 
scan at least three days post admission is to ensure that patients are being 
scanned when deemed clinically stable, when the process of imaging the 
trauma patient places them at minimal risk.  As with CT, transferring 
patients to MRI can be problematic and care needs to be taken with 
monitoring and anaesthetic equipment.  Once in the scanner, patients are 
difficult to access.  We will ensure, therefore, that patients are transferred 
to MRI only when they are awake, stable, self-ventilating and 
accompanied by appropriately trained staff that can safely monitor 
patients throughout the process of scanning, from ward transfer to 
moving the patients in and out of the MRI suite.  This first MRI will be 
conducted no later than two weeks post admission in order to ensure we 
get images that will reflect the acute state of the heart.  Although not 
routinely used, MRIs are sometimes required in patients with head and 
spinal injuries and in the event, we will combine perfusion scans with 
those of the spinal tract.  At twelve months, we will compare the MRI 
images to those on admission and assess, if any, the degree to which 
 241 
cardiac morphology and function has changed.  There is also evidence to 
suggest that MRI perfusion scans have prognostic value in cardiac disease.   
Hence we will combine images with the patient’s physiological state and 
any cardiac events that may occur over the course of the year over which 
we will follow them up to determine the extent to which this is true. 
MRI is a safe investigation, contra-indicated only in patients with non-
compatible metal work.  Naturally these patients will be excluded from 
this test, but all others will be scanned if they consent. 
Cardio-Pulmonary Exercise Testing (CPEx)  (TACID B only) 
CPEx testing will be used for the first time in trauma.  The purpose of this 
test will be to assess the patient’s exercise tolerance following a traumatic 
episode.  CPEx is now routinely used in the routine pre-operative 
assessment of older patients with significant co-morbidities about to 
undergo major surgery.  There is no evidence in the literature of contra-
indications and certainly anecdotally this is a safe test.  There will be a 
doctor at all times with the patient during this investigation and thus the 
individual will be medically supervised throughout CPEx testing. 
It will be conducted prior to the discharge of the patient and again at one 
year following the patient’s injury.  We will be assessing the individual for 
evidence of decreased exercise tolerance, with lowered cardiopulmonary 
physiological ability. 
This will determine whether and to what extent trauma causes longer 
term cardiac disability.  
Questionnaires  (TACID A&B) 
The questionnaires used are most appropriate to trauma patients and have 
been validated to this end.  Patients will be asked to complete them on 
discharge and at one year post injury.  The purpose of the questionnaire is 
to obtain a subjective assessment of the patient’s state, both in the acute 
and longer term setting. 
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Risks & Benefits 
Risks 
All aspects of the study will always be undertaken minimising patient risk 
and discomfort.  Patient care will never be compromised or delayed for 
the purposes of the study.  The risks of blood sampling include potential 
bruising at the site of venepuncture and discomforts limited to needle 
puncture (where no arterial line is already in place).    
Computerised Tomography scans are well described sources of radiation 
with small but nevertheless measurable cancer risks.  Patients in the study 
will have only one CT scan performed and this will be indicated on the 
basis of their mechanism of injury and clinical state on presentation to the 
Emergency Department.  No additional CT imaging will be performed for 
the study however further scans may be clinically indicated during the 
course of the patients’ admission independent of the study. 
Echocardiography is widely reported throughout the literature as both a 
safe and useful clinical tool.  The complications of this procedure, when 
performed as a transoesophageal approach, however, primarily relate to 
the gastrointestinal, cardiovascular, and respiratory systems, and include 
infection, toxic drug reaction, local reaction through contamination of the 
probe, and ultrasound cavitation.  For this reason we will be only using 
transthoracic Echos. 
Magnetic Resonance Imaging is a safe and well tolerated procedure with 
only few patients at risk of claustrophobic symptoms during scanning.  
Naturally, scans will not be undertaken in all those for whom MRI is 
contra-indicated (implants, pacemakers etc…). 
There is no evidence in the literature of risks associated with CPEx testing. 
We will record all adverse events associated with the study and review 
them both as they occur and collectively at monthly intervals. 
Participation in research may involve some degree of loss of privacy.  This 
risk will be minimised, however, by our data protection methods.  
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Furthermore, we are not performing any tests that may subsequently 
result in significant personal, financial or social detriment to our research 
subjects.  We will make every effort to ensure that our data is secure and 
patients’ privacy is protected. 
Benefits  
Because this is primarily an observational study, there will be no direct 
benefit to patients.  The study reveals, however, the potential to identify 
those with previously unrecognised cardiac disease, thereby facilitating 
the process of further managing these patients and controlling risk factors 
for cardiovascular disease.  This may in time lead to a subsequent 
reduction in cardiac events. 
Patients are also given the opportunity to be followed up over a longer 
and more intensive course than patients outside the study thus providing 
the former with greater support and prolonged medical input. 
In terms of benefits to society, trauma remains the leading cause of death 
in patients between 1 and 40 years of age, and is the 5th most frequent 
cause of death overall.   
The World Health Organization predicts that by 2020 road traffic 
accidents alone will be the 3rd leading cause of death worldwide.  To 
better comprehend, therefore, the physiological responses to shock and 
generic trauma from a cardiac perspective will enable, in future, the better 
delivery of care of this large cohort of patients. 
As mentioned previously, Coronary Heart Disease is the leader killer in 
the UK, and by better understanding its impact in the trauma patient we 
hope that society will benefit through the evolution of care of these 
patients.  A large database will result from this study, and should facilitate 
further investigations in this field. Eventually, through this research, we 
will hopefully understand the role of cardiac medications in trauma, the 
effect of shock on the diseased heart and may even be able to stratify and 
prognosticate injured patients with heart disease to name but a few 
examples. 
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Furthermore, once the study is completed we hope to demonstrate how 
best to identify the presence of cardiac dysfunction or injury and how to 
quantify it.  We will highlight the best time frame under which to 
undertake this and what prognosis to expect.  This will help guide 
clinicians on who needs admission and who is safe to be discharged, who 
needs follow up and who does not.  This targeted approach will help 
relieve some of the financial and resources burden incurred through 
inappropriate admissions and investigations.  It will direct doctors 
towards those at risk of adverse cardiac events thereby ensuring these 
patients are managed in such a way as to minimise long term morbidity 
and mortality resulting from the heart. 
Risk to Benefit Analysis 
Patients may have unrecognised heart disease diagnosed and thus will 
benefit from secondary preventative measures that can be implemented to 
avoid subsequent cardiac events.  They will also be followed up more 
intensely and longer than would ordinarily be the case.   
The bulk of the study is observational, and the interventions undertaken 
place the patients at no or minimal harm and inconvenience.  The project 
has been designed to reduce discomfort and any risks to the study 
subjects.  Patients care will not be compromised in any way for the 
purposes of the study. 
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Consent 
Informed Consent will be obtained by the chief investigator or co-
investigators.  If patients are deemed unable to consent for themselves a 
legally authorised representative will be asked to give permission to enrol 
the patient into the study.  The Trauma Team Leader, independent of the 
research, will give consent on behalf of the patient for the first blood draw, 
ECG and CT chest which will take place during resuscitation in the 
Emergency Department.  Emergency consent only will be required for this 
cohort, enrolled into the larger cohort study. 
All trauma patients routinely have bloods taken in the resuscitation room 
during the primary survey and thus this study will induce no extra stress 
or morbidity as a result of blood drawn for the study.  An ECG is 
performed as standard during resuscitation and poses no risk to the 
patient. 
If a CT is deemed necessary by the trauma team leader, as is the case in all 
severely injured patients, it will be performed on clinical grounds and 
data required for the study can be elucidated from these images.  The 
trauma patient is therefore not inappropriately exposed to radiation for 
the purposes of research. 
Where patients are awake with relatively minor injuries, and deemed able 
to give informed consent to take part in the research we will undertake 
this as soon as possible.  However, as we are able to use blood from the 
initial draw for trauma management, and ECGs and CT will be clinically 
indicated, we will still request a professional legally appointed 
representative consent.  To consent a patient in the initial phases of trauma 
evaluation would be difficult and might compromise patient care. 
This research study focuses on both the early and later stages of injury, 
from admission through to twelve months post trauma.  The majority of 
severely injured trauma patients present unconscious from a traumatic 
brain injury, hypovolaemic shock, intubated in the prehospital phase of 
their care or acutely in the emergency department.  These patients form an 
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important cohort of the study as we seek to determine whether patients 
with severe injury develop post-traumatic cardiac dysfunction.  These 
patients are likely to be enrolled into the sub-study and will therefore 
need to consent for themselves, and agree to be followed up over the 
course of the year.  Patients who are not unconscious have recently been 
through a major psychologically disturbing event, may have been a victim 
of violence and are frequently in pain.  Hence they may be unable to 
comprehend, or it may be inappropriate to discuss the details of a complex 
research trial at this time.   
The patient will be examined regularly to determine if and when he/she is 
able to consent for himself/herself even if surrogate consent has already 
been obtained.  While the duration of unconsciousness for trauma patients 
is very variable, most will regain consciousness in 2-10 days.  When 
awake, the trial and all study procedures performed and yet to be 
completed will be explained to the patient.  Subjects will once again be 
given the option to give consent to continue participation or to withdraw 
from the study.  Until the patient is able to consent for themselves the 
consent from the patient’s legally authorised representative will be 
sought.   
All study procedures already performed in addition to those yet to be 
completed will be explained, and their consent for ongoing participation 
will be requested.  They will also be informed that they have the right to 
deny continued involvement on the patient’s behalf.   
If a patient remains unidentified, the police and hospital social workers 
will continue to assist the investigator in identification of the patient. Daily 
attempts to locate family to discuss the patient’s condition and study 
involvement will be made.  Documentation of these attempts will be made 
in the patient’s medical record.   
A quarterly report will be sent to the LREC regarding the Consent Process.  
It will include the number of subjects entered into the study, the quantity 
of whom consented prior to entry, the number of subjects for whom 
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consent was waived, the number of subjects or surrogates who later 
refused or agreed to continue in the study and ongoing study results 
available. 
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Appendix II 
Cambridgeshire 3 Research Ethics Committee 
Victoria House 
Capital Park 
FULBOURN 
Cambridge 
CB21 5XB 
 
 Telephone: 01223 597597  
Facsimile: 01223 597645 
03 September 2010 
 
Professor Karim Brohi 
Consultant in Trauma, Vascular & Critical Care Surgery 
Royal London Hospital 
Trauma Clinical Academic Unit 
Royal London Hospital 
Whitechapel Road, London 
E1 1BB 
 
Dear Professor Brohi 
 
Study Title: Trauma Associated Cardiac Injury, Dysfunction & Death 
(TACIDD) 
REC reference number: 10/H0306/47 
 
Thank you for your letter of 23 August 2010, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee by the 
Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion 
for the above research on the basis described in the application form, protocol 
and supporting documentation as revised, subject to the conditions specified 
below. 
 
Mental Capacity Act 2005 
 
I confirm that the committee has approved this research project for the purposes 
of the Mental Capacity Act 2005. The committee is satisfied that the requirements 
of section 31 of the Act will be met in relation to research carried out as part of 
this project on, or in relation to, a person who lacks capacity to consent to taking 
part in the project.  
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to 
the start of the study (see “Conditions of the favourable opinion” below). 
The Committee has not yet been notified of the outcome of any site-specific 
assessment (SSA) for the non-NHS research site(s) taking part in this study. The 
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favourable opinion does not therefore apply to any non-NHS site at present. I will 
write to you again as soon as one Research Ethics Committee has notified the 
outcome of a SSA. In the meantime no study procedures should be initiated at 
non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D 
approval”) should be obtained from the relevant care organisation(s) in 
accordance with NHS research governance arrangements.  Guidance on 
applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular 
site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as 
follows: 
  
Document    Version    Date    
 Investigator CV: Karim Brohi   07 June 2010  
 Protocol  1.1  02 June 2010  
 REC application  3  03 June 2010  
 Covering Letter    04 June 2010  
 Study Flowchart  07 June 2010  
 Letter from Sponsor    01 June 2010  
 GP/Consultant Information Sheets  1.1  02 June 2010  
 Participant Information Sheet: Information Sheet A  - Subject  1.2  30 July 2010  
 Participant Consent Form: TACIDD A professional legally 
appointed representative consent form  
1.2  30 July 2010  
 Response to Request for Further Information    23 August 2010  
 Participant Information Sheet: Information Sheet B - Subject  1.2  30 July 2010  
 Participant Information Sheet: Information Sheet C Consultee  1.2  30 July 2010  
 Participant Information Sheet: Information Sheet D - Consultee  1.2  30 July 2010  
 Participant Consent Form: A  1.1  02 June 2010  
 Participant Consent Form: Tissue  1.2  30 July 2010  
 Participant Consent Form: A -Subject  1.2  30 July 2010  
 Participant Consent Form: B -Subject  1.2  30 July 2010  
 Participant Consent Form: TACIDD B professional legally 
appointed representative consent form  
1.2  30 July 2010  
 Evidence of insurance or indemnity: Barts & The London   01 June 2010  
  
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
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After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to 
make your views known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
1.  Notifying substantial amendments 
2.  Adding new sites and investigators 
3.  Progress and safety reports 
4.  Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in 
the light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 
10/H0306/47 Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Mr John Richardson 
Chair 
 
Email: lynda.mccormack@eoe.nhs.uk 
 
Enclosures: “After ethical review – guidance for researchers”  
 
Copy to: Mr Gerry Leonard 
R&D Department 
Queen Mary Innovation Centre 
Walden Street 
London 
E1 2EF 
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Appendix III 
Patient information sheet   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet A – Subject 
Version 1.2, 30/07/2010  
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  Trauma Associated Cardiac Injury and Dysfunction (TACID A)  
Principal Investigator: Mr. Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
Subject Name: _____________.   NHS Ref: ___________ Study Ref: ________ 
 
Introduction 
You are being invited to take part in a research study. This research will help us 
to improve the care of patients who suffer severe injuries in the future. Before you 
decide, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully. 
Talk to others about the study if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
Why is this research being carried out? 
Trauma (serious injury) is a serious health problem worldwide. Once discharged 
home, trauma patients are more likely to be limited in their daily activities 
compared to similar people who have not been injured.  Injury, shock and blood 
loss may damage the heart, which might lead to the above. If this is the case, the 
extent and frequency of heart damage and dysfunction in trauma patients is not 
known, and we hope that this research will help us to determine if, who and how 
significantly the heart might be affected by trauma.   
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Coupled with this, we want to find out what happens to trauma patients who 
already have diseased hearts before injury, and compare their outcomes to 
similar patients with normal healthy hearts.  
Why have I been chosen? 
On ___ - ___ - ______ (date), you were injured and admitted to the Royal 
London Hospital.  At the time, you were unable to give informed consent.  When 
you arrived in the emergency department, a full trauma team of doctors and 
nurses attended to you.  The trauma team leader, who is not part of this research 
study, gave consent as your representative.  As part of the immediate 
management, a heart trace (ECG) was performed and blood taken and sent to 
the laboratory for analysis.  A small amount of extra blood (approximately 1 
teaspoonful) was drawn and saved for research purposes.  We are now asking 
for your consent to allow us to use the samples we have collected and to 
continue to participate in the study, since all the procedures have not yet been 
completed. 
Do I have to take part? 
No, participation is completely voluntary.  It is up to you to decide whether or not 
to take part.  If you do, you will be given this information sheet to keep and be 
asked to sign a consent form.  You are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
If you agree to continue with the study the following will happen: 
1. We will store and process the samples we have already collected. 
2. We will continue to collect blood samples and heart traces (ECGs) until the 
3rd day in hospital.  3 of each in total.  Each blood sample is equivalent to 1 
teaspoonful, and the total amount of blood drawn over 3 days is less than 1 
fluid ounce.  Wherever possible we will draw the blood out of a line already in 
a blood vessel, or coincide the blood draw with tests required for your care, 
in order to minimise any discomfort from the procedure. 
3. We will perform an echocardiogram (Echo) during your admission, at a time 
that is convenient to you and medically appropriate.  An Echo is an 
ultrasound of the heart, and will give us information on the appearance and 
function of your heart.  
4. This will take approximately 30 minutes, and is undertaking by placing some 
jelly on your chest followed by a probe that produces the images.  It is very 
safe, but if the chest wall is injured, can be a little uncomfortable.   
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We will give you painkillers if this is the case, which will allow the test to be 
performed pain free. 
5. When you go home, or at 30 days after your accident, we will ask you to fill 
in a questionnaire designed to assess your health perception.  It is easy to 
complete and should take no more than 10 minutes.   
6. We also need permission to access your health records, so that we can 
assess your health one year after your accident.  This information is 
confidential, and will only be seen by the research team.  It will only be used 
for the purpose described above in this study. 
What do I have to do? 
If you agree to continue with the study the following will happen: 
1.  We will collect ___ (number) of further blood samples and ___ ECGS from 
you, on ___________(date/times) 
2.  We will perform an Echo at a convenient time to you during the course of your 
admission. 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific 
risks associated with each investigation are as follows: 
1. Blood samples: 
The risks of drawing blood include temporary discomfort from the needle stick 
and bruising. 
2. Echocardiogram: 
There is no risk to your health from an Echo, however, if you have chest wall 
injuries, you may find the procedure a little uncomfortable.  We will give you 
painkillers if this is the case and only proceed when you are happy for us to do 
so. 
What are the possible benefits of taking part in the study? 
In the event that we detect an abnormality with your heart, we will refer you with 
your consent to a specialist in order to ensure you get appropriate care and 
follow up.  In addition, we hope that the information we get will help to improve 
the care of trauma patients in the future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  The detailed information on 
this is given in Part 2. 
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Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be 
handled in confidence.  The details are included in Part 2. 
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in 
the study, please read the additional information in Part 2 before making any 
decision. 
 
Date: ___/___/_____         Researcher Initial: _____ 
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PART 2 
What will happen if I don’t want to carry on with the study? 
If you decide, at any time, to withdraw from the study all study procedures will be 
stopped immediately.  Any information and samples that have already been 
collected will be processed as part of the study unless you wish to have your 
samples withdrawn from the study, in which case we will destroy them.  Your 
decision will in no way result in a change in the type or quality of care you 
subsequently receive. 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after you.  It is 
extremely unlikely that this small change to normal practice would cause any 
problems.  However, if taking part in this study harms you, there is no special 
compensation arrangement.  If you are harmed due to someone’s negligence, 
then you may have grounds for legal action but you may have to pay your legal 
costs. Regardless of this, if you wish to complain or have any concerns about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be 
available to you.  Please contact Patient Advisory Liaison Service (PALS) if you 
have any concerns regarding the care you have received, or as an initial point of 
contact if you have a complaint.  Please telephone 020 7377 6335, minicom 020 
7943 1350, or email pals@bartsandthelondon.nhs.uk.  You can also visit PALS 
by asking at any hospital reception. 
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential and will be stored securely in coded form.  If you 
consent to take part in the research, the people conducting the study will abide 
by the Data Protection Act 1998, and the rights you have under this Act.  Only 
authorised personnel such as researchers and research auditors will have 
access to the data.  Any subsequent use of the samples will have to be 
performed with approval from a research ethics committee, otherwise the 
samples will be destroyed.  
What will happen to the samples that I give? 
We would like your permission to store your blood samples for further research.   
Any further use of your samples outside of this research study will have to be 
approved by a research ethics committee.   
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What will happen to the results of the research study? 
We hope to publish the results in a scientific journal.  It will not be possible to 
identify any individual who has taken part from this scientific report.  Copies of 
the report will be available on request. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given ethical approval by the Cambridgeshire 
3 Research Ethics Committee. 
Who can I contact for further information? 
1. If you require further information about the study, please contact the 
TACID study offices via the Trauma Surgery secretary at 020 7377 7000, 
x7695 or email: Henry.De’Ath@bartsandthelondon.nhs.uk 
2. If you require impartial, local advice, please contact the Patient Advice 
and Liaison Service, telephone: 020 7943 1335 or e-mail: 
pals@bartsandthelondon.nhs.uk 
Thank you for taking the time to read this sheet.  
Date: ___/___/_____         Researcher Signature: ______________ 
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Appendix IV 
Information for Consultee   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet C - Consultee 
Version 1.2, 30.07.2010  
 
Cambridgeshire 3 Research Ethics Committee 
REC number: 10/H0306/47 
 
Title: Trauma Associated Cardiac Injury and Dysfunction (TACID A) 
Principal Investigator: Mr. Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
Subject Name: _____________.   NHS Ref: ___________ Study Ref: ________ 
 
Introduction 
We feel your relative/friend is unable to decide for himself/herself whether to 
participate in this research.  To help decide if he/she should join the study, we 
would like to ask your opinion whether or not they would want to be involved.  We 
would ask you to consider what you know of their wishes and feelings, and to 
consider their interests.  Please let us know of any advance decisions they may 
make about participating in research.  These should take precedence.  If you are 
unsure about the role of consultee you may seek independent advice.  We will 
understand if you do not want to take on this responsibility.  The following 
information is the same as would have been provided to your relative/friend. 
Why is this research being carried out? 
Trauma (serious injury) is a serious health problem worldwide.  Once discharged 
home, trauma patients are more likely to be limited in their daily activities 
compared to similar people who have not been injured.  Injury, shock and blood 
loss may damage the heart, which might lead to the above. If this is the case, the 
extent and frequency of heart damage and dysfunction in trauma patients is not 
known, and we hope that this research will help us to determine if, who and how 
significantly the heart might be affected by trauma.   
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Coupled with this, we want to find out what happens to trauma patients who 
already have diseased hearts before injury, and compare their outcomes to 
similar patients with normal healthy hearts.  
Why have they been chosen? 
On ___ - ___ - ______ (Greenland P), your relative or significant other was 
injured and admitted to the Royal London Hospital.  At the time, they were unable 
to give informed consent.  When they arrived in the emergency department, a full 
trauma team of doctors and nurses attended to them.  The trauma team leader, 
who is not part of this research study, gave consent as their representative.  As 
part of the immediate management, a heart trace (ECG) was performed and 
blood taken and sent to the laboratory for analysis.  A small amount of extra 
blood (approximately 1 teaspoonful) was drawn and saved for research 
purposes.  We are now asking for your consent to allow us to use the samples 
we have collected and to allow their continued participation in the study, since all 
the procedures have not yet been completed. 
Do I have to agree? 
No, participation is completely voluntary.  It is up to you to decide whether or not 
your relative/significant other should take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a declaration form.  You are still 
free to withdraw at any time and without giving a reason.  A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of care your 
relative/significant other receives. 
What will happen to them if they take part? 
1. If you agree to continue with the study the following will happen: 
2. We will store and process the samples we have already collected. 
3. We will continue to collect blood samples and heart traces (ECGs) until the 
3rd day in hospital. 3 of each in total.  Each blood sample is equivalent to 1 
teaspoonful, and the total amount of blood drawn over 3 days is less than 1 
fluid ounce.  Wherever possible we will draw the blood out of a line already in 
a blood vessel, or coincide the blood draw with tests required for their care, 
in order to minimise any discomfort from the procedure. 
4. We will perform an echocardiogram (Echo) during the admission, at a time 
that is convenient and medically appropriate.  An Echo is an ultrasound of 
the heart, and will give us information on the appearance and function of the 
heart.  This will take approximately 30 minutes, and is undertaking by placing 
some jelly on the patient’s chest followed by a probe that produces the 
images.   
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It is very safe, but if the chest wall is injured, can be a little uncomfortable.  
We will give painkillers if this is the case, which will allow the test to be 
performed pain free. 
5. When home, or at 30 days after the accident, we will ask your relative or 
significant other to fill in a questionnaire designed to assess their health 
perception.  It is easy to complete and should take no more than 10 minutes.  
6. We also need permission to access their health records, so that we can 
assess their health one year after your accident.  This information is 
confidential, and will only be seen by the research team.  It will only be used 
for the purpose described above in this study. 
What do they have to do? 
If you agree to continue with the study the following will happen: 
1.  We will collect ___ (number) of further blood samples and ___ ECGS from 
them, on_________(date/times) 
2.  We will perform an Echo at a convenient time to you during the course of 
his/her admission. 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific 
risks associated with each investigation are as follows: 
1.  Blood samples: 
The risks of drawing blood include temporary discomfort from the needle stick 
and bruising. 
2.  Echocardiogram: 
There is no risk to their health from an Echo, however, if they have chest wall 
injuries, they may find the procedure a little uncomfortable.  We will give them 
painkillers if this is the case and only proceed when they are happy for us to do 
so. 
What are the possible benefits of taking part in the study? 
In the event that we detect an abnormality with your relative/significant other’s 
heart, we will refer them with your consent to a specialist in order to ensure they 
get appropriate care and follow up.  In addition, we hope that the information we 
get will help to improve the care of trauma patients in the future. 
What if there is a problem? 
Any complaint about the way you or your relative have been dealt with during the 
study or any possible harm they might suffer will be addressed.  The detailed 
information on this is in Part 2. 
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Will taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
relative/significant other will be handled in confidence.  The details are included 
in Part 2. 
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in 
the study, please read the additional information in Part 2 before making any 
decision. 
 
Date: ___/___/_____         Researcher Initial: _____ 
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PART 2 
What will happen if I don’t want them to carry on with the study? 
If you or your relative/significant other decides, at any time, to withdraw from the 
study all study procedures will be stopped immediately.  Any information and 
samples that have already been collected will be processed as part of the study 
unless you wish to have their samples withdrawn from the study, in which case 
we will destroy them.  Your decision will in no way result in a change in the type 
or quality of care they subsequently receive. 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after your 
relative/significant other.  It is extremely unlikely that this small change to normal 
practice would cause any problems.  However, if they are harmed by taking part 
in this study, there is no special compensation arrangement.  If they are harmed 
due to someone’s negligence, then you may have grounds for legal action but 
you may have to pay your legal costs.  Regardless of this, if you wish to complain 
or have any concerns about any aspect of the way you or your relative have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you.  Please contact 
Patient Advisory Liaison Service (PALS) if you have any concerns regarding the 
care they have received, or as an initial point of contact if you have a complaint.  
Please telephone 020 7377 6335, minicom 020 7943 1350, or email 
pals@bartsandthelondon.nhs.uk.  You can also visit PALS by asking at any 
hospital reception. 
Will taking part in the study be kept confidential? 
All information collected during the course of the research will be kept strictly 
confidential and will be stored securely in coded form.  If you consent to take part 
in the research the people conducting the study will abide by the Data Protection 
Act 1998, and the rights you and your relative have under this Act.  Only 
authorised personnel such as researchers and research auditors will have 
access to the data.  Any subsequent use of the samples will have to be 
performed with approval from a research ethics committee, otherwise the 
samples will be destroyed.  
What will happen to the samples that are given? 
We would like your permission to store his/her blood samples for further 
research.   Any further use of the samples outside of this research study will have 
to be approved by a research ethics committee. 
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What will happen to the results of the research study? 
We hope to publish the results in a scientific journal. It will not be possible to 
identify any individual who has taken part from this scientific report.  Copies of 
the report will be available on request. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given ethical approval by the Cambridgeshire 
3 Research Ethics Committee. 
Who can I contact for further information? 
1. If you require further information about the study, please contact the ACIT 
Study offices via the Trauma Surgery secretary at 020 7377 7000, 
ext7695 or email: Henry.De’Ath@bartsandthelondon.nhs.uk 
 
2. If you require impartial, local advice, please contact the Patient Advice 
and Liaison Service, telephone: 020 7943 1335 or e-mail: 
pals@bartsandthelondon.nhs.uk 
Thank you for taking the time to read this sheet.  
 
Date: ___/___/_____         Researcher Signature: ______________ _____ 
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Appendix V 
Trauma Associated Cardiac Injury and Dysfunction (A) 
 
Trauma patients are eligible for participation in TACID A trial unless they 
meet one of the following: 
 
 Patients transferred from other hospitals 
 Not expected to survive <72 hours  
 Pregnant 
 Patients <16  
 Prisoners 
 Trauma team leader deems recruitment inappropriate 
 
 
 
 
 
 
Patient Name  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   
 
 
Patient ID _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
DOB  _ _/_ _/__    Approximate Age _ _ 
 
 
Date Recruited _ _/_ _/_ _ Time of Baseline Blood/ECG   _:_  
 
I, as trauma team leader, fully understand the TACID A research study 
and informed consent process.  I have read the consent documents and 
have provided consent in my capacity as a professional legally appointed 
representative of the above named patient and am independent of the 
trial. 
 
 
Name  _ _ _ _ _ _ _ _ _ _ _ _ _ _  Title _ _ _ _ _ _ _ _ _ 
 
 
Signature _ _ _ _ _ _ _ _ _ _ _ _ _ 
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DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consent Form A – Subject 
Version 1.2, 02.06.2010            
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  TRAUMA ASSOCIATED CARDIAC INJURY AND DYSFUNCTION (A) 
Principal Investigator:  Mr. Karim Brohi, FRCS FRCA    
Please initial box to 
indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 30.07.2010 
(version 1.2) for the above study and have had the opportunity to ask questions.  I have  
been given a copy of the patient’s information sheet to keep.   [  ] 
2. I understand that my participation in this study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.        [ ] 
3. I understand that sections of any of my medical notes may be looked at by professional 
individuals involved in this study or by regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access to my 
records. I understand that my personal data will be processed and stored securely in 
compliance with the 1998 Data Protection Act.  [ ]  
4. I agree to take part in the above study.    [ ] 
 
 
                   
Name of patient    Date    Signature 
 
 
I have explained this in terms which, in my judgement, are suited to the understanding of 
the patient. 
 
 
                                
Name of person taking consent  Date    Signature 
(if different from Investigator) 
 
 
                    
Investigator    Date                          Signature 
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DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consultee Declaration Form C 
Version 1.2, 30.07.2010            
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  TRAUMA ASSOCIATED CARDIAC INJURY AND DYSFUNCTION (A) 
Principal Investigator:  Mr. Karim Brohi, FRCS FRCA    
Please initial box to 
indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 30.07.2010 
(version 1.2) for the above study and have had the opportunity to ask questions.  I have  
been given a copy of the consultee information sheet to keep.  [  ] 
2. I understand that his/her participation in this study is voluntary and that I am free to 
withdraw him/her at any time, without giving reason, without their medical care or legal 
rights being affected.       [ ] 
3. I understand that sections of any of his/her medical notes may be looked at by 
professional individuals involved in this study or by regulatory authorities where it is 
relevant to them taking part in research.  I give permission for these individuals to have 
access to his/her records. I understand that his/her personal data will be processed and 
stored securely in compliance with the 1998 Data Protection Act.  [ ] 
4. I agree to allow my relative/significant other take part in the above study. [ ] 
 
 
         
Name of Patient   Relationship 
 
                   
Name of Consultee   Date   Signature 
 
 
I have explained this in terms which, in my judgement, are suited to the understanding of 
the patient. 
 
 
                                
Name of person taking consent  Date   Signature 
(if different from Investigator) 
 
 
                    
Investigator    Date                Signature 
 
 
 
